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Executive Summary 
 
Uncertainties in estimating health risks from galactic cosmic rays are a major limitation to the 
length of space missions and the evaluation of potential risk mitigations. NASA limits astronaut 
exposures to a 3% risk of exposure-induced death (REID) and protects against uncertainties in 
risks projections using an assessment of 95% confidence intervals in the projection model. Revi-
sions to the NASA projection model for lifetime cancer risks from space radiation and new esti-
mates of model uncertainties are described in this report. Our report first reviews models of space 
environments and transport code predictions of organ exposures, and characterizes uncertainties 
in these descriptions. We then summarize recent analysis of low linear energy transfer (LET) 
radio-epidemiology data, including revision to the Japanese A-bomb survivor dosimetry, longer 
follow-up of exposed cohorts, and reassessments of dose and dose-rate reduction effectiveness 
factors (DDREFs). We compare these newer projections and uncertainties with earlier estimates 
made by the National Council of Radiation Protection and Measurements (NCRP). Current under-
standing of radiation quality effects and recent data on factors of relative biological effectiveness 
(RBE) and particle track structure are then reviewed. Recent results from radiobiology experiments 
from the NASA Space Radiation Laboratory provide new information on solid cancer and leukemia 
risks from heavy ions, and radiation quality effects are described. We then consider deviations 
from the paradigm of linearity at low doses of heavy ions motivated by non-targeted effects 
(NTE) models. 
 
The new findings and knowledge are used to revise the NASA risk projection model for space 
radiation cancer risks. Key updates to the model are: 
1) Revised values for low-LET risk coefficients for tissue-specific cancer incidence. Tissue-
specific incidence rates are then transported to an average U.S. population and used to 
estimate the probability of risk of exposure-induced cancer (REIC) and REID. 
2) An analysis of lung cancer and other smoking-attributable cancer risks for never-
smokers that shows significantly reduced lung cancer risks as well as overall cancer 
risks compared to risk estimated for the average U.S. population. 
3) Derivation of track-structure-based radiation quality functions that depend on charge 
number, Z, and kinetic energy, E, in place of a dependence on LET alone. 
4) The assignment of a smaller maximum in the quality function for leukemia than for solid 
cancers. 
5) The use of the International Commission on Radiological Protection tissue weights is 
shown to overestimate cancer risks from solar particle events (SPEs) by a factor of 2 or 
more. Summing cancer risks for each tissue is recommended as a more accurate approach 
to estimate SPE cancer risks. However, gender-specific tissue weights are recommended 
to define Effective doses as a summary metric of space radiation exposures. 
6) Revised uncertainty assessments for all model coefficients in the risk model (physics, 
low-LET risk coefficients, DDREF, and quality factors [QFs]), and an alternative uncer-
tainty assessment that considers deviation from linear responses as motivated by NTE 
models. 
7) A probabilistic risk assessment (PRA) model for SPEs is described. 
 
Results of calculations for the average U.S. population show more restrictive dose limits for 
astronauts above age 40 y compared to NCRP Report No. 132, a modest narrowing of uncer-
tainties if NTEs are not included, and much broader uncertainties if NTEs are included. Risks for 
never-smokers compared to the average U.S. population are estimated to be reduced by more 
than 20% and 30% for males and females, respectively. Lung cancer is the major contributor to 
the reduction for never-smokers, with additional contributions from stomach, bladder, oral cavity, 
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and esophageal cancers. Table 6.9 summarizes the revised estimates for the number of “safe 
days” in space at solar minimum for heavy shielding conditions. Results from previous estimates 
are compared to estimates for both the average U.S. population and a population of never-
smokers. Greater improvements in risk estimates for never-smokers are possible, and would 
be dependent on improved understanding of transfer models for the histological types of lung 
cancer (for eg, small cell lung cancers and non-small cell lung cancer) as well as data on QFs 
for these types of lung cancers. 
 
 
Table 6.9. Estimates of safe days in deep space, which are defined as the maximum number of 
days with 95% CL [confidence level] to be below the NASA 3%REID limit. Calculations are for 
solar minimum with 20 g/cm2 aluminum shielding. Values in parenthesis are for alternative 
assessment that assumes additional constraints on QF uncertainties as given by Eq(6.7). 
aE, y NASA 2005 NASA 2010 
U.S. Avg. Population 
NASA 2010 
Never-smokers 
  Males 
35 158 140 (186) 180 (239) 
45 207 150 (200) 198 (263) 
55 302 169 (218) 229 (297) 
  Females 
35 129 88 (120) 130 (172) 
45 173 97 (129) 150 (196) 
55 259 113 (149) 177 (231) 
 
 
The dependence of radiation QFs or risk cross sections on particle type and energy likely varies 
in a tissue-specific manner, with the mechanisms of cancer induction, cell killing, and other 
factors. An alternate uncertainty assessment that presumes a high level of constraint on the 
radiation quality dependences of cancer risk as determined by existing radiobiological data is 
described, and shown to reduce uncertainties (values shown in parenthesis in Table 6.9) signif-
icantly. Improvements in understanding of radiation quality effects and space physics is partially 
negated by higher dosimetry and statistical errors assessments from more recent human radia-
tion epidemiology assessments compared to the prior NCRP estimates. In this report, example 
calculations for International Space Station missions and deep space missions to near-Earth 
objects, the moon, and Mars are described. Cancer risk for each location on the martian 
surface is also described, which should be valuable for mission planning. The uncertainty 
assessments made in this report are an important component of the PRAs that are essential 
for exploration missions. 
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1. Introduction 
 
Exposures to astronauts from galactic cosmic rays (GCR) — made up of high-energy protons 
and high-energy and charge (HZE) nuclei, and solar particle events (SPEs) — that are comprised 
largely of low- to medium-energy protons are a critical challenge for space exploration. Experi-
mental studies have shown that HZE nuclei produce both qualitative and quantitative differences 
in biological effects compared to terrestrial radiation,1-5 leading to large uncertainties in predicting 
exposure outcomes to humans. Radiation risks include carcinogenesis,6 degenerative tissue 
effects such as cataracts7,8 or heart disease,9-11 and acute radiation syndromes.6 Other risks, 
such as damage to the central nervous system (CNS), are a concern for HZE nuclei.1,5 For 
International Space Station (ISS) missions and design studies of exploration of the moon, near-
Earth objects (NEOs), and Mars, NASA uses the quantity risk of exposure-induced death (REID) 
to limit astronaut risks. A REID probability of 3% is the criteria for setting age- and gender-specific 
exposure limits, while protecting against uncertainties in risk projection models is made using 
estimates of the upper 95% confidence level (CL). 
 
Risk projection models serve several roles, including: setting the age- and gender-specific 
exposure-to-risk conversion factors needed to define dose limits, projecting mission risks, and 
evaluating the effectiveness of shielding or other countermeasures. For mission planning and 
operations, NASA uses the model recommended in NCRP [National Council of Radiation Pro-
tection and Measurements] Report No. 132 to estimate cancer risks from space.6 The model 
employs a life-table formalism to model competing risks in an average population, epidemiological 
assessments of excess risk in exposed cohorts such as the atomic-bomb survivors, and esti-
mates of dose and dose-rate reduction factors (DDREFs) and linear energy transfer (LET)-
dependent radiation quality factors (QFs) to estimate organ dose equivalents. 
 
NASA recognizes that projecting uncertainties in cancer risk estimates along with point 
estimates is an essential requirement for ensuring mission safety, as point estimates alone 
have limited value when the uncertainties in the factors that enter into risk calculations are large. 
Estimates of 95% confidence intervals (CI) for various radiation protection scenarios are meaning-
ful additions to the traditional point estimates, and can be used to explore the value of mitigation 
approaches and research that could narrow the various factors that enter into risk assessments. 
Figure 1.1 illustrates the approach used at NASA as the number of days in space or an astro-
naut’s career exposure accumulates. Because of the penetrating nature of the GCR and the 
buildup of secondary radiation in tissue behind practical amounts of all materials, we argued 
previously12-14 that improving knowledge of biological effects to narrow CI is the most cost-
effective approach to achieve NASA safety goals for space exploration. Furthermore, this 
knowledge is essential to perform cost-benefit analysis of mitigation measures, such as 
shielding approaches and biological countermeasures, and to practice the safety require-
ment embodied in the principle of as low as reasonably achievable (ALARA). 
 
Uncertainties for low-LET radiation, such as -rays or x rays, have been reviewed several times 
in the past, and indicate that the major uncertainty is the extrapolation of cancer effects data from 
high to low doses and dose-rates.15,16 The (National Academy of Science [NAS]) Committee on 
the Biological Effects of Ionizing Radiation (BEIR) VII16 and United Nations Special Committee 
on the Effects of Atomic Radiation (UNSCEAR) committees17 recently provided new assessments 
of low-LET radiation risks. Uncertainties consist of the transfer of risk across populations and 
the sources of error in epidemiology data, including dosimetry, recording bias, and statistical 
errors. Probability distribution functions (PDFs), described previously,15 were used to estimate 
low-LET risk uncertainties. For space radiation risks, additional uncertainties occur related to 
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estimating the biological effectiveness of hydrogen, helium, and HZE nuclei, and to predicting 
particle energy spectra at tissue sites.12 The limited understanding of heavy ion radiobiology is 
the largest contributor to the uncertainty for space radiation effects.1,12 
 
 
Figure 1.1. Risk management with ALARA and large uncertainties. The cumulative risk 
distribution function for an “acceptable” level of risk is displaced, so that the permissible exposure 
limit (PEL) is based on the 95% CL to take into account the uncertainties in projection models. 
ALARA practices and action levels are then also displaced dependent on the level of 
uncertainties.18 
 
We discuss in this report modifications to the NASA model, which projects cancer risks and 
probability distributions that describe uncertainties for space missions, and apply the model to 
several exploration mission scenarios. Our estimates use REID as the basic risk quantity rather 
than excess lifetime risk (ELR) or lifetime attributable risk (LAR) to adjust for competing risks as 
well as for cancer deaths moved earlier in time by radiation.19 To improve the transfer of cancer 
rates derived from exposed populations to a population of astronauts, we describe incidence-
based risk transfer models and project mortality risks using adjustments between cancer mortality 
and incidence in the U.S. population as recommended by the BEIR VII report.16 The impacts 
of smoking on population rates are assessed to make risk estimates for a population of never-
smokers. Previous risks assessments was based on the use of a single parameter, LET, to 
describe the relative biological effectiveness of all cosmic rays with no specific dependence 
on charge number of velocity. LET is known to be a poor descriptor of energy depiction on a 
microscopic scale. A key hypothesis to our revised approach is that, to improve the extrapolation 
of radiobiological data and to optimize uncertainty reduction, greater emphasis on particle track 
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structure in describing energy deposition and subsequent biological events at the molecular, 
cellular, and tissue levels is required. We describe data and theoretical analysis that support the 
redefinition of radiation quality in terms of track structure parameters, and the assignment of 
distinct radiation QFs for solid cancer and leukemia with significantly lower values recommended 
for leukemia compared to solid cancer. The relationship between event- and fluence-based 
models and organ dose equivalent approaches is discussed. 
 
We used Monte-Carlo simulations of subjective PDFs that represent current knowledge 
of factors that enter into risk assessments2,12,15,20 to propagate uncertainties across multiple 
contributors. We can write a risk equation in a simplified manner as a product of several factors 
including the dose, D, quality factor, Q, a low-LET risk coefficient normally derived from the data 
of the atomic-bomb survivors, R0, and the dose and dose-rate reduction effectiveness factor, 
DDREF, that corrects risk data for dose-rate modifiers. Monte-Carlo uncertainty analysis uses 
the risk equation, but the equation is modified by normal deviates that represent subjective 
weights and ranges of values for various factors that enter into a risk calculation. First, we 
define XR(x) as a random variate that takes on quantiles x1, x2, …, xn such that p(xi) =P(X=xi) 
with the normalization condition  p(xi)=1. C(xi) is defined as the cumulative distribution function, 
C(x), which maps X into the uniform distribution U(0,1), and we define the inverse cumulative 
distribution function C(x)-1 to perform inverse mapping of U(0,1) into x: x=C(x)-1. Then we write 
for a simplified form of the risk equation for a Monte-Carlo trial, : 
 
 00 ( , )
R
R phys Q
D
x x xFLQRisk R age gender
DDREF x 
      
 (1.1) 
 
where R0 is the low-LET risk coefficient per unit dose, the absorbed dose, D, is written as the 
product of the particle fluence, F, and LET, L, and Q is the radiation QF. The xR, xphys, xDr, and xQ 
are quantiles that represent the uncertainties in the low-LET risk coefficient, space physics 
models of organ exposures, dose-rate effects, and radiation quality effects, respectively. Monte-
Carlo trials are repeated many times, and resulting values are binned to form an overall PDF 
taking into account the model uncertainties. In this report, updates to the risk coefficients and 
QFs as well as and the revised PDFs for the various factors are described based on recent data 
and findings. In practice, the risk model does not use the simple form of Eq(1.1). Instead, risk 
calculations are based on a double-detriment life-table calculation that considers age, gender, 
and tissue-specific, radiation-induced cancer rates within a competing risk model with all causes 
of death in an average population.6,17 
 
The model of Eq(1.1) and similar models make several important assumptions that we note here: 
 
1) Risk assessments are population-based calculations that are applied to individuals 
rather than individual-based calculations. Legal and ethical obstacles to individual-based 
risk assessment are being described elsewhere along with the current scientific 
limitations to such approaches for low dose-rate exposures .21,22 
2) A linear and additive response over each the contribution of each particle to cumulative 
risk is assumed. The linearity and additivity of radiation component assumptions are em-
bodied in the use of QFs, Q. QFs are subjective judgments of experimental determinations 
of maximum relative biological effectiveness (RBE) factors determined as the ratio of initial 
slopes for linear dose response curves for ions compared to -rays denoted as RBEmax. 
Under this assumption, the DDREF applies only to -rays. No dependence of space 
radiation risks on dose-rate is presumed. 
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3) The risk model implicitly assumes that only quantitative differences between low- and 
high-LET radiation are important for risk assessment, thereby neglecting any impacts 
from qualitative differences. 
 
Ground-based research at the NASA Space Radiation Laboratory (NSRL) continues to 
document important quantitative and qualitative differences in the biological effects of HZE 
nuclei, including in the types of deoxyribonucleic acid (DNA) damages and chromosomal 
arrangements, gene expression, and signal transduction induced by radiation. Important 
differences between these processes at high vs. low doses have also been documented. Non-
targeted effects (NTE), including bystander effects and genomic instability in the progeny of 
irradiated cells,23,24 are currently of great interest in radiation protection as they challenge the 
traditional paradigm of dose responses, which increase in a manner proportional to dose without 
threshold. These assumptions are clearly motivated by a DNA mutation mechanism or other 
targeted DNA effects (targeted effects [TE]). NTEs often are suggestive of qualitative differ-
ences between low- and high-LET radiation. Ultimately, low-LET and simulated space radiation 
can be compared for the same endpoint, such as overall cancer risk or tissue-specific cancer 
risks, albeit there are both qualitative and quantitative differences in causative steps leading to 
these endpoints. However, elucidation of the biological importance of quantitative differences 
through mechanistic research is essential for improving current risk models. A long-time out-
standing question is the use of dose-based models to describe cosmic-ray tracks as they pass 
through tissue. Figure 1.2 illustrates some of the differences between dose-based risk models 
and particle track structure. Quantitative and qualitative differences occur, and the use of 
radiation QFs may not be justified in all or certain cases. 
 
 
Figure 1.2. A comparison of particle tracks in nuclear emulsions and human cells. The right panel 
illustrates tracks of different ions, from protons to iron, in nuclear emulsions, clearly showing the 
increasing ionization density (LET=E/x) along the track by increasing the charge Z. The left 
panel shows three nuclei of human fibroblasts exposed to -rays and Si- or Fe-ions, and immuno-
stained for detection of -H2AXP14P. Each green focus corresponds to a DNA double-strand break 
(DSB). While the H2AX foci in the cell that is exposed to sparsely ionizing -rays are uniformly 
distributed in the nucleus, the cells that are exposed to HZE particles present DNA damage along 
tracks (one Si- and three Fe-particles, respectively), and the spacing between DNA DSB is 
reduced at very high LET.2 
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NASA radiation protection methods are based on recommendations issued by the NCRP6,25 and 
the International Commission on Radiological Protection (ICRP)26, but independent approaches 
have been developed and continue to be developed that lead to better implementation in the 
context of space exploration. In those instances, details of NASA practice differ from these 
recommendations. For example, NASA uses cancer-mortality-based career limits rather than 
limits that are based on overall health detriment, as recommended by the ICRP, and gender-
specific career limits calculated for individual astronaut mission exposure histories rather than 
attained age. Distinct short-term limits are followed originating in recommendations from the 
National Research Council (NRC) (1970). NASA continued to use Q(L) (ie, QF as a function of 
LET) rather than ICRP radiation weighting factors based on NCRP recommendations,6,25 and 
also uses distinct RBEs for non-cancer risks instead of the QFs employed in estimating cancer 
risks. NASA estimates the 95% CLs as a requirement for dose limits, and recently considered 
limits for the CNS and heart disease.27 Dosimetry28 and ALARA implementation for space 
missions, including the timing of spacewalks,29 and operational biodosimetry30 also distinguish 
NASA procedures from terrestrial radiation protection procedures. 
 
While the revised approach described in this report for space radiation cancer risk assessments 
leads to additional modifications from prior methods recommended by NCRP or ICRP; it is 
nevertheless consistent with the overall principles of NCRP and ICRP because the higher risk 
levels of long-term space missions require more accurate assessments than are used in most 
ground-based scenarios. To quote the ICRP from its recent assessment of QFs:31 
 
“Accurate determinations may seem to be an academic issue in radiation 
protection. Under routine circumstances, where exposures are substantially 
below the limits, this is indeed the case. Then there is no need for accurate 
assessments. However, in radiological protection, as in other formally adopted 
and legally binding protection or safety systems, a limit must also be rigorously 
defined quantity because exposures must, in certain critical cases, be assessed 
accurately. Looseness that can involve uncertainties by a factor of 2 or more is 
tolerable under many routine conditions, but it will make the system inoperable in 
exactly those critical circumstances where compliance with regulatory limits is in 
question and must be reliably quantified.” [p. 68, para. 230] 
 
Thus, the required accuracy for radiation projection for long-term space travel makes many of 
the methodologies recommended by the ICRP and the NCRP inadequate for NASA. However, 
the approach described in the present report is consistent with the NCRP overall recommended 
principles of risk justification, risk limitation, and ALARA. In the final section of this report, we will 
discuss predictions for space missions as well as changes to dosimetry and computer codes 
procedures that result from our recommended changes to the NASA cancer projection model. 
 
1.1 Basic Concepts 
 
Radiation exposures are often described in terms of the physical quantity absorbed dose, D, 
which is defined as the energy deposited per unit mass. Dose has units of Joule/kg that define 
the special unit, 1 Gray (Gy), which is equivalent to 100 rad (1 Gy = 1 rad). In space, each cell 
within an astronaut is exposed every few days to a nuclear particle that comprises the GCR. 
The GCR is the nuclei of atoms accelerated to high energies in which the atomic electrons are 
stripped off. It is common to discuss the number of particles per unit area, called the fluence, F, 
with units of 1/cm2. As particles pass through matter, they lose energy at a rate dependent on 
their kinetic energy, E, and charge number, Z, and approximately the average ratio of charge to 
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mass, (ZT/AT) of the materials they traverse. The rate of energy loss is called the LET, which, for 
unit density materials such as tissue, is given in units of keV/m. Dose and fluence are related 
by D =  F LET, where  is the density of the material (eg, 1 g/cm3 for water or tissue). The 
dependence of energy loss on the ZT/AT ratio implies that hydrogen, with its ratio equal to 1, is 
the optimal material for slowing particles. There is a broad energy range for the cosmic rays, 
and the spectra of particles is denoted as the fluence spectra, j(E), where j refers to the particle 
type described by Z and the mass number, A. The particle velocity scaled to the speed of light, 
denoted as , is related to the kinetic energy. E and  are related using the formula =1 + E/m 
where m is the nucleon rest mass (938 MeV) and =(1-1/2)-1/2. Kinetic energies are often ex-
pressed in units of MeV per atomic mass unit (u), MeV/u because particles with identical E 
then have the same . The total kinetic energy of the particle is then A times E. 
 
The GCR of interest has a charge number, Z from 1 to 28, and energy from less than 1 MeV/u 
to more than 10 000 MeV/u with a median energy of about 1000 MeV/u. The GCR with energies 
less than about 2000 MeV/u is modulated by the 11-y solar cycle, with more than two times 
higher GCR flux at solar minimum when the solar wind is weakest compared to the flux at solar 
maximum. The most recent solar minimum was in 2008-2009, and the next will occur in about 
2019. SPEs occur about 5 to 10 times per year, except near solar minimum, and consist largely 
of protons with kinetic energies below 1 MeV up to a few hundred MeV. However, most SPEs 
lead to small doses (<0.01 Gy) in tissue; and only a small percentage (<10%) would lead to 
significant health risks if astronauts were not protected by shielding. At this time there is very 
little capability to predict the onset time and determine whether a large or small SPE will occur 
until many hours after an SPE has commenced. Mission disruption many thus occur for many 
SPEs, although the health risks are very small. 
 
Nuclear and atomic interactions in materials are best described using the material thickness, x, 
described as an areal density, t = x, where is the atomic density of the material with values 
for common materials of  = 1.0, 2.7, and 0.96 for tissue, aluminum, and high-density polyeth-
ylene, respectively. The range of a particle is defined as the average distance traveled before 
the particle loses all of its kinetic energy and stops. The range increases with E and is a few 
g/cm2 at 50 MeV/u, and more than 100 g/cm2 at 1000 MeV/u. Nuclear reactions, which occur 
through interactions of cosmic rays with the nuclei of atoms in shielding materials or tissue, lead 
to the production of secondary radiation, including neutrons and charged particles from the atoms 
of the shielding material or tissue. The mean free path for a nuclear reaction increases with the 
mass of the cosmic ray; about 10 g/cm2 for heavy nuclei such as iron (A=56; Z=26), and more 
than 20 g/cm2 for protons (A=1; Z=1). Shielding thickness of 10 to 20 g/cm2 is sufficient to protect 
against most SPEs; however, thicknesses of several hundred g/cm2 are needed to significantly 
reduce organ doses from GCR, making shielding impractical as an efficient method of 
protection. 
 
Energy loss by cosmic rays occurs through ionization and excitation of target atoms in the 
shielding material or tissue. The ionization of atoms leads to the liberation of electrons that often 
have sufficient energy to cause further excitations and ionizations of nearby target atoms. These 
electrons, which are called -rays, can have energies more than 1 MeV for ions with E>1000 
MeV/u. About 80% of the LET of a particle is due to ionizations leading to -rays. The number of 
-rays created is proportional to Z*2/2, where Z* is the effective charge number that adjusts Z by 
atomic screening effects important at low E and high Z. The lateral spread of -rays, called the 
track-width (illustrated in Figure 1.2) of the particle, is dependent on but not on Z being deter-
mined by kinematics. At 1 MeV/u, the track-width is about 100 nm (0.1 m); and at 1000 MeV/u, 
the track-width is about 1 cm. A phenomenological approach to describing atomic ionization and 
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excitation is to introduce an empirical model of energy deposition. Some definition of a charac-
teristic target volume is needed to apply this model. A diverse choice of volumes is used in 
radiobiology, including volumes with diameters <10 nm to represent short DNA segments, and 
of diameters from a few to 10 microns to represent cell nuclei or cells. Energy deposition is the 
sum of energy transfer events due to ionizations and excitations in the volume including those 
from -rays. For large target volumes, energy deposition and energy loss (LET) become approx-
imately the same. Two particles with different Z and identical LET will have different values for E 
and, therefore, different track-widths. The particle with lower Z will have a narrower track-width 
and more localized energy deposition, and in many experiments has been shown to be have a 
higher biological effectiveness than a particle with higher Z. In tissue, however, the higher Z 
nuclei often have a larger range and can traverse more cell layers than the lower Z nuclei at 
the same LET. 
 
The biological effects of different types of particles are usually compared using the ratio of 
doses that leads to an identical effect. This ratio is called the RBE factor. Human data for low-
LET radiation, such as -ray or x-ray exposures leading to increased cancer risk, have been 
studied in the survivors of the atomic-bombs in Japan during World War II, medical patients 
exposed therapeutically to radiation, and nuclear reactor works. However, there are no human 
data for high-LET radiation such as cosmic rays with which to make risk estimates. Therefore, 
RBEs in which the dose in the numerator is that of -rays and the dose in the denominator of a 
nuclear particle being studied, are often used to compare results from biological experiments 
with nuclei created at particle accelerators to the results of epidemiological studies in humans 
exposed to -rays or x rays. RBEs vary widely with the biological endpoint, cell or animal system, 
type of radiation, and doses used in experiments. Traditionally, it has been the role of advisory 
panels to make a subjective judgment of available RBE data to make estimates for human risk. 
Such judgment is used to define a radiation QF. For terrestrial radiation exposures QFs, Q has 
been defined uniquely by LET, Q(LET). Values of Q from 1 to 30 have been used in the past for 
different LET values with Q=1 below 10 keV/m and Q=30 at 100 keV/m used at this time. For 
the more complex radiation environments in space, however, the inaccuracy of LET as a descriptor 
of biological effects has been a long-standing concern. Multiplication of the absorbed dose by 
the QF is referred to as the dose equivalent, H = Q(LET) D, which has units denoted as 1 Sv 
(1 Sv = 100 rem; of 1 mSv = 0.1 rem). For calculating cancer risks, radiation transport codes 
are used to describe the atomic and nuclear collisions that occur inside spacecraft and tissue. 
Resulting particle spectra, averaged over the tissues of concern for cancer risk (eg, lung, 
stomach, colon, bone marrow, etc.), are used to describe the organ dose equivalent, HT.  
 
Because human epidemiological data are predominantly for high dose-rates, methods to 
estimate cancer risks at low dose-rates are needed. The traditional approach to this problem 
has been to estimate a DDREF that reduces the high dose-rate risk estimate for its application 
to low dose and dose-rates. DDREF values from 1.5 to 2.5 have been recommended in the past. 
The use of radiation QFs and DDREFs is a major concern for space radiation risks because 
there are both quantitative and qualitative differences observed in experimental systems of 
cancer risks. It is unclear whether these quantities are sufficiently accurate to form a basis for 
risk estimates. NASA limits astronaut cancer risks to a lifetime REID of 3%. Because long space 
missions are projected to approach and exceed this risk limit, uncertainty analyses of the 
models and methods used to make risk estimates are performed, including values and 
descriptions of HT, Q, and DDREF, which is the focus of this report.
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2. Space Radiation Environments and Transport Models 
 
In this section, we review models of the space radiation environments and organ exposures 
as well as recent developments in their physical characterization in support of human missions. 
To characterize uncertainties in physics models of space radiation the kinetic energy (E), mass 
number (A), and charge number (Z), the dependent fluence distribution F(E,A,Z) behind space-
craft and tissue shielding must be evaluated. The space physics uncertainty for estimating particle 
fluence distributions, F(E,A,Z), at tissues of interest behind shielding has three components: 
space environments(xenv), radiation transport(xtran), and spacecraft and tissue shielding de-
scriptions (xshield). Overall uncertainties contributing to Monte-Carlo trial,  can be written as: 
 
 ( , , ) ( , , )M env tran shieldF E A Z F E A Z x x x   (2.1) 
 
where FM is a baseline model for the fluence distribution at sensitive tissues that is being 
estimated. We review each of these factors in the current section. There are also variability 
considerations to be addressed when considering organ exposures from space radiation. These 
variables include: orientation of crew members inside a vehicle, peculiarities of an individual’s 
size and composition relative to the standard human geometry model used in calculations or 
perhaps phantom measurements, or the exact position in which a crew member’s dosimetry is 
worn. Variability analysis can be made, employing similar methods to those used here for 
uncertainty analysis,32 and considered in future reports. 
 
The types and energies of particle radiation in space are summarized in Figure 2.1. The 
predominant types of particle radiation in the Earth environment are solar flare protons, trapped 
protons and electrons, and GCR. There are temporal variations as well as spatial distributions 
for each radiation source. 
 
 
Figure 2.1.  Schematic of energy ranges of space radiation environments (Wilson et al., 1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Schematic of energy ranges of space radiation environments.33 
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It is convenient to consider the particulate radiation in space as arising from these distinct 
sources as defined by their location: the solar particle radiation, the GCR, and the trapped 
particle radiation. We consider models of GCR and SPE next. The trapped radiation makes no 
contribution outside of low-Earth orbit (LEO) and only a very minor contribution for ISS organ 
exposures because here GCR dominates, representing more than 80% of organ dose equiv-
alents.30,34 The uncertainties in the trapped environments are not described here. 
 
 
2.1 Galactic Cosmic Ray Models 
 
The GCR pervades the near-Earth environment omnidirectionally, and has a range of energies 
that exceeds 10 GeV/u. The GCR consists of fully ionized nuclei because the electrons are 
stripped from the atoms during the acceleration of ions to high energies. Most cosmic rays prob-
ably originate in our galaxy, especially in supernova explosions,35,36 although the highest energy 
components (1017 eV amu-1) may be of extragalactic origin.37 The region outside the solar sys-
tem in the outer part of the galaxy is believed to be filled uniformly with GCR. The GCR nuclei 
constitute approximately one third of the energy density of the interstellar medium and, on a 
galactic scale, form a relativistic gas whose pressure is important to take into account in the dy-
namics of galactic magnetic fields. GCR nuclei are the only direct and measurable sample of 
matter from outside the solar system. It is a unique sample since it includes all of the elements, 
from hydrogen to the actinides. The GCR arriving beyond the Earth magnetic field at the distance 
of the Earth from the sun (1 AU [astronomical unit]) is composed of approximately 98% nuclei 
and approximately 2% electrons and positrons.38 In the energy range 108 to 1010 eV/u, where it 
has its highest intensity, the nuclear component consists roughly of 87% protons, approximately 
12% helium nuclei, and a total of approximately 1% for all heavier nuclei from carbon to the 
actinides.38 
 
Although GCR probably includes every natural element, not all GCR are important for space 
radiation protection purposes. The elemental abundances for species heavier than iron (atomic 
charge number Z > 26) are typically 2 to 4 orders of magnitude smaller than the elemental 
abundance for iron.38 some elements such as the L nuclei (Li, Be, B), F, and several nuclei 
between Si and Fe are quite rare38,39 in the solar system; whereas in the GCR flux, nuclei of 
these elements are present nearly as commonly as those of their neighbors. This shows that the 
GCR originates in the breakup of heavy particles during GCR propagation, which would not be 
present in the GCR at stellar sources.40,41 
 
Experimental studies of high-charge (Z) and energy (E) nuclei (HZE) were made on the 
Pioneer, Voyager, and Ulysses spacecraft to measure the isotopic composition of GCR ele-
ments near Earth and in deep space.40,42-47 In recent years, the Advanced Composition Explorer 
(ACE) has made substantial contributions to our understanding of GCR composition and solar 
modulation.48 Data of the GCR and SPE near Mars were also collected by the Martian Radia-
tion Environment Experiment [MARIE] on the Mars Odyssey spacecraft.49 
 
 
2.1.1 Model of galactic cosmic rays charge and energy spectra 
Badhwar and O’Neill50 have developed a self-consistent solution to the Fokker-Plank equation 
for particle transport in the heliopause that has been fit to available GCR data. This model accu-
rately accounts for solar modulation of each element (hydrogen through nickel) by propagating 
the local interplanetary spectrum (LIS) of each element through the heliosphere by solving the 
Fokker-Planck diffusion, convection, and energy loss boundary value problem. A single value of 
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the deceleration parameter, (t), describes the level of solar cycle modulation and determines 
the GCR energy spectrum for all of the elements at a given distance from the sun. More recently 
O’Neill51 reanalyzed the model using data from ACE. 
 
The energy spectrum of each element at the outer heliosphere boundary is accurately described 
by a power law in total energy per nucleon. O’Neill51 has shown that the ACE data demonstrate 
that inclusion of , particle speed relative to the speed of light, in the simple power allows for 
very accurate agreement with GCR data for all elements down to energies of approximately 
50 MeV/u. 
 
 jlis(E) = j0   / (E + E0)  (2.2) 
 
where jlis(E) is the differential LIS for an element, E is the kinetic energy/nucleon of the particle, 
and E0 is the rest energy/nucleon of the particle (~938 MeV/u). The free parameters are , , and 
j0, which are determined from fits to the ACE data and differ for each element. By using this rep-
resentation, the root mean square (RMS) error for the interstellar GCR composition of less than 
±10% is found for all major GCR components. Because the LIS is constant over very long time 
scales, the largest uncertainty in models of GCR environments is describing solar modulation 
effects. 
 
 
2.1.2 Isotopic composition of galactic cosmic rays 
The GCR model of Badhwar and O’Neill50,51 describes the elemental composition and energy 
spectra of the GCR, including its modulation by the magnetic field of the sun. only the most abun-
dant GCR nucleus is considered for each element in this representation, and other isotopes of 
identical charge are counted as the abundant isotope. However, theoretical models and satellite 
measurements of the GCR also consider the isotopic composition of the GCR and its modification 
through transport in interstellar space where nuclear fragmentation occurs, including estimating 
the primary nuclear composition at stellar sources.40,41,52 The isotopic description of the primary 
GCR may modify the neutron fluence at high energy because, in many cases, neutron-rich 
isotopes make important contributions in the near-Earth GCR. 
 
The approach used by Cucinotta et al39 is to estimate from satellite measurements an energy-
independent isotopic fraction, fj, that is constrained to obey the sum-rule as follows: 
 
 ( , ) ( , , )
j
j jA
Z E f A Z E    (2.3) 
 
where the left side of Eq(2.3) is the elemental spectra from the Badhwar and O’Neill model and 
 j jf 1 . Experimental data on mass distributions of the GCR have included measurements 
on the Pioneer, Voyager, and Ulysses spacecraft. Since secondary fragment production is mod-
ulated by the transit time in the heliosphere, the isotopic fraction is dependent on the position in 
the solar cycle. However, we compared radiation shielding calculations in which the isotopic com-
ponents were modulated over the solar cycle to calculations fixed by the Ulysses estimates near 
solar minimum and found the differences to be small. The Ulysses estimates are then used for 
the isotopic composition for radiation transport calculations, such as with the HZETRN code.39 
 
Table 2.1 shows the LIS parameters and average model RMS in percentage for elements.51 
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Table 2.1. LIS parameters and average model RMS error in % for elements.51 
5BZ 6BElement   0BJ0 1B#ION1 2B#DAYS2 3B% ACE3 4B% CLI4
1 Hydrogen 2.765 0.0 1.2500E-3 1000 7 9.3 12.0
2 Helium 3.053 0.0 4.0000E-5 1000 21 9.9 11.3
3 Lithium 2.704 0.887 2.8000E-7 N/A 365 5.6 5.9
4 Beryllium 2.776 1.196 1.4000E-7 N/A 365 8.9 7.5
5 Boron 3.040 0.369 1.8000E-7 1000 48 7.6 9.5
6 Carbon 2.835 0.0 1.3000E-6 2000 21 4.9 7.8
7 Nitrogen 2.973 0.250 2.2500E-7 1000 35 6.8 8.7
8 Oxygen 2.800 0.0 1.4000E-6 2000 18 4.5 7.3
9 Fluorine 2.882 0.816 2.2000E-8 200 74 11.6 13.6
10 Neon 2.823 0.0 1.8700E-7 1000 43 5.9 8.2
11 Sodium 2.803 0.0 3.8094E-8 500 79 6.2 7.5
12 Magnesium 2.826 0.0 2.4841E-7 1000 28 5.5 7.4
13 Aluminum 2.903 0.472 3.3718E-8 300 49 8.3 9.7
14 Silicon 2.823 0.0 1.8340E-7 1000 32 5.3 7.1
15 Phosphorus 2.991 1.399 5.3011E-9 100 95 12.5 14.2
16 Sulfur 2.838 0.690 3.7502E-8 300 54 8.7 9.5
17 Chlorine 3.041 1.929 5.0000E-9 100 101 16.8 16.7
18 Argon 2.918 1.291 1.3000E-8 100 43 13.0 11.6
19 Potassium 3.169 1.827 5.8000E-9 100 52 15.0 16.7
20 Calcium 2.910 0.996 2.8000E-8 200 36 9.5 10.3
21 Scandium 2.926 1.267 5.8351E-9 100 73 13.0 12.3
22 Titanium 2.790 0.532 2.4982E-8 200 45 10.8 11.4
23 Vanadium 3.028 0.617 5.6000E-9 100 48 13.1 13.5
24 Chromium 2.945 0.582 1.4400E-8 200 43 10.2 11.1
25 Manganese 2.794 0.0 1.2000E-8 200 66 11.7 12.5
26 Iron 2.770 0.0 1.4000E-7 1000 32 6.1 6.7
27 Cobalt 2.764 0.0 9.4052E-10 30 94 22.5 21.5
28 Nickel 2.712 0.0 8.3950E-9 100 64 13.7 14.2
1Minimum number of ions per channel collected to define the interval data point. 
2Average collection time. 
3Average model – ACE % error from solar minimum (1997.6) to solar maximum (2000.9) using the value of 
ACE(t) determined from the ACE cosmic ray isotope spectrometer (CRIS) oxygen fit. 
4Average model – ACE error with the value of CLI(t) determined from the CLIMAX neutron monitor used 
instead of that from fit to Oxygen. 
 
 
For the Z=1 and Z=2 ions, the following empirical formula can be used to estimate the primary 
(near-Earth) 2H and 3He spectra:39 
 
  23 4( ) 0.0764 0.097exp[ 0.5(ln( /1660) /1.306) ] ( )He HeE E E     (2.4a) 
 2 4( ) 0.2 ( )H HeE E   (2.4b) 
  
where 3He(E) and 2H(E) are subtracted from the Badhwar and O’Neill model spectra for 4He(E) 
and 1H(E), respectively. Primary 3H and neutron spectra are not considered because of their 
short half-lives. Examples of the GCR energy spectra for hydrogen and helium are shown in 
Figure-2.2a and for the isotopes of Ne, Si, and Fe at solar minimum in Figure-2.2b. 
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Figure 2.2.a. Energy spectra near solar minimum (=428 MV) and solar maximum (=1050 
MV) for primary GCR light ions. 
 
 
Figure 2.2b. Energy spectra near solar minimum (=428 MV) for primary GCR isotopes of Ne, 
Si, and Fe. 
 
 
2.1.3 Solar modulation of the galactic cosmic rays 
The intensity of the GCR flux varies over the approximately 11-y solar cycle due to changes in 
the interplanetary plasma that originates in the expanding solar corona.50,53 The intensity and 
energy of GCR entering the heliosphere is lowered as the rays are scattered by irregularities in 
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the interplanetary magnetic field embedded in the solar wind. Parker52 showed that the steady-
state, spherically symmetric Fokker-Planck equation accurately accounts for diffusion, convec-
tion, and adiabatic deceleration of these particles. The Fokker-Planck equation is readily solved 
numerically to propagate the LIS for each element to a given radius from the sun. A single diffu-
sion coefficient, Eq(2.5), was used by Badhwar and O’Neill as well as by others to describe the 
effect of the magnetic field of the sun on particles entering the heliosphere. 
 
 k(r,t)=(k0/VSW)P[1+(r/r0)2]/(t)) (2.5) 
 
where VSW is the constant solar wind speed (400 km/s), r is distance from the sun in AU, t is time 
in years, k0 is constant,  is particle speed relative to the speed of light, P is particle rigidity in MV, 
and (t) is solar modulation parameter in MV. 
 
In the Badhwar and O’Neill model the effect of magnetic field, including disturbances and the 
radial gradient, is described by the diffusion coefficient. An inverse square law (for 1/k(r, t)) for a 
spherical cavity is assumed. To fit each of the various elements from hydrogen to nickel with the 
simple analytical LIS form, the modulation cavity scaling parameter r0 was set to be 4.0 AU by 
O’Neill.51 The physical significance of the 4 AU cavity scaling is not yet clear; the actual boundary 
of the cavity was set at 50 AU. The single-fit parameter that determines the level of solar modu-
lation is k0/(t). O’Neill51 and others set k0 to a constant (k0  = 1.61021 cm2/s) and then deter-
mined the value of (t) that fits the measured spectra. The (t) is related to the energy and 
rigidity required for interstellar particles to propagate through the heliosphere to the radius 
of interest. 
 
The modulation parameter at solar minimum or maximum varies to some extent for each solar 
cycle.54 A worst-case solar minimum, based on the 1977 minima, has been widely used for 
shielding design studies. The most recent solar minima (2009) was reported as slightly deeper 
with a modulation parameter of ~410 MV compared to 428 MV for 1977. For solar maximum a 
wide range of modulation parameters values is observed for each cycle; and, more importantly, 
the occurrence of large SPEs is not well predicted relative to the position in the solar cycle as 
described below. Therefore, a modulation parameter of about 1100 MV provides a reasonable 
GCR background to investigate SPE risks. 
 
Defining a worst-case GCR environment for mission design studies entails several 
considerations. We note that most NASA design studies have used a GCR environment 
representing the 1977 solar minimum to correspond to the worst case. Each solar cycle will 
have a distinct solar modulation and will depend on the polarity of the solar field, which itself 
switches from positive to negative polarity on a 22-y cycle. Negative polarity cycles are more likely 
to show deeper solar minima (smaller modulation parameters). As mission length increases, using 
a single-modulation parameter would overestimate the conditions at solar minimum. Figure 2.3 
shows the GCR modulation averaged over increasing mission length, which describes the 
impact of using a fixed-modulation parameter.55 On the one hand, solar modulation over recent 
cycles does not reflect historical periods. Castagnoli et al56 made estimates based on a sunspot 
number that suggests much deeper minima in past centuries, as shown in Figure 2.4. (Note that 
there is a shift in the modulation parameter of about 70 MV due to the method of estimate in the 
Catagnoli approach compared to that of Badhwar and O’Neill). On the other hand, we note that 
no error bars are given for such estimates, and, more importantly, the modulation is for lower 
energy particles that have smaller penetration depth in shielding and tissue. The effect of 
increased modulation beyond that of the 1977 solar minimum decreases with increasing 
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shielding depth, perhaps representing a 10% increase in GCR organ dose equivalents when 
comparing 428 MV to, say, 350 MV based on our earlier analysis.57 
 
 
Figure 2.3. The average GCR deceleration (modulation) parameter for increasing mission length, 
as if a mission started at any time in a solar cycle and lasted for the indicated period. 
 
 
Figure 2.4. A reconstruction of the GCR solar modulation parameter described  by Castagnoli et 
al56 (2003). Filled circles are experimental values calculated from the GCR spectra measured with 
balloons and spacecraft. 
 
 
2.2 Solar Particle Events 
 
Radiation protection from SPEs can be divided into the pre-mission design phase and real-
time responses during the mission (not discussed herein). The SPE frequency and total particle 
fluence, energy spectra, and duration must be described for mission design assessments. A solar 
flare is an intense local brightening on the face of the sun close to a sunspot. The solar abnor-
mality results in an alteration of the general outflow of solar plasma at moderate energies and 
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local solar magnetic fields carried by that plasma. An important source for SPEs is energetic 
ions accelerated to higher energies by interplanetary shocks generated by coronal mass ejec-
tions (CMEs).5 As solar plasma envelops the Earth, the magnetic screening effects inherent in 
plasmas act to shield the Earth from the GCR (this is known as a Forbush decrease.58 In fact, 
for most solar events, ISS crew doses are lowered by the Forbush effect, which leads to a de-
crease in GCR doses that offsets any increase in organ dose equivalents from solar protons. 
 
For solar cycles 19-21 (1955-1986), the list of major SPEs and the proton fluences have 
been assembled by Shea and Smart,59 who placed all available flux and fluence data in a use-
ful continuous database. An SPE list and the geostationary operational environmental satellite 
(GOES) measurements of the 5-minute average integral proton flux (from 1986 to the present 
[solar cycles 22 and 23]) can be obtained through direct access to the National Oceanographic 
and Atmospheric Agency (NOAA) National Geophysical Data Center (NGDC). Table 2.2 lists 
the large SPEs in the past five solar cycles for which the omnidirectional proton fluence with 
energy above 30 MeV, Φ30, exceeded 109 protons/cm2. Only 13 events with at least this size 
occurred in nearly 60 y of observation. As described below, this probability is similar to the 
probability for all events dating back to the 15th century.60 Between the years 1561 and 1950, 
71 SPEs with 30> 2109 protons cm-2 (Ref. 61) were also identified from impulsive nitrate 
enhancements in polar ice cores. About 40 other SPEs with lower cutoff of 108 protons/cm2 
occurred in the same time period. As a rule of thumb, events of size below a 30-MeV fluence of 
108 protons per cm2 would present organ doses less than about 0.01 Gy for nominal shielding 
(even smaller doses in LEO) and, therefore, have only small health consequences to astronauts. 
We show the relationship between the SPE event date and size with the GCR solar modulation 
parameter in Figure 2.5. It has been demonstrated that an increase in SPE occurrence is asso-
ciated with increasing solar activity; however, no recognizable pattern has been identified. Large 
events have definitely occurred during solar active years, but these events have not occurred 
exactly during months of solar maximal activity. Moreover, they are more likely to take place in 
the ascending or declining phases of the solar cycle.62 This sporadic behavior of SPE occur-
rence is a major operational problem in planning for missions to the moon and Mars. 
 
 
Table 2.2. Summary of 30 > 109 protons/cm2 values for the largest SPEs during solar cycles 19 
through 23. 
Solar Cycle SPE 30, protons/cm2
19 11/12/1960 9.00 x 109 
20 8/2/1972 5.00 x 109 
22 10/19/1989 4.23 x 109 
23 7/14/2000 3.74 x 109 
23 10/26/2003 3.25 x 109 
23 11/4/2001 2.92 x 109 
19 7/10/1959 2.30 x 109 
23 11/8/2000 2.27 x 109 
22 3/23/1991 1.74 x 109 
22 8/12/1989 1.51 x 109 
22 9/29/1989 1.35 x 109 
23 1/16/2005 1.04 x 109 
19 2/23/1956 1.00 x 109 
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2.2.1 Hazard function for solar particle event occurrence 
More than 90% of the SPEs that occurred in solar cycles 19-23 would pose a small health risk, 
these can nevertheless result in significant mission disruption. This suggests that a probabilistic 
risk assessment (PRA) model is needed for mission design. Kim et al60 have used survival anal-
ysis to develop a model of SPE size and frequency for a standard solar cycle that provides such 
a PRA tool. The model considers all SPEs for solar cycles 19-23 (1955-1986) and the ice-core 
nitrate estimates of large events since the 15th century, and assembles the available flux and 
fluence data in the form of a continuous database (Figure 2.5). A total of 370 SPEs were identi-
fied during solar cycles 19–23. Events were found to be statistically differ significantly in overall 
distribution of 30 from cycle to cycle. However, fluence data of 30 were combined over all five 
cycles to estimate an overall probability distribution of an average cycle. Figure 2.6 shows sam-
ple cumulative tail probabilities of 30 for cycles 19-23 and the overall cumulative tail probability 
(thick line). Also included in Figure 2.6 are the probabilities of the impulsive nitrate events of 71 
SPEs with 30 > 2109 protons cm-2 (Ref. 61) with and without seasonal correction, and they do 
not differ significantly from the modern sets of large 30 data.60 Table 2.3 lists all of the available 
database of SPEs for the omnidirectional proton fluence of E, where E = 10, 30, 50, 60, or 100 
MeV. While the expected frequency of SPEs is strongly influenced by solar modulation, the SPE 
occurrences themselves are chaotic in nature. Figure 2.7 shows the onset times of all SPEs in 
solar cycles 19-23. 
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Figure 2.5. Historical data on fluence of protons above 30 MeV per cm2 (F(>30 MeV) from large 
SPEs relative to solar modulation parameter (). Only events with >30 MeV >108 particles per cm2 
are shown in the lower graph. 
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Figure 2.6. Probability (P) of an SPE event exceeding the displayed threshold 30. 
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Figure 2.7. The onset dates of SPEs occurring between January 1, 1956 and December 31, 2007. 
 
 
Observations over solar cycles 19-23 were represented by a hazard function for the probability 
of SPE occurrence for a given mission length as a function of time within a cycle. Because there 
are typically more SPEs near the middle of cycles than there are near the beginning and end of 
cycles, the hazard function should take on relatively low values at the ends of each solar cycle 
and reach a peak somewhere near the middle of each solar cycle. After studying different 
models for the hazard function and assessing goodness of fit, the functional form best 
explaining all SPEs was found as:60 
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for a “typical” nonspecific cycle of 4000 days duration (0 < t < 4000), where 0, K, p, and q are 
parameters to be estimated. Resulting maximum-likelihood parameter estimates were 0 = 
19.52, K = 55.89, p = 4.073 and q = 4.820. From Eq(2.6), it can also be shown that , the time 
of peak hazard, is 4000(p – 1)/(p + q –2) days into a cycle. For the observed data,  was 
estimated at 1783 days. 
 
 
Table 2.3. Published databases of recorded SPEs. 
Solar Cycle # of SPE # of Day Period ΦE 
Cycle 23 92 4262 5/1/1996- 12/31/2007* 10,30,50,60,100 (NGDC 2010) 
Cycle 22 77 3742 2/1/1986- 4/30/1996 10,30,50,60,100 
(a) 
Cycle 21 70 3653 2/1/1976- 1/31/1986 10,30 
(b) 
Cycle 20 63 4140 10/1/1964- 1/31/1976 10,30 
(b) and 10,30,60 (c) 
Cycle 19 68 3895 2/1/1954- 9/30/1964 10,30,100 
(b) and 10,30 (d) 
Impulsive 
Nitrate Events 71 390 y 1561 – 1950 30 
(e) 
*The end of cycle 23 estimated.59,61,63-65 
 
 
The expected number of events for a mission in a time interval (t1, t2), N(t1, t2) were estimated 
more accurately by using the basic properties of a Poisson process and the estimated t) at 
time t of a solar cycle than could be obtained by simple counting of cases in the SPE data oc-
curring in a given time period (t1, t2). For conservatism, missions can be assumed to take place 
centered on the time of greatest hazard,  = 1783 days into a solar cycle, so that t1 = 1783 – d/2 
and t2 = 1783  + d/2, where d is mission length (days). 
 
 
2.2.2 Representation of solar particle event energy distribution 
Wilson et al66 studied typical spacecraft shielding to show that protons with energies up to about 
200 MeV or more are needed to fully characterize SPE organ doses. Unfortunately, only fluence 
at 100 MeV or below is reported for many historical events, which leads to inaccuracies in trans-
port code predictions of SPE risks. Common functional forms to represent spectra are exponential 
or power law functions in rigidity, the Weibull function, and more recently a double power-law for 
studying high-energy SPEs where ground level enhancements (GLEs) were observed with neutron 
monitors (the so-called Band function67,68). Figure 2.8 compares two of the extreme examples of 
differences that occur in extrapolating energies beyond measurements with different functional 
forms. The best fit for the functional forms is shown in the upper panel, and predictions of Effec-
tive doses vs. shielding depth are shown in the lower panels. Models are smaller for many other 
SPEs differences between energy spectra; however, the comparison of Figure 2.8 shows the 
importance of accurate determination of proton energy spectra from major SPEs. 
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Figure 2.8. Comparison of exponential, Weibull, or Band functions fit to proton fluence measurements for the 
November 1960 and August 1972 events (upper panels) and the resulting predictions of Effective doses (lower 
panels). 
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Figure 2.9. (Left panel) Simulated distribution of integral proton fluence above 30 MeV, 30 as a function of 
increasing mission length. (Right panel) The blood-forming organ (BFO) dose behind 5 g/cm2 aluminum shields 
from the 34 largest SPEs in the Space Age ranked by 30-MeV proton integral fluence, F>30 MeV calculated by the 
BRYTRN code.60 The black circles show the doses from each of the 34 events. The error bands show the 90% CLs 
due to the variability of the proton energy spectra of the 34 events. The red dashed line shows the NASA 30-day 
dose limit for the BFO. 
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A recognizable pattern of event size distribution during the past 5 solar cycles has not been iden-
tified, and the event size 30 is independent of elapsed time between two consecutive events.60 
Therefore, the individual event size 30 for each SPE occurrence must be independent of the 
expected number of events for a given mission duration, N(d). For the randomness of individual 
event size, 30 was simulated with a random draw from a gamma distribution. An empirical dis-
tribution of total fluence 30 ranging from 5th to 95th percentile is shown in Figure 2.9 for a range 
of potential mission lengths. With the expected number of events, which took into account the 
randomness of SPE occurrences, total event sizes of 30 in a mission period have been simulated 
ranging from its 5th to 95th percentile. Intense SPEs were considered as potentially debilitating 
events. Also shown in Fig. 2.9 are the resulting BFO doses taking into account the actual proton 
spectra for the 34 largest events in cycles 19 through 23. Very few SPEs would exceed the 
NASA 30-day limit for acute risks with minimal shielding, leaving the residual cancer risks the 
major concern. In assessing radiation risk from SPEs during a given mission period, the simu-
lation illustrates that risk assessors must take into account not only the randomness of SPE 
occurrences and each event size of 30, but also the variation of energy spectra for the SPEs, 
because the detailed SPE energy spectrum is the important parameter. 
 
 
2.3 Physics Model Description of Organ Exposures 
 
Descriptions of the fluence for each particle type and energy at each tissue of interest must 
be characterized before risk projections can be made. Fortunately, radiation transport codes 
validated by extensive measurements have been combined with accurate descriptions of the 
space environment to make accurate predictions of exposures to sensitive tissue sites behind 
spacecraft shielding or on planetary surfaces. Radiation transport codes were studied extensively 
in the past, and currently there are only minor scientific questions that lead to errors in the assess-
ment of space radiation environments. Boltzmann equation solvers or Monte-Carlo algorithms 
can be used for this purpose when they are combined with models of the space environment 
as well as spacecraft and organ shielding. Monte-Carlo codes require long computational times 
to describe spacecraft with thousands of parts. Complex geometries are typically handled with 
simplifications in the representation by combining parts and material composition, thus negating 
any advantages compared to the one-dimensional transport methods that could be found by 
treatment of detailed three-dimensional effects. Boltzmann equation solvers such as the HZETRN 
code69 are able to use ray-tracing techniques to consider a very detailed geometry in a one-
dimensional approach that is adequate for fast ions, especially for the omnidirectional radiation 
sources in space. The relative contribution from low-energy charged ions that deviate from the 
straight-ahead approximation can be solved by quadratures, leaving only the angular deflections 
of neutrons and intermediate energy light ions with sufficient energy to produce nuclear reactions 
to be addressed when considering a deviation from one-dimensional transport. However, their 
relative contribution to a GCR space transport problem may be small, reducing the significance 
of any errors due to a one-dimensional approach. 
 
The underlying physical processes described by transport codes are atomic energy loss, 
straggling, and nuclear collisions. For describing atomic processes, the LET (stopping power), 
range, and energy straggling parameters are known to ±5% accuracy.33 A wide range of nuclear 
interactions occurs in GCR transport leading to a diverse range of secondary particles as described 
in Table 2.4.5,70 The nuclear cross sections needed for space radiation transport include nuclear 
absorption, heavy ion fragmentation, light ion scattering, and particle production cross sections. 
Nuclear absorption cross sections are well described by current models with accuracies of ±5% 
for most collision pairs of interest.71 Fragmentation cross sections for heavy fragments are known 
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to about a ±25% accuracy39,72 with most of the error localized to a nearby to a fragment with a 
similar A, Z, and kinetic energy, thus reducing the impact of errors in estimating biological 
effects. 
 
Table 2.4. Reaction products in nuclear collisions important in study of space 
radiation studies. 
Type1 Secondary Mechanism Comment 
N-A, A-A Nucleon Knockout, 
cascade 
Low LET, Large 
R 
N-A, A-A Nucleon Evaporation Medium or high 
LET, small R 
N-A, A-A Light ion KO, 
Evaporation, 
Coalescence 
Low to medium 
LET, small to 
large R 
N-A Heavy ion Elastic or TF Small R, High 
LET 
A-A Heavy ion PF Large R 
A-A Heavy ion TF Small R, High 
LET 
N-A, A-A Meson, -ray, 
e-, etc. 
Inelastic NN  Large R, low 
LET 
1N is the nucleon (proton or neutron), A is nucleus, PF is projectile fragment, TF is 
target fragment, and R is range. 
 
For lighter secondaries (A<5), details on the energy spectra and angular distributions are also 
needed, which have been extensively studied since the 1950s and well described by the various 
Monte-Carlo transport models. However, cross-section data are sparse for some projection-target 
combinations, especially above 1,000 MeV/u, and improvements in how differential cross 
sections are represented in transport codes is required. 
 
While three-dimensional aspects of transport from angular scattering are a small correction for 
high-energy ions, they should be considered for neutrons and other light0mass ions. Estimates 
of neutron contributions to organ dose equivalents in space from as little as 5% to as much as 50% 
have appeared in the literature. Neutrons are secondary radiation produced largely by cosmic 
ray protons and helium particles because of their larger abundances compared to heavy ions, 
and tertiary or higher-order effects between neutrons and charged particles are frequent behind 
shielding. Differences in interpretation of neutron contributions often arise due to differential mea-
surement techniques or scoring approaches in transport codes. However, the consistent agree-
ment between physical dosimetry and biological dosimetry from space shuttle and ISS crew30 
as well as the HZETRN code reported in the past73 suggests that the contributions of neutrons 
are reasonably well understood. This topic is discussed in more detail below. Mesons, e-, and 
-rays are also secondary radiation that are not always considered in transport models. However, 
because they are low-LET radiation with small QFs, and exploration spacecraft with current 
launch capabilities will be mass constrained with average shielding of approximately 10 g/cm2, 
their impact on overall risks should be small. 
 
Three approaches to assessing uncertainties in transport models describing exposures to 
sensitive tissue sites behind spacecraft shielding from space radiation exist: 
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1) Comparison of ground-based measurements for defined beams on thin and thick targets 
for different material compositions and amounts 
2) Intercomparison of radiation transport codes using matched configurations and 
environments 
3) Comparison of transport codes to space flight measurements74 
 
We summarize recent results in each of these areas next. 
 
 
2.3.1 Comparisons of ground-based measurements to transport codes 
Extensive thin target measurements and theoretical calculations were made in the past to 
describe proton-, neutron-, and heavy-ion-induced nuclear collisions. NCRP Report No. 1535 
reviews this information, including experimental data for cross sections and theoretical reaction 
models. Several important data sets on heavy-ion interactions and neutron cross sections have 
occurred since this report further improves databases for transport code calculations. We there-
fore do not review thin target data accuracies in this report. Instead, we will discuss recent thick 
target measurements, which further document the accuracy of radiation transport code models. 
The NSRL has made extensive measurements for a variety of HZE nuclei of the Bragg ioniza-
tion curve in polyethylene or aluminum shielding. A recently developed Monte-Carlo-based 
transport code, the GCR Event-based Risk Model (GERMCode), uses the quantum multiple 
scattering fragmentation model (QMSFRG) of nuclear interaction database, and the range-
energy subroutines denoted as RMAT from HZETRN to describe the NSRL beam line for 
radiobiology applications.70 Figure 2.10 compares the NSRL measurements with the 
GERMCode for 28Si, 37Cl, 48Ti, and 56Fe nuclei. Excellent agreement between the model and the 
measurements is seen at all depths, including past the Bragg peak or primary ion range to 
which only secondary radiation contributes. In Figure 2.11 we show comparisons of the 
GERMCode measurements by Zeitlin et al75 to elemental distributions of secondary fragments 
at two depths in polyethylene shielding for 1-GeV/u Fe beams. Agreement between theory and 
measurements is typically within ±20%. Energy loss in silicon detectors has been measured 
behind graphite-epoxy. Data were compared to calculations of the GRNTRN code,76 which has 
many important overlaps with the HZETRN code. The results in Figure 2.12 show good 
agreement between code and measurement.77 
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Figure 2.10. Comparisons of the GERMCode70 to NSRL measurements (www.bnl.gov) for 
depth-dose in polyethylene for nearly monoenergetic 56Fe(0.59 GeV/u),  48Ti (0.98 GeV/u), 
37Cl(0.5 GeV/u), and 28Si(0.403 GeV/u) nuclei. 
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Figure 2.11. Comparison of the GERMcode with QMSFRG nuclear cross-section model to thick 
target data from Zeitlin et al75 for fragmentation of 1-GeV/u 56Fe beam at two depths of 
polyethylene. 
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Figure 2.12. Comparisons of GRNTRN code to measurements for the summed energy loss in a 
silicon detector from fragments of a 1053-MeV/u 56Fe beam behind 10 g/cm2 graphite-epoxy 
(51%/49%) (reproduced from Walker et al).77 
 
2.3.2 Intercomparisons of transport codes 
Recently Wilson (private communications, 2009) has organized intercomparisons of the 
HZETRN code to several Monte-Carlo codes for well-defined shielding configurations and 
identical source energy spectra for GCR and SPEs. The Monte-Carlo codes considered were 
HETC-HEDS,78 FLUKA,79 and PHITS.80 These results, as summarized in both Figure 2.13 and 
Figure 2.14, are in very good agreement for depth-dose, depth-dose-equivalent, and light-
particle energy spectra. Some of the comparisons on organ doses did not consider all of the 
contributions from target fragments that introduce minor differences. These comparisons show 
that overall agreement between transport code predictions, when compared with identical 
source spectra and shielding configuration, is quite high. A possible minor discrepancy is the 
mesons, electrons, and -rays that may contribute 5% to 10% of the absorbed dose from GCR 
behind ISS levels of shielding, and 1% to 3% of the dose equivalent because of their small QFs 
or RBEs compared to HZE nuclei, or to stopping protons and helium nuclei. These processes 
have not been fully integrated into all versions of the various existing codes, and should be 
considered for deep-shielding predictions (>50 g/cm2). 
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Figure 2.13. Intercomparison of several transport codes for SPE depth dose and depth dose 
equivalent for aluminum and iron shielding (J Wilson, private communication). 
 
 
Figure 2.14. Intercomparison of secondary light particle spectra calculated with several space 
radiation transport codes for 20-g/cm2 aluminum shielding (J. Wilson, private communication). 
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2.3.3 Space flight measurement comparisons to transport codes 
Organ doses and dose equivalents can be estimated from space radiation transport models 
assuming they were made up of the following components: the GCR, solar particles, or trapped 
protons including their secondary components (protons, neutrons, etc.). Shielding amounts are 
described by the areal density, x, in units of g/cm2, which represents the physical thickness, t in 
units of cm, times the material density, , in units of g/cm3, or x=t. The GCR contribution varies 
slowly with the amount of shielding, but the SPE or trapped proton dose decreases rapidly with 
increasing depth-making small contributions relative to GCR to the Effective dose at large shield-
ing depth (>20 g/cm2). We used the HZETRN code with nuclear interaction cross sections gen-
erated by the QMSFRG model to make various predictions to space flight data. The QMSFRG 
model provides an accurate database with an agreement of over 85% of the measured heavy 
ion fragmentation cross sections <±25% error,39,72 and a smaller error for the total absorption 
cross sections <±5% error. A two-dimensional matrix, corresponding to the vehicle and tissue 
shielding thicknesses, can be computed for the flux of ion j of energy, E (units of MeV/u) for the 
thickness x (units of g/cm2) in spacecraft shielding, and thickness z (units of g/cm2) of tissue 
denoted as j(E,x,z) (units of ions per cm2 per MeV/u per mission time). The absorbed dose 
and dose equivalent are evaluated by: 
 
 ( , ) ( , , ) ( )jjjD x z dE E x z S E    (2.7) 
 
 ( , ) ( , , ) ( ) ( ( ))j jj jjH x z dE E x z S E Q S E    (2.8) 
 
where Sj(E) is the ion LET, which depends on kinetic energy and mass and charge of nuclei. A 
unit conversion coefficient is ignored in Eq(2.7) and Eq(2.8), and throughout this report in similar 
equations. Organ doses for a tissue, T, are evaluated using computerized male and female 
geometry models and averaged over shielding at a spacecraft location, n, as  
 
 ( ) ( , , ) ( ) ( ( ))jT x z j jz
j x
H n a b dE E x z S E Q S E      (2.9) 
 
where ax and bz are shielding fractions of equal solid angle intervals from a shielding model for 
the spacecraft or organ. The so-called “point” dose, Dpt, is defined by Eq(2.7) for z=0. In radiation 
protection practices, the Effective dose25,26 is defined as an average of organ dose equivalents 
using tissue weighting factors, wT, as 
 
 ET =  wT  HT (2.10) 
 
The tissue weights, which are gender-averaged, include contributions for the gonads for 
hereditary risk. Contributions from largely nonlethal cancers such as nonmelanoma skin and 
thyroid cancers are included in the ICRP definition. Because of the large attenuation of SPE 
doses at deep-seated organs compared to skin, thyroid, and gonad organ dose equiva-
lents, SPE Effective doses can be dominated by such doses such that the use of Effective 
dose may lead to a substantial overestimation of cancer mortality risk. The usage of 
gender and age averaging for tissue weights leads to further inaccuracies, and can be 
avoided as described later in this report. 
 
Table 2.5 compares the physical dosimetry to transport code assessments of point dose and 
dose equivalent inside the shuttle orbiter for a multitude of missions. Very good agreement is 
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found. Phantom torsos comprised of realistic distributions of human tissue-equivalent materials 
have been flown on several space shuttle missions, as reported earlier by Badhwar et al81 for 
organ-absorbed doses and Yasuda et al82 for organ dose equivalents estimated using a com-
bined thermoluminescent dosimeter (TLD) and CR-39 plastic track detector methodology. Table 
2.6a shows absolute predictions of the HZETRN/QMSFRG model (without any scaling to dosim-
etry) to the measurements of Yasuda et al82 on space shuttle mission STS-91, which flew in a 
51.6-deg inclination orbit to the Russian Mir space station on a similar orbit as was flown by ISS. 
The comparisons show excellent agreement between measurements and models. The NASA 
phantom torso experiment that was flown on STS-91 was reflown on ISS Increment 2 in 2001. 
This experiment included several small, active silicon detectors located at critical organs to pro-
vide time-dependent dose data. The correlation of the time-dependent data to the ISS trajectory 
allows for separation of individual contributions from trapped protons and GCR to organ doses. 
Table 2.6b shows absolute comparison of the HZETRN/QMSFRG results (without scaling) to 
the measurements, indicating very good agreement.73 The results show that the ratio of the 
GCR to trapped proton absorbed dose is about 1.5:1. Average QFs without tissue shielding for 
GCR (~3.5) are more than twice as high that of the trapped protons (~1.5);34,73 these results 
therefore support the conclusion that organ dose equivalents for ISS missions and many space 
shuttle missions are predominantly from GCR (>80%). The resulting transport code predictions 
have been used to estimate Effective doses for all space missions (through 2008)73 as shown in 
Figure 2.15. More recent phantom data have been collected by Reitz et al.83 
 
 
Table 2.5. Comparison of HZETRN code to space flight measurements of absorbed dose or dose equivalent behind 
various shielding amounts and several space missions. 
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Table 2.6.a. Comparison of measured organ dose equivalent for STS-91 mission by Yasuda et al.82 using combined 
CR-39/TLD method to predictions from the HZETRN/QMSFRG space transport model. 
 Organ Dose Equivalent, mSv 
Tissue Measured HZETRN/QMSFRG Difference (%) 
Skin 4.5 +0.05 4.7 4.4 
Thyroid 4.0 +0.21 4.0 0 
Bone surface 5.2 +0.22 4.0 -23.1 
Esophagus 3.4 +0.49 3.7 8.8 
Lung 4.4 +0.76 3.8 -13.6 
Stomach 4.3 +0.94 3.6 -16.3 
Liver 4.0 +0.51 3.7 -7.5 
Bone marrow 3.4 +0.40 3.9 14.7 
Colon 3.6 +0.42 3.9 8.3 
Bladder 3.6 +0.24 3.5 -2.8 
Gonad 4.7 +0.71 3.9 -17.0 
Chest 4.5 +0.11 4.5 0 
Remainder 4.0 +0.57 4.0 0 
Effective dose 4.1 +0.22 3.9 -4.9 
 
Table 2.6.b. Comparison of small active dosimetry data from ISS Increment 2 phantom torso (for July-August 
2001) to predictions from the HZETRN/QMSFRG model.73 
Organ Trapped, mGy/d GCR, mGy/d Total Dose, mGy/d Difference 
(%)  Expt. Model Expt. Model Expt. Model 
Brain 0.051 0.066 0.076 0.077 0.127 0.143 13.3 
Thyroid 0.062 0.072 0.074 0.077 0.136 0.148 9.4 
Heart 0.054 0.061 0.075 0.076 0.129 0.137 6.7 
Stomach 0.050 0.057 0.076 0.077 0.126 0.133 5.5 
Colon 0.055 0.056 0.073 0.076 0.128 0.131 2.5 
 
 
Astronaut, i
0 100 200 300 400 500 600 700 800
M
is
si
on
 D
os
e
0.1
1
10
100
1000
Badge Dose, mGy
Effective Dose, mSv
Biodosimetry, mGy-Eq Skylab, Mir and ISS
Mercury
Apollo and Shuttle
Gemini
Hubble Missions
 
Figure 2.15. Summary of mission badge dose, Effective dose, and population average biological 
dose equivalent for astronauts on all NASA space missions, including Mercury, Gemini, Apollo, 
Skylab, Apollo-Soyuz, space shuttle, NASA-Mir and ISS missions.73 
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Energy spectra for light particles measured with particle hodoscopes are in good agreement 
with the HZETRN code as shown in Figure 2.16.84 Measurements of heavy-ion spectra require 
a large area detector, and very few such measurements have been made in human-rated vehi-
cles because of mass requirements. Other space flight measurements of LET or microdosimetry 
measurements of lineal energy spectra using tissue-equivalent proportional counters (TEPCs) 
have also been shown to be in good agreement with transport codes.85,86 Agreement is 
obviously improved when models of detector response are used to make such comparisons. 
Corrections of measurements often involve model-dependent assumptions, such as the 
conversion from silicon to tissue-equivalent LET spectra in which the conversion factor is 
dependent on energy and charge number. Also, the combined TLD plus CR-39 method for 
estimating dose equivalent82 involves corrections on the high-LET sensitivity of TLDs and the 
low-LET sensitivity of CR-39. Comparisons of codes to TEPCs data requires the conversion of 
energy and charge spectra into lineal energy spectra, which differ substantially from LET 
spectra. Comparisons of models to measurements of neutron spectra on the Russian Mir space 
station were in good agreement (Fig. 2.17). The major fraction of the neutron dose is for 
energies >10 MeV, with a smaller fraction <10 MeV. At these higher energies, secondary recoil 
nuclei produced by neutrons are very similar in Z and E to those produced by high-energy 
protons. Therefore, at equal fluence, high-energy protons are more biologically effective than 
neutrons of the same energy because of the charge carried by protons. 
 
 
Figure 2.16. Comparisons of proton (Panel A) and Deuteron (Panel B) energy distributions from 
GCR on the STS-48 mission to HZETRN results.84 The dash line and solid line are without or with 
cluster knockouts, respectively. 
 
 
Figure 2.17. Comparisons of transport codes to ISS neutron spectra measurements.87 
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2.3.4 Predictions for exploration missions 
We show the organ doses for GCR at solar minimum and the 1972 SPE for depths of 5 and 
20 g/cm2 diameter in aluminum spheres In Table 2.7. The 1972 solar event is represented by 
the protons fluence spectrum derived by King.65 SPE spectra are greatly attenuated with shield-
ing and show important variations in doses between tissue types, while GCR produces only a 
modest variation between organs at both depths. The point doses shown correspond to the dose 
without tissue shielding. Values of point doses are well above organ doses for SPEs and similar 
to organ doses for GCR. Doses to the skin can be several times higher than those of the internal 
organs for SPEs.88 Average skin doses do not properly describe the risk to specific skin loci, 
which are highly variable. Annual GCR Effective doses are calculated in Figure 2.18 for various 
charge groups inside a spacecraft of 50g/cm2 aluminum from GCR at solar minimum in inter-
planetary space (blue bars). These heavy nuclei are a concern for radiation risks because they 
have the highest biological effectiveness and leave columns of damage at the molecular level 
as they traverse a biological system, and because a plausible mitigation measure by shielding 
is impossible due to the high penetration power of energetic particles of GCR. 
 
 
Table 2.7. Organ doses for males inside aluminum shields for 1972 SPE and GCR at solar minimum. 
(a) 5-g/cm2 aluminum 
Organ/tissue 
August 1972 SPE Annual GCR at solar minimum 
D 
mGy 
G 
mGy-Eq 
H 
mSv 
D 
mGy 
G 
mGy-Eq 
H 
mSv 
Avg. Skin 2692.3 4052.1 4259.7 198.8 375.8 832.3 
Avg. BFO 306.9 462.5 442.1 185.7 337.2 614.0 
Stomach 112.3 169.6 168.0 182.2 324.4 547.6 
Colon 251.4 379.0 363.8 185.6 336.4 606.2 
Liver 174.1 262.7 255.0 183.1 327.9 566.6 
Lung 205.6 310.1 299.4 184.5 332.9 590.9 
Esophagus 195.4 294.8 285.0 184.0 331.3 584.4 
Bladder 118.7 179.2 176.8 181.6 322.5 540.8 
Thyroid 333.2 502.1 479.0 186.8 341.1 632.7 
Chest/Breast 1615.9 2430.6 2323.9 194.1 365.6 770.2 
Gonads/Ovarian 748.1 1125.7 1072.2 186.5 339.7 640.9 
Front brain 571.7 860.9 816.4 190.6 354.4 696.9 
Mid brain 279.6 421.5 403.9 187.7 344.1 640.2 
Rear brain 557.5 839.6 796.2 190.5 354.0 695.2 
Lens 1959.0 2946.2 2829.4 196.2 372.4 806.3 
Gallbladder 118.7 179.2 176.8 181.6 322.5 540.8 
Remainder 406.3 611.9 585.9 186.1 338.2 619.5 
Point Dose 5389.0 8125.0 8663.0 218.2 434.4 1140.7 
E, mSv 
wT (ICRP 1991) 612.3 611.1 
wT (ICRP 2007) 676.2 620.7 
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(b) 20-g/cm2 aluminum 
Organ/tissue 
August 1972 SPE Annual GCR at solar minimum 
D 
mGy 
G 
mGy-Eq 
H 
mSv 
D 
mGy 
G 
mGy-Eq 
H 
mSv 
Avg. Skin   87.8     132.8 144.0 193.5 342.3 599.8 
Avg. BFO 23.4 35.7 42.9 182.0 314.9 494.2 
Stomach 12.1 18.6 25.5 179.1 306.4 465.5 
Colon 21.0 32.1 39.4 181.9 314.6 491.3 
Liver 15.6 23.8 30.7 179.8 308.6 473.6 
Lung 18.3 28.0 35.2 180.9 312.0 484.4 
Esophagus 17.5 26.8 34.0 180.5 310.9 481.4 
Bladder 12.0 18.4 25.0 178.6 305.0 462.2 
Thyroid 25.7 39.1 46.5 182.9 317.5 502.5 
Chest/Breast 67.2 101.9 107.0 189.0 333.8 558.7 
Gonads/Ovarian 37.5 57.0 62.5 182.5 316.1 503.3 
Front brain 37.6 57.1 64.8 186.1 326.6 530.5 
Mid brain 24.0 36.7 44.8 183.7 319.8 506.9 
Rear brain 37.0 56.4 64.0 186.0 326.4 529.8 
Lens 76.7 116.1 120.9 190.8 338.4 574.0 
Heart* 18.3 28.0 35.2 180.9 312.0 484.4 
Gallbladder 12.0 18.4 25.0 178.6 305.0 462.2 
Remainder 26.0 39.6 46.5 182.3 315.6 496.3 
Point Dose 164.7 248.9 267.8 210.7 384.3 751.4 
E, mSv 
wT (ICRP 1991) 45.83  492.48 
wT (ICRP 2007) 48.45 496.74 
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Figure 2.18. Effective doses for GCR charge groups, overall projectile-like dose (primaries and 
projectile fragments), and target fragments inside a spherical spacecraft of 5-g/cm2 aluminum 
shield thickness: Annual exposure in interplanetary space, Mars surface, and for a 30-month Mars 
mission as solar minimum. 
32 
 
The interplanetary GCR fluxes at solar minimum on the martian surface were propagated 
through the martian atmosphere of 16 g/cm2 carbon dioxide. Annual Effective doses are shown 
in the same figure on the martian surface (red bars) from GCR at solar minimum, in which 
radiation protection by martian atmospheric shielding and the shadow effect of Mars itself were 
estimated.89   Also shown in Figure 2.17 is the estimate of Effective dose for males during the 
30-month Mars mission (green bars), which is composed of interplanetary transit to/from Mars 
for 6 months each way and a Mars surface stay for 1.5 y. Organ doses for males and females 
show small differences due to the variations in body shielding of the various organs. Total 
Effective dose is estimated at about 1.1 Sv for a male crew member inside a 5-g/cm2 aluminum 
sphere at solar minimum. 
 
The steep dose gradients of SPEs make the ICRP-defined tissue weights, wT, used in the 
calculation of Effective doses inaccurate for NASA applications. SPEs lead to skin, thyroid, 
breast, and gonad doses that are much larger than the doses for the tissues that comprise the 
majority of cancer risks such as lung, colon, and stomach. Thus an overestimation of cancer 
mortality risks by several fold occurs when Effective doses are combined with total cancer risk 
coefficients to estimate risk. This is illustrated by calculations for the August 1972 SPE Table 
2.7 in which, at 5-g/cm2 aluminum shielding, the Effective dose is more than 3-fold higher than 
the lung dose equivalent. Further examples were shown by Kim et al90 using the NASA Space 
Radiation Program ProE ray tracer,91 which is a computer-aided design (CAD) engineering design 
model, and the BRYNTRN transport code to calculate organ dose equivalents and Effective doses 
inside a four-person crew capsule similar to the Orion capsule (Fig. 2.19). Results shown in 
Table 2.8 are at locations of the four crew persons inside the capsule (dosimetry locations 
[DLOCs] 1 to 4), where a more than 2-fold difference between Effective dose and deep-seated 
organ dose equivalents occurs. The August 1972 event is about the 70th percentile in spectral 
hardness of SPEs observed in the Space Age. This implies that the ICRP approach is even less 
accurate for fatal cancer risk estimates for most other SPEs compared to results for the 1972 
event because the dose gradient is larger for the many “softer” SPE spectra. 
 
 
Figure 2.19. Visualization of detailed directional dose assessment at a dosimetry location (DLOC1) inside a 
conceptual spacecraft representative of a lunar transfer vehicle (LTV). The spacecraft is shown in a translucent view 
to reveal the exact dosimetry location (left), and the same directional dose assessment is shown separately in the 
large view (right). 
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Table 2.8. August 1972 SPE organ dose quantities for males using the fully automated ProE 
structural distribution model LTV, the computerized anatomical man model (CAMERA), and the 
BRYNTRN codes. The King spectra for the SPE is used. Calculations are at the location of each 
crew member in the LTV. 
                   Organ Dose Equivalent, mSv DLOC1 DLOC2 DLOC3 DLOC4 
Al-Eq xavg, g/cm2 15.18 15.08 15.85 15.33 
CAM 
organ 
dose 
Avg. skin 1266 1211 1041 1086 
Eye 868 844 736 771 
Avg. BFO 169 168 152 159 
Stomach 73.8 73.7 67.7 70.3 
Colon 144 144 130 136 
Liver 104 103 94.1 98.0 
Lung 122 121 110 115 
Esophagus 116 116 105 110 
Bladder 75.4 75.3 69.0 717 
Thyroid 184 183 166 173 
Chest 722 706 619 648 
Gonads 353 347 308 322 
Front brain 295 293 263 275 
Mid brain 162 162 147 153 
Rear brain 289 287 258 270 
Effective Dose, mSv 213 210 188 196 
Point Dose Eq., mSv 2557 2427 2079 2168 
 
 
2.4 Probability Distribution Function for Space Physics Uncertainties 
The above comparisons show good agreement between ground-based and space flight 
measurements with predictive transport code models. We did not review shielding models such 
as ray tracers and combinatorial geometry models for spacecraft or geometry models, including 
voxel-based models for organ shielding. However, the comparisons described suggest overall 
agreement for a combined environment (xenv), transport(xtran), and shielding (xshield) model to be 
within ±15% for Effective dose comparisons. The HZETRN model does not appear to be system-
atically higher or lower to the various measurements in such comparisons. It could be argued that 
past flight measurements have not been sufficiently robust, or other assignments of radiation 
QFs may increase particle components not emphasized in the current ICRP 60 model26 used in 
Effective dose calculations. We therefore will assign a slightly higher overall physics model un-
certainty than our estimate of ±15%. Below we will consider particle track-structure models to 
describe radiation quality effects. Particle track-structure and energy deposition in biomolecules, 
cells, and tissues is naturally described by the parameter Z*2/2, where Z* is the effective charge 
number of the ion and  is the velocity scaled to the speed of light. We will describe new recom-
mendations for radiation QFs that replace the LET dependence from ICRP Report 6026 with one 
that depends on Z*2/2 for light- and heavy-charge particle groups. 
The PDF for describing the uncertainty in radiation exposures at tissue sites is described in 
Table 2.9. Uncertainty analysis will be made using the HZETRN code with QMSFRG nuclear 
cross sections and the Badhwar and O’Neill GCR environment model.39,51,69 We will consider 
uncertainties for the fluence distributions of two groups of ions: light ions with charge numbers 
of Z=1 to 4; and heavy ions with charge numbers of Z=5 to 28. The HZETRN code used in this 
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analysis does not consider photons and mesons, which are low-LET radiation, and therefore 
slightly underestimates fluence spectra at low values of Z*2/2. HZETRN also tends to underes-
timate low-energy neutrons (E<1 MeV) compared to Monte-Carlo based codes, which predom-
inantly produce biological damage through light ion recoils and photons. For the PDF for light 
ion contributions to the fluence spectra, F(Z*2/2), we assume a normal distribution with a mean 
shifted to higher values (M=1.05), and the standard deviation (SD) of 0.33 for light ions compared 
to heavy ions in which the SD is assigned as 0.25. These choices are consistent with the good 
agreement found between transport codes and laboratory and flight measurements. Individual 
components may have higher SDs; however in an earlier report,14 we noted the importance of 
the constraints implied by transport codes comparisons flight measurements of dose and dose 
equivalent when defining PDFs for particle spectra uncertainties. For considering deep-shielding 
conditions (for eg, thicker shielding than the ISS) with average shielding of 20 g/cm2 from which 
the uncertainty assessment was made, a larger physics uncertainty should be considered. 
However, we note that the ISS is likely to contain more mass than exploration spacecraft 
because of the higher costs to launch mass outside of LEO. 
 
Table 2.9. Assessment of physics uncertainties for light and heavy particles using a Gaussian distribution with 
median (M) and SDs. 
F(Z*2/2) Median (M) Standard Deviation (SD) 
Light ions (Z≤4) 1.05 1/3 
Heavy ions (Z>4) 1.0 1/4 
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3. Cancer Risk Projections for Low-linear Energy Transfer 
Radiation 
 
The current radiation cancer risk projection model used at NASA is based on NCRP Report No. 
132;6 however, this has been updated by NASA (PELs, 2006) to use the solid cancer mortality 
analysis made in LSS [Life-span Study of the Japanese atomic-bomb survivors] Report 13.9 
These methods form the basis by which to calculate the current dose limits used at NASA; ie, 
age- and gender-specific Effective dose to reach a probability of 3% for REID. In recent years 
there have been important new analyses of human epidemiology data by the BEIR VII Commit-
tee,16 UNSCEAR,17 Preston et al,92 National Cancer Institute (NCI),93 Little et al,10,94 Pawel et 
al,95 and others. Important changes since NCRP Report No. 132 include a reevaluation of the A-
bomb survivor doses denoted as DS02.96 Longer follow-up studies of the exposed cohorts with 
the most recent incidence data from the LSS from the Radiation Effects Research Foundation 
(RERF) cover the years 1958 through 1998.92 Meta-analysis of different exposed cohorts for 
specific tissues such as breast and thyroid cancers has been reported. Application of new meth-
odologies includes Bayesian analysis of dosimetry errors10 and empirical Bayes methods for 
tissue-specific cancer risk uncertainties.95 New analyses of the DDREF were made by the BEIR 
VII and Jacobs et al97 from a meta-analysis of 12 published radiation worker studies. An important 
change advocated by the BEIR VII report is to estimate cancer mortality risks by the transfer of 
incidence rates in exposed cohorts to populations under study (eg, the U.S.), and then to estimate 
mortality risks using the ratio of host population cancer mortality and incidence rates. Previous 
recommendations from the NCRP used mortality-based risk transfer models.6 In this section, we 
will review the mathematical approaches to calculate low-LET cancer risks and intercompare 
recent fits to the most recent LSS data. 
 
The instantaneous incidence rate of cancer, (t), is defined in terms of the probability 
distribution function, F(t), of the time to cancer occurrence. The survival function, S(t), is the 
probability of being cancer-free at age t (the interval [0,t]), and is given by 1-F(t). The probability 
density function, f(t), is then dF(t)/dt. The hazard rate is the instantaneous incidence rate as is 
given by 
 
 
( )( )
1 ( )
f tt
F t
    (3.1) 
 
The cumulative hazard, (t), also known as the cumulative incidence rate, is 
 
 0
( ) ( )
t
t z dz  
 (3.2) 
 
The survival probability is related to the cumulative hazard function by 
 
 ( ) exp[ ( )]S t t   (3.3) 
 
To model radiation risk along with radiation hazard rates, the age- and gender-specific survival 
probability (often represented by a life-table) must be described because of the role of competing 
causes of death. For multiplicative risk models (described below), the age- and gender-specific 
hazard rates for cancer incidence or mortality in the population under study also must be 
defined. 
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The instantaneous cancer rate (mortality or incidence) can be a function of dose, D, or dose-
rate, Dr, gender, age at exposure, aE, attained age, a, or latency, which is the time after expo-
sure, L=a-aE. These dependencies may vary for each cancer type that could be increased by 
radiation exposure. Hazard rates for cancer incidence, I, and cancer mortality, M, can be 
modeled with similar approaches. The REID is calculated by folding the probability of surviving to 
time, t, which is represented as the survival function, S0(t), for the background population times 
into the probability for radiation cancer death at a previous time with the instantaneous radiation 
cancer mortality rate and then integrating over the remainder of a lifetime: 
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Similarly, the risk of exposure-induced cancer incidence (REIC) uses a radiation cancer 
incidence rate folded with the probability to survive to time, t, and integrated over the remainder 
of a lifetime: 
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The BEIR VII report16 uses the quantity lifetime attributable risk (LAR) instead of REID as the 
primary measure of risk. Others committees98 have used the quantity ELR. (Note: NCRP Report 
No. 132 discusses results in terms of ELR; however, the formula on page 127 of the report sug-
gests that REID was calculated in the report.) The LAR and ELR risk measures have important 
deficiencies and are not used at NASA. The ELR ignores cancer deaths that would have occurred 
anyway in a population but are moved to an earlier time point due to radiation exposure. ELR 
therefore underestimates risks. The LAR ignores the radiation contribution to the survival prob-
ability in Eq(3.4) or Eq(3.5). It thus leads to an overestimation of risk, especially at high doses, 
and also can lead to errors in uncertainty analysis when large risk values are sampled in 
Monte-Carlo trials. 
 
 
3.1 Cancer Mortality and Incidence Rates 
 
Radiation cancer incidence (or mortality) rates are most often modeled in the multiplicative risk 
model that is also denoted as the excess relative risk (ERR) model in which the radiation cancer 
rates are proportional to background cancer rates given by: 
 
 0( , , ) ( )[1 ( , , )]I E I Ea a D a ERR a a D    (3.6) 
 
where i0(a) is the age-specific (and tissue- and gender-specific) cancer rate from background 
cancers in the population under study. A second model is also used; this study, denoted as the 
excess additive risk (EAR) model, does not explicitly depend on the background cancer rates 
given by: 
 
 ( , , ) ( , , )I E Ea a D EAR a a D   (3.7) 
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Radiation cancer rates can be fitted to data on all cancers or various sub-categories including 
tissue-specific cancer rates. Overall cancer incidence data have lower statistical uncertainties 
than overall mortality data because of higher counts. Projecting tissue-specific cancer incidence 
probabilities has higher statistical uncertainties due to lower counts compared to fitting grouped 
data such as all solid cancers and leukemias. However, projections based on tissue-specific in-
cidence data offer many advantages including the possibility to apply tissue-specific transfer 
models between populations, tissue-specific radiation quality, and dose-rate dependencies. 
Attributable risks calculations for estimating probability of causation on disease discovery are 
evaluated with tissue-specific incidence models.93 The astronaut informed-consent process is 
also improved if information on specific cancer types for both incidence and mortality risks is 
provided. More recently, an empirical Bayes method has been shown to provide an improved 
representation of statistical errors in tissue-specific risks.95 
 
A multiplicative risk model for projecting cancer mortality (REID) from tissue-specific cancer 
incidence uses identical ERR functions determined for incidence to project tissue-specific mor-
tality using population cancer incidence rate to mortality rate scaling.16 Similarly, an additive risk 
model derived from incidence data can be used for mortality risk prediction by adjusting EAR 
functions derived from incidence data by the ratio of background mortality to incidence rates:16 
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Various advisory reports have used distinct approaches to arrive at assumptions on how to 
combine multiplicative and additive risk model estimates. A weighting of the multiplicative transfer 
model, denoted as T, can be introduced. The additive transfer model weight is then given by 1-T. 
NCRP Report No. 132 recommended to use an arithmetic mean of the additive and multiplicative 
risk models for all solid cancers and the additive risk model for leukemia risk. Although the recent 
UNSCEAR report17 did not make a recommendation on risk transfer models, we note that its mul-
tiplicative risk model provides the best fit to the LSS. The BEIR VII report uses geometric means 
of the additive and multiplicative transfer models for most cancer types with a weight T of 0.7 
including leukemia, but deviates for lung, breast, and thyroid cancer risk estimates. For lung 
cancer, BEIR VII assigns a weight T of 0.3, favoring additive transfer based on an older 
analysis of smoking interactions with radiation in the LSS .96 
 
Projecting tissue-specific astronaut risks from space radiation requires functional forms for the 
ERR and EAR for cancer incidence for astronaut ages at first flight, typically age at  exposure, 
aE> 30 y. The recent report of Preston et al92 uses Poisson regression models with appropriate 
adjustments to test several dose response models with a linear dose-response model providing 
the best fits of REIC for most solid cancers. Results are represented by ERR functions of the 
form 
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And of the same functional form, but with different parameters for EAR: 
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where f(D) represents a dose-response function. Several dose-response functions were consid-
ered; however, a linear function was found to provide the best fit, ie, f(D)=D. These functions 
have no dependence on latency, L. Although the BEIR VII report used similar models as Eq(3.9) 
and Eq(3.10), fit LAR was used instead of REIC, and no age at exposure dependence of the 
rates for exposures was assumed over age 30 y (ie, c=0 in these equations for aE>30 y with 
other parameters thus modified in fitting the data). 
 
The UNSCEAR report used Poisson maximum-likelihood methods and Bayesian analysis to 
represent dosimetry errors to fit generalized ERR and EAR models for cancer incidence. The 
ERR functions were of a more general form than the BEIRVII or RERF models: 
 
 2 1 2 3 4( , , , ) ( ) exp[ 1 ln( ) ln( ) ln( )]
D
E S E EERR a a L D D D e a a a a
           (3.11) 
 
with a similar form for the EAR function. Equation (3.11) includes a dependence on latency that 
was not tested in Eq(3.9) or Eq(3.10). In a manner similar to the results of Preston et al,92 the linear 
dose response model provided optimal fits to the tissue-specific cancer incidence data. The addi-
tion of latency dependence was significant for several tissues including EAR models for colon, 
breast, and nonmelanoma skin cancer, and ERR and EAR functions for the category of all other 
solid cancer incidence. The UNSCEAR report, in its functional form given by Eq(3.11), considered 
an exponential term with argument, D, in the exponent to represent cell sterilization effects. This 
approach would be useful in the pursuit of space radiation models, but would take a significant 
amount of study to determine the radiation quality dependence of the cell sterilization term 
across different tissues, and might be confounded by a correlation between RBE value 
estimates and cell sterilization effects. 
 
The various approaches described above to fitting the most recent data set from the LSS are 
based on stratified dose groups with follow-up time from 1958 through 1998. The UNSCEAR and 
Preston et al92 models used REIC or REID as the basic risk quantity while BEIR VII used LAR. 
Each report assumed a dose-independent neutron RBE of 10. Tissue-specific doses were ap-
proximated by colon dose estimates for solid cancers and bone marrow doses for leukemia. 
Not all of the minor tissues considered in each report were identical, which leads to differences 
in the definition of the remaining terms representing all cancer types excluded from tissue-
specific analysis. 
 
Tests of goodness of fit to the LSS cancer mortality and incidence data were made by the 
UNSCEAR committee17 using both the BEIR VII and the UNSCEAR models, and suggested that 
the UNSCEAR more general model as described by Eq(3.11) provided the best fit to these data 
sets. (See the UNSCEAR report Appendix D for details.) Several dose response models were 
tested, and the result showed the linear dose response model provided the best fit for tissue-
specific incidence and a linear-quadratic (LQ) model to total solid cancer mortality data. 
 
 
3.2 Adjustment for Low Dose-rates 
 
The models described above for projection of radiation cancer risks should be adjusted for 
dose-rate modifiers because epidemiology data are largely for acute doses of -rays, which are 
expected to be more effective than doses delivered at low doses or dose-rates (<0.2 Gy or 0.05 
Gy/hr). This adjustment can be made by reducing the cancer incidence or mortality rates by a 
DDREF. DDREF values of about 2 have been used in the past. Uncertainties and recent data 
on DDREFs are described below. Here we note that recently smaller values of the DDREF have 
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been described by BEIR VII16 and other reports compared to the recommendation of NCRP 
Report No. 132.6 In contrast, the UNSCEAR-preferred model fit to total solid cancer mortality 
was an LQ dose response model.10,17 An identical approach to leukemia risk estimation could 
therefore be followed where no DDREF is applied, while the quadratic dose term is ignored for 
low dose-rates. However, the optimal fit to cancer incidence by UNSCEAR was a linear dose 
response model, where a DDREF would normally still be applied. 
 
 
3.3 Comparisons of Tissue-specific Risk Models 
 
We compared the BEIR VII,16 UNSCEAR,17 and Preston et al92 model fits for age- and gender-
specific REIC and REID probabilities using the 2005 U.S. population data for cancer incidence, 
mortality, and life-table for all causes of death.99 All calculations are made with a DDREF of 1.75 
for solid cancer risks, and the linear component of the leukemia model. Preston et al92 considered 
several tissues not considered by BEIR VII and UNSCEAR, including tumors of the oral cavity 
and esophagus. Figures 3.1 and 3.2 compare these models for the %-REIC using identical U.S. 
population rates from 200599 and a DDREF value of 1.75. Appendix A contains tables of esti-
mates of REIC and REID for several cancer types. In Appendix B we consider estimates for 
specific demographic factors within the U.S. population. Lung cancer makes the largest contri-
bution to the risk, and the differences between the additive and the multiplicative models for 
lung cancer risks are found to be substantial, which is well documented.6 Importantly, the 
models predict REIC values about 2 times higher than REID, or about a 20% increase 
compared to the analysis of NCRP Report No. 132.6 
 
 
3.4 Age at Exposure Dependence of Cancer 
 
NCRP Report No. 9898 recommendations to NASA with regard to the age dependence of 
career dose limits was a substantial change from the contemporary dose limits for astronauts, 
and was also distinct from radiation protection methods at other government agencies or nations.27 
Tables of career limits were calculated for a 10-y career under the assumption that exposures 
were distributed evenly over the 10-y period,98 and the report noted that more detailed calcu-
lations are needed if other career lengths are considered. NCRP Report No. 132 employed sim-
ilar methodologies to NCRP Report No. 98, although it used the revised human epidemiology 
findings that occurred between the publications of the different reports. Table 3.1 compares the 
age-dependent dose limits from the two reports. The more recent report recommended reducing 
Effective dose limits by more than 2-fold below age 50 y compared to the former NCRP report. 
 
The largest difference between the NCRP estimates from 2000 and the BEIR VII model or 
recommended NASA 2010 approach is the reduction of the age at exposure dependence of 
cancer risk estimates and dose limits, with a more than a 3-fold change over the possible ages 
of astronauts in the NCRP model compared to a less than 50% change in the incidence-based 
risk transfer model approach. Figure 3.3 compares REID values for solid cancer risk in the two 
approaches. The upper panels for males and females compares calculations using the rates from 
LSS report 13, the UNSCEAR mortality fits (linear term only), and the BEIR VII model. The NCRP 
and BEIR VII calculations use an identical DDREF of 2, and the UNSCEAR result uses the linear 
term from an LQ fit with DDREF=1. All calculations use the 2005 U.S. population data and T=0.5 
for all tissues. The NCRP and UNSCEAR mortality transport models show a similar dependence 
on aE, and would be in even closer agreement if the UNSCEAR model were applied with a 
DDREF of about 1.3, or if the NCRP model DDREF was reduced from 2 to about 1.7. The  
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Figure 3.1. Comparison of %REIC per Sv for males and females as a function of age at exposure  
for mixture model U.S. for the BEIR VII, UNSCEAR, and Preston et al92 tissue-specific cancer 
rates. Left panels for males; right panels for females. 
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Figure 3.2. Comparison of %REIC per Sv for males and females as a function of age at exposure 
for mixture model and for the BEIR VII, UNSCEAR, and Preston et al92 tissue-specific cancer 
rates. Left panels for males; right panels for females. 
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The BEIR VII model shows a very different aE dependence. These assumptions have much 
larger impacts than those that would result from suggested changes to DDREF values recom-
mended by the BEIR VII report16 in which a DDREF of 1.5 increases the solid cancer risk esti-
mate by 33% compared to a DDREF of 2 used in the past, and a smaller overall change when 
leukemia risk is included for the total cancer risk. The lower panels in Figure 3.3 show calcula-
tions using transport of incidence rates converted to REID using the BEIR VII approach. A much 
weaker dependence on aE is predicted compared to REID calculations based on the transport of 
mortality rates. The incidence-based transfer model makes good sense when one considers the 
changing rates for incidence and mortality over time since 1945, and differences between LSS 
and U.S. background rates. Cancer mortality rates in the U.S. are reported to be decreasing, 
while incidence rates remain more stable100 except for lung cancer due to the reductions in 
tobacco usage.101 The ratio of mortality to incidence is expected to continue to change in 
future if cancer treatments improve. 
 
 
Table 3.1. Comparison of NCRP recommendation for career radiation limits for different ages at first exposure 
corresponding to a 3% risk of fatal cancer for 10-y careers from NCRP Report No. 9898 to NCRP Report No. 132.6 
Values for other career lengths require a separate evaluation. 
 E(Sv), NCRP Report No. 98 E (Sv), NCRP Report No. 132 
Age at 
Exposure, y 
Female Male Female Male 
25 1.0 1.5 0.4 0.7 
35 1.75 2.5 0.6 1.0 
45 2.5 3.2 0.9 1.5 
55 3.0 4.0 1.7 3.0 
 
 
The biological basis for the age at exposure dependence of cancer risks should be considered 
with regard to the age dependences of radiation risks for astronauts with typical ages between 
30 and 60 y. Radiation action as either a cancer initiator or promoter could be suggested to lead 
to differences in the age at exposure dependence of risk, and there are other competing biolog-
ical factors to consider. Adults likely contain a much higher number of premalignant cells than do 
preadults.16,17 However, differences in cell numbers for different ages of astronauts or between 
the average U.S. population and a population of healthy workers such as astronauts is unknown. 
The probability of a likely smaller population of preneoplastic cells being modified at low dose 
and dose-rates compared to normal cell populations should be considered in relationship to its 
relative probabilities of transformation. Aberrant changes to the tissue microenvironment102 could 
increase with age, perhaps acting as a promotional effect for cells damaged from radiation ex-
posure. The role of age in relationship to changing numbers of senescent cells, stem cells, or 
other susceptible cells and possible reduced DNA repair capacity could also be considered. 
Test of the LSS data for an increasing risk with aE, as motivated by promotional effects 
considerations, were made by Little94 and were not supportive of such a hypothesis. 
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Figure 3.3. %REID per 0.1 Sv for solid cancer  calculations in different models. Upper panels for 
males (left upper panel) and females (right upper panel) the %REID using mortality rate transport 
models. Lower panels show results using incidence rate transport models for males (left lower 
panel) and females (right lower panel). 
 
 
3.5 Radiation Risks for Never-smokers 
 
Astronauts and many other radiation workers or medical patients exposed to radiation for 
diagnostic reasons share common healthy attributes such as good nutritional and exercise 
habits and abstinence from smoking. More than 90% of astronauts are never-smokers (lifetime 
use less than 100 cigarettes) and the remainder are former smokers. The choice of a reference 
population to estimate risks was not considered in the past, at which time the average U.S. pop-
ulation was assumed in the NCRP projection models used at NASA. The reference population 
enters risk calculation in two ways: First, risk models consider competing causes of death from 
non-radiation risks, by which longer life span increases lifetime radiation risk. Second, multiplica-
tive or additive risk transfer models for applying data from exposed populations to the reference 
populations are used in the risk models, with the multiplicative risk projection proportional to the 
cancer risks in the population under study. A military aviation population could be an appropriate 
choice for reference population data for the astronauts; however, data of sufficient accuracy have 
not been reported. Instead, we studied how cancer and all causes of death rates for the 50 U.S. 
states and the District of Columbia as well as other demographic factors affected risk calculations. 
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These data99 show a wide variation in average life span and age-specific cancer rates, but we 
found that they result in only a small variation of REID probabilities. 
The influence of the U.S. average rates for all causes of death and cancer incidence or mortality 
as an appropriate population on which to base risk assessments for healthy workers such as 
astronauts was investigated. Calendar year differences in rates occur, and comparison of U.S. 
rates from 1999 through 2005 showed a small trend toward increasing radiation risk as longevity 
increased. Table 3.2 shows the average, SD, and minimum and maximum values based on the 
range of values for each of the 50 U.S. states and Washington DC using NCRP Report No. 132 
and BEIR VII models using mixture models (see also Supplementary Data in Appendix B). A 
very small variation of REID estimates was observed in these comparisons. Figure 3.4 shows 
the correlation between median life span and age-adjusted cancer rates with REID projections 
using %REID per Sv estimates in the BEIR VII model, with DDREF=1.5 for each state in the 
U.S. and Washington DC vs. the median life span and fatal cancer rates for females (upper 
panel) and males (lower panel) exposed at age 30 y. Trends are for small REID increases with 
longer life spans, and small REID decreases with decreasing cancer rates. These differences 
are closely tied to the assumptions of additive or multiplicative risk transfer, with larger changes 
found if multiplicative risk transfer is assumed. 
 
Lung cancer incidence and mortality rates for never-smokers were recently compiled by Thun 
et al103 from an analysis of never-smokers in 13 cohorts and 22 cancer registries. Furthermore, 
Furukawa et al104 considered several interaction models between smoking and radiation in the 
A-bomb survivor cancer incidence data. A generalized multiplicative model for the combined ef-
fects of radiation and smoking was similar in form to Eq(3.9) for the radiation components, but 
with distinct coefficients. For never-smoker risk estimates, we adjusted the survival probability 
for the average U.S. population by adjusting the age-specific rate for all causes of death for lung 
cancer rates for never-smokers of Western European descent.103 We considered other radiogenic 
cancers that are also linked to tobacco use, including cancers of the stomach, esophagus, oral 
cavity, and bladder. Age-specific rates for never-smokers for these cancers were not available. 
Instead, adjustments to rates for an average U.S. population were made using gender-specific 
relative risks for never-smokers,101 which are given in Table 3.3. These rates are applied to the 
portion of rates corresponding to multiplicative risk transfer. Other radiogenic cancers are not 
counted as smoking attributable by the Centers for Disease Control (CDC),105 although acute 
myeloid leukemia (AML) shows a small effect for smokers, and smoking contributions to breast 
cancer risk are also a possible concern.106 
 
A significant decrease in REID and REIC probabilities compared to calculations for the 
average U.S. population was observed when lung cancer risk calculations were estimated for 
never-smokers. Figure 3.5 shows comparisons between the data of Thun et al103 with the SEER 
2005 average U.S. population data for lung cancer incidence and mortality rates. We used these 
rates to estimate lung cancer risks in the BEIR VII, UNSCEAR, and RERF models as shown in 
Tables 3.4 and 3.5 for estimates of REIC and REID, respectively. A more than 8-fold decrease 
is estimated in the multiplicative transfer model when never-smoker rates are compared to the 
U.S. population average. The model of Furukawa et al104 leads to a minor reduction for females 
compared to the usage of never-smoker baseline rate estimates alone, and is about the same 
for males. We note that Furukawa et al104 used lung dose estimates for the LSS cohort, while 
the reports noted above used colon doses to represent all solid cancer risks including the risk 
of lung cancer. Using a mixture model with vT=0.5 reduced the lung cancer estimate for never-
smokers by 2-fold compared to the average U.S. population. Because lung cancer is the largest 
contributor to overall radiation cancer risks, these lower estimates for never-smokers have large 
impacts on overall risk estimates. 
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Table 3.2a. Variation of %REID per Sv for females in individual states and Washington DC vs. age at 
exposure in models of BEIR VII (DDREF=1.5) and the NCRP 132 (DDREF=2). 
 
 
Table 3.2b. Same as Table 3.2a for males. 
 
 
 
 
Figure 3.4. %REID per Sv estimates in the BEIR VII model, with DDREF=1.5 for each state and Washington DC 
vs. median life span and fatal cancer rates for females (left panel) and males (right panel) exposed at age 30 y. 
 
 
Very little information has been reported for contributions for different lung cancer histologies to 
radiation risk, such as the fraction from small cell lung carcinoma (SCLC) vs. non-small cell lung 
carcinoma (NSCLC), in part due to statistical limitations. Much more is known for the histologies 
of lung cancers associated with tobacco use.107 Land et al108 reported that radiation lung cancer 
mortality risks were mostly associated with SCLC in the A-bomb survivors and uranium miners 
who received doses from -particles. A study of Hodgkin’s disease patients treated with high 
State Median life span Cancer rate 35 45 55 35 45 55
Average 82.4 133.8 5.4 5.2 4.7 4.7 3.5 2.3
Standard Deviation 1.1 17.1 0.2 0.2 0.2 0.2 0.1 0.1
Minimum 80.1 89.6 4.8 4.6 4.2 4.3 3.2 2.1
Maximum 85.6 165.6 5.7 5.5 5.1 5.0 3.8 2.5
  BEIR VII 
State Median life span Cancer rate 35 45 55 35 45 55
Average 77.7 150.6 3.9 3.8 3.6 3.9 2.9 2.0
Standard Deviation 1.8 30.9 0.2 0.1 0.1 0.1 0.1 0.1
Minimum 73.2 96.0 3.5 3.4 3.3 3.6 2.7 1.8
Maximum 80.3 219.0 4.2 4.1 3.8 4.1 3.1 2.1
BEIR VII NCRP 132 
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doses of radiation in Europe and the U.S. indicated that NSCLC was associated with radiation 
exposure, and no significant risks for never-smokers.109 For high-LET -particles, the BEIR VI 
committee found sub-multiplicative models fit data for uranium miners the best, and ruled out 
additive risk models.110 The choice of risk transfer model is a major uncertainty because never-
smokers have a very small incidence of SCLC in the U.S., suggesting that additive risk transfer 
should be used to transfer the LSS data to the U.S. for SCLC risk, or else no risk of SCLC 
cancer would be predicted for never-smokers. 
 
 
Figure 3.5. Comparison on age-specific cancer incidence and mortality rates for the 2005 U.S. 
average population and recent analysis for never-smokers by Thun et al.103 Left panel for females, 
and right panel for males. 
 
 
Table 3.3. Estimates of relative risks (RRs) for never-smokers (NS) compared to U.S. average population for 
several cancers attributable to both smoking and radiation exposure. For males, current smokers, former smokers, 
and NS are estimated at 24%, 40%, and 36% of the population above age 50 y. For females, we use 18%, 35%, and 
47% of the population above age 50 y. 
  RR to Never‐smokers (NS)  RR for NS to U.S. 
Avg. 
Males  Current smokers  Former smokers  NS  RR (NS/U.S.) 
Esophagus  6.76  4.46  1  0.27 
Stomach  1.96  1.47  1  0.71 
Bladder  3.27  2.09  1  0.50 
Oral Cavity  10.89  3.4  1  0.23 
Lung*  23.26  8.7  1  0.11 
Females  Current smokers  Former smokers  NS  RR (NS/U.S.) 
Esophagus  7.75  2.79  1  0.35 
Stomach  1.36  1.32  1  0.85 
Bladder  2.22  1.89  1  0.65 
Oral Cavity  5.08  2.29  1  0.46 
Lung*  12.69  4.53  1  0.23 
*Lung data shown only for comparison; with calculations in report using age-specific rates described in the text. 
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Table 3.4. Lung cancer incidence per Sv (REIC/Sv) in several models with DDREF = 2. 
  %REIC, Females %REIC, Males 
 Age at Exposure 35 y 45 y 55 y 35 y 45 y 55 y 
Model Type Model rates Average U.S. Population, 2005 
Additive BEIR VII 1.34 1.33 1.31 0.77 0.76 0.74 
 UNSCEAR 1.60 1.57 1.42 0.86 0.83 0.78 
 RERF 1.67 1.66 1.59 0.87 0.87 0.83 
Multiplicative BEIR VII 3.92 3.61 2.97 1.23 1.15 0.96 
 UNSCEAR 4.65 4.49 3.98 1.45 1.41 1.27 
 RERF 5.15 5.56 5.28 1.51 1.65 1.60 
Mixture BEIR VII 2.70 2.54 2.19 0.99 0.96 0.85 
 UNSCEAR 3.14 3.03 2.73 1.15 1.12 1.02 
 RERF 3.43 3.63 3.46 1.19 1.26 1.21 
  Never-smokers 
Multiplicative BEIR VII 0.54 0.50 0.44 0.16 0.17 0.16 
 UNSCEAR 0.69 0.67 0.62 0.17 0.17 0.16 
 RERF 0.70 0.76 0.77 0.15 0.17 0.18 
Mixture BEIR VII 1.01 0.99 0.93 0.45 0.44 0.42 
 UNSCEAR 1.15 1.12 1.04 0.51 0.50 0.47 
 RERF 1.18 1.21 1.18 0.51 0.52 0.50 
Generalized 
Multiplicative 
RERF, Generalized 
Multiplicative for 
never-smokers 
0.50 0.58 0.62 0.16 0.19 0.22 
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Table 3.5. Fatal lung cancer risks per Sv (REID/Sv) in several models with DDREF=2. 
  %REID, Females %REID, Males 
 Age at Exposure 35 y 45 y 55 y 35 y 45 y 55 y 
Model Type Model rates Average U.S. Population, 2005 
Additive BEIR VII 1.20 1.20 1.18 0.65 0.66 0.66 
 UNSCEAR 1.28 1.27 1.22 0.71 0.71 0.69 
 RERF 1.33 1.34 1.32 0.72 0.73 0.73 
Multiplicative BEIR VII 2.88 2.74 2.38 0.95 0.92 0.83 
 UNSCEAR 3.56 3.50 3.23 1.17 1.17 1.11 
 RERF 3.71 4.16 4.21 1.13 1.30 1.37 
Mixture BEIR VII 2.04 1.97 1.78 0.80 0.79 0.74 
 UNSCEAR 2.43 2.39 2.23 0.94 0.94 0.89 
 RERF 2.53 2.77 2.78 0.92 1.02 1.05 
  Never-smokers 
Multiplicative BEIR VII 0.44 0.41 0.37 0.15 0.15 0.14 
 UNSCEAR 0.57 0.57 0.54 0.15 0.15 0.14 
 RERF 0.55 0.61 0.66 0.14 0.15 0.16 
Mixture BEIR VII 0.85 0.84 0.81 0.40 0.40 0.38 
 UNSCEAR 0.96 0.95 0.91 0.46 0.45 0.42 
 RERF 0.98 1.01 1.02 0.46 0.47 0.45 
Generalized 
Multiplicative 
RERF, Generalized 
Multiplicative for 
never-smokers 
0.39 0.47 0.53 0.16 0.17 0.20 
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4. Uncertainties in Low-linear-energy-transfer Risk Model Factors 
 
NCRP Report No. 12615 reviewed uncertainties for low-LET radiation risk assessments, and the 
recommended PDFs were used by NASA for its previous space radiation risk assessments.14,21 
Several reports published since 1997, as noted above, provide new sources of information to 
update uncertainty assessments. We first summarize NCRP Report No. 126 and then describe 
other information to update the low-LET uncertainty PDFs. For Monte-Carlo sampling purposes, 
the low-LET mortality rate per Sievert, L, is written as 
 
Dr
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    (4.1) 
 
where 0 is the baseline mortality rate per Sievert and the xα are quantiles (random variables) 
whose values are sampled from an associated PDF, P(x). Note that the DDREF applies only to 
the solid cancer risk and not to the leukemia risk under the given assumptions. NCRP Report 
No. 12615 defined the following subjective PDFs, P(x), for each factor that contributes to the 
low-LET-risk projection: 
 
1) Pdosimetry represents random and systematic errors in the estimation of doses received 
by atomic-bomb blast survivors. It was assumed by the NCRP as a normally distributed 
PDF for bias correction of random and systematic errors in the dosimetry (DS86) with a 
mean of 0.84 and an SD of 0.11. 
2) Pstatistical represents the distribution in uncertainty in the risk coefficient r0. It is assumed 
as a normally distributed PDF with a mean of 1 and an SD of 0.15. 
3) Pbias represents any bias resulting for over-reporting or underreporting of cancer deaths. 
Pbias is assumed as a normal distribution with a most probable value of 1.1 and a 90% CI 
from 1.02 to 1.18 corresponding to an SD of 0.05. 
4) Ptransfer represents the uncertainty in the transfer of cancer risk following radiation 
exposure from the Japanese population to the U.S. population. Both additive and relative 
risks models were considered by NCRP Report No. 12615 in assessing the uncertainties 
in such transfer. Ptransfer is log-normal with a mean of 1 and an SD of 0.26 (GSD 
[geometric standard deviation]=1.3). 
5) PDr represents the uncertainty in the knowledge of the extrapolation of risks to low dose 
and dose-rates embodied in the DDREF. The NCRP assumed PDr to be a truncated 
triangle distribution starting at 1 and ending at 5 with a peak at 2 and a relative value of 
¼ or ½ at 1 or 5, respectively, compared to the peak values for the DDREF at 2. This 
PDF is used to scale the low-LET risk coefficient (mortality rates) in our estimates for 
space radiation. 
6) PU represents unknown uncertainties. The NCRP assumed this uncertainty followed 
a normal distribution with a central value of 1 and an SD of 0.3 with 90th-percentile sub-
jective CIs of [0.5, 1.5]. 
 
The NCRP also considered a PDF for bias correction in projection of cancer risks over a 
lifetime, which is important for those exposed below age 30 y but not for astronauts. The lifetime 
projection and NCRP-unknown uncertainties were ignored in the previous NASA model. 
 
The analysis and data for updating low-LET cancer risk assessments and uncertainties since 
NCRP Reports Nos. 126 and 132 are as follows: 
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1) Publication of the revised atomic-bomb dosimetry assessment96 for the LSS of survivor 
called dosimetry system 2002 (DS02). 
2) Longer follow-up and reanalysis of the LSS cancer incidence data by BEIR VII,16 
UNSCEAR17 (see also Little et al10), and Preston et al.92 
3) Meta-analysis of other human epidemiology models for breast and thyroid cancer risks 
(BEIR VII). 
4) Development of empirical Bayes and Bayesian models for tissue-specific cancer 
incidence data that represent significantly reduced tissue-specific statistical errors,95,111 
respectively. 
5) Assessment of dose response models fitted to human data sets and in the evaluation of 
DDREF values, including the BEIR VII analysis16 and analysis of radiation worker studies 
that support a DDREF value near unity.97 
 
 
4.1 Life-span Study Dosimetry Errors 
 
Errors in dosimetry related to epidemiology data include random and systematic errors. The 
completion of the revised dosimetry of the atomic-bomb survivors, called dosimetry system 
2002, DS02,94 led to minor reductions in the neutron dose estimates as well as modest changes 
in estimates of the -ray organ doses compared to the earlier DS86. Recent analysis by BEIR 
VII, UNSCEAR, and Preston et al.112 assume larger dosimetry errors than that of NCRP Report 
No. 126.15 The DS86 evaluation was subjectively assessed in light of the anticipated dosimetry 
reevaluation that cumulated in the newer DS02 system. The UNSCEAR report made a Bayesian 
analysis of dosimetry errors.10,17 Preston et al92 assume an overall 35% error in DS02 estimates. 
UNSCEAR assumed a log-normal distribution with a GSD of 30%. Other reports112-114 estimate 
the impact of using a fixed-neutron RBE of 10 in fitting the A-bomb data and other errors. Here, 
since a larger RBE value and a dose-dependent value are plausible, especially for solid cancers 
based on radiobiology experiments with cells and small animals, an overall reduction in the -ray-
derived risk coefficients would be expected. A dose-dependent RBE tested by Suzuki et al112 
indicated that reductions as high as 30% in the -ray risks were plausible if the neutron RBE ac-
tually had a much higher value than the 10 that was assumed in recent reports. Another source 
of error is the use of stratified dose groups instead of individualized dose estimates.10 Tissue sites 
in which meta-analysis over several exposed cohorts is considered introduces other dosimetry 
considerations. Cohorts exposed for medical conditions often involved x-ray exposures that have 
RBEs of two or more compared to -rays at low doses.115-117 Underreporting of doses from other 
sources is also a potential bias. After considering these various descriptions and the previous 
NCRP Report No. 126 assessment, we assume a log-normal PDF for the combined dosim-
etry uncertainties with a geometric mean of 0.9 and GSD of 1.3. This represents a signifi-
cant increase in dosimetry error compared to the NCRP Report No. 126 recommendation. 
 
 
4.2  Statistical Errors 
 
NCRP Report No. 126 represented statistical errors by a normal PDF with a mean of 1 and an 
SD of 0.15. It would be expected that the SD would improve with continued analysis and longer 
follow-up times. Pawel et al95 found, using so-called Empirical Bayes (EB) models, that tissue-
specific statistical errors are much better represented when all data are assumed to originate 
from a common parent distribution. A result of this analysis is reproduced in Table 4.1. For our 
subjective PDF representing statistical errors, we assume a normal distribution with a mean of 1 
and an SD of 0.15 to represent the overall cancer risk estimate. Estimates of statistical uncertain-
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ties for individual sites can be made with the larger values suggested by the EB model; however, 
these uncertainties would be small compared to DDREF or radiation quality uncertainties. 
 
 
4.3  Errors from Reporting Bias 
 
We estimated the REID probabilities based on the cancer incidence data in this report while 
NCRP Report Nos. 132 and 126 used cancer mortality data. As noted by NCRP Report No. 126, 
errors in incidence data are expected to be smaller than those of mortality data. We assumed a 
normal distribution with a mean of 1 and a standard error of 0.05 for the reporting bias error. 
 
 
Table 4.1. Comparison of maximum likelihood estimates (MLEs) to EB method for gender-adjusted, site-specific 
ERR from the LSS.95 
 ERR/Sv Estimate Standard Error 
Tissue MLE EB MLE EB 
Kidney 0.40 0.40 0.32 0.19 
Esophagus 0.63 0.48 0.31 0.19 
Prostate 0.18 0.32 0.30 0.19 
Bladder 0.84 0.58 0.29 0.18 
Pancreas 0.38 0.39 0.22 0.15 
Remainder 1.15 0.85 0.19 0.15 
Ovary 0.27 0.32 0.19 0.15 
CNS 0.37 0.38 0.17 0.14 
Oral Cavity 0.34 0.36 0.15 0.13 
Lung 0.70 0.63 0.13 0.11 
Gallbladder -0.01 0.08 0.13 0.11 
Colon 0.49 0.47 0.11 0.10 
Rectum 0.14 0.19 0.10 0.10 
Liver 0.31 0.32 0.10 0.09 
Breast 0.67 0.63 0.10 0.09 
Stomach 0.32 0.32 0.06 0.06 
Uterus 0.04 0.05 0.05 0.05 
 
 
4.4 Dose and Dose-rate Reduction Effectiveness Factor Uncertainties 
 
The DDREF applies to solid cancer risk estimates over the appropriate range of equivalent 
organ doses and dose-rates to be expected in space. ISS missions lead to crew doses of 0.02 
to 0.06 Gy and Effective doses of about 0.05 to 0.15 Sv. To date, the highest lifetime Effective 
dose for astronauts has been about 0.3 Sv.73 For exploration missions, Effective doses as high 
as 1.5 Sv could occur. Dose-rates in space range from about 0.3 to 0.6 mGy/d for GCR. A large 
SPE would have maximum dose-rates at deep tissues for modest spacecraft shielding amounts 
of about 0.3 Gy/hr. These values suggest that experimental information for -rays for DDREFs 
that are applicable for doses from about 0.05 to 2 Gy are the most appropriate for the NASA risk 
estimates. This is distinct from exposure to the public or terrestrial workers, to whom exposures 
below 0.05 Gy are the major concern. NCRP Report No. 9898 recommends a dose-rate effective-
ness factor (DREF) of 2.5. NCRP Report No. 1326 recommends a DDREF of 2.0. The BEIR VII 
report16 recently recommended a DDREF of 1.5 based on a Bayesian analysis of the LSS data 
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and selective mouse tumor data. Reducing the DDREF from 2.0 to 1.5 would increase the solid 
cancer risk estimates by 33% with all other factors the same. 
 
The UNSCEAR reports that best-fitting model to the LSS total solid cancer mortality data was 
an LQ dose response model, however, differences between fits using linear and LQ response 
models were consistent with the DDREF values reported by BEIR VII (Table 4.2). The NCI radio-
epidemiological assessment model93 considers a weighted discrete distribution of DDREF values 
with a mean value from the distribution of about 1.75. A recent meta-analysis of 12 radiation worker 
studies by Jacobs et al97 suggests a DDREF of 0.83 [0.53, 1.96] when these data are compared 
to the LSS. However, other differences between populations, and adjustments for dose protrac-
tion and a photon RBE different than unity for different types of low-LET exposures are con-
founding factors in a comparison of radiation worker data to the LSS data. 
 
The use of LSS data to make DDREF estimates raises some conceptual issues. It is well 
known that the curvature or quadratic component of any dose response in the LSS is small and, 
of course, there were no exposures at low dose-rate. The lack of curvature could be due to in-
herent uncertainties in the data or the impact of pooling data from a heterogeneous population. 
Data for individual tumors have larger statistical limitations than overall solid cancer mortality risk; 
however, these data appear to be even better represented by linear dose response than by the 
mortality data in which UNSCEAR finds a linear-quadratic model a better choice for the latter. If 
the response is truly linear, a dose-rate dependence related to linear induction mechanisms should 
be considered. Also, these more recent lower DDREF estimates raise important issues as to the 
appropriateness of experimental data in human cell culture models or strains of mice that often 
show a significant quadratic dose response component. 
 
Several concerns arise in the BEIR VII analysis of animal data. First, BEIR VII did not consider 
all animal tumor data available but only a small set of such data. Second, mouse leukemia and 
lymphoma data were pooled with solid tumor data in the BEIR VII analysis of the DDREF; these 
data apply only to solid cancer risk estimates in humans. Certain mouse tumor types included are 
also believed to be poor models of human cancers. A notable example of this is ovarian tumors 
in mice, which seem to be inappropriate because the mechanisms for their induction is believed 
to be cell killing. Further, the report did not consider surrogate endpoint data in human cells, which 
would show a large range of DDREF values, and suggests that biological responses are through 
distinct mechanisms at low doses (< 0.1 Gy) compared to high doses of more than 1 Gy. 
 
We evaluated data in the literature for other mouse tumor studies not considered by BEIR VII, 
as well as for surrogate cellular endpoints including mutation, neoplastic transformation, and 
chromosomal aberrations. A wide range of DDREF values from unity to approximately 10 can 
be found. Of note is the studies by Loucas and Cornforth118,119 of chromosomal aberrations 
using MFISH [multicolor fluorescence in-situ hybridization], which found a linear response for 
acute effects and a dose-rate reduction factor for chronic irradiation of more than 5 albeit both 
dose response curves were adequately described as linear. Table 4.3 shows a survey of 
different recommendations and data sets. An average value that is slightly less than 2 is 
estimated. Based on available information, we chose to use the National Institutes of 
Health (NIH) report93 mean value of DDREF=1.75, which is intermediate between the BEIR 
VII and the NCRP Report No. 132 recommendations. We assume a log-normal PDF for the 
DDREF uncertainty with a geometric mean (GM)=1 and GSD=1.4 as shown in Figure 4.1. 
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Table 4.2. Summary of various estimates of the DDREF from human or experimental studies with cells and 
animals. 
Estimate or Recommended Value DDREF Estimate 
*NCRP Report No. 9898 2.5 
NCRP Report No. 1326 2 
BEIR VII: selected mouse tumor studies 1.5 [1.0, 4.4] 
BEIR VII: LSS data analysis 1.3 [0.8, 2.6] 
BEIR VII: Combined Bayesian Analysis 1.5 [1.1, 2.3] 
ICRP117 2 
*UNSCEAR17 1.22 
NCI93 1.75 
Jacob et al97 Radiation-Worker studies vs. LSS 0.83 [0.53, 1.96] 
Oncogenic changes in cell culture models ~1 to > 10 
*Solid tumors in mice from NCRP Report No. 64120 3.48 
NASA 2010 model 1.75 
*NCRP used the related quantity DREF instead of DDREF. 
**UNSCEAR did not make a DDREF recommendation; however, a comparison of its fitted LQ and 
linear dose response models to LSS data leads to value shown. 
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Figure 4.1. Monte-Carlo results for a sampling of log-normal distribution for the DDREF 
uncertainty with the values DDREF=1.75, GM=1, and GSD=1.4. The distribution is truncated at 
0.75, which allows a 0.05 probability of an inverse dose-rate effect where DDREF<1. 
 
 
4.5 Transfer Models Uncertainties 
 
Two models are often considered for transferring radiation-associated incidence or mortality 
rates from other populations such as the Japanese to a U.S. population. The multiplicative 
transfer model uses the fitted ERR functions and assumes radiation risks are proportional to 
spontaneous or background cancer risks. The additive transfer model uses fitted EAR functions 
such that radiation acts independently of other cancer risks. The NCRP recommends6 a mixture 
model for solid cancers with equal additive contributions from the multiplicative and the additive 
transfer models. For leukemia risk, the additive transfer model was recommended. 
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Table 4.3 Tissue-specific transfer weight T for multiplicative risk transfer. Additive risk transfer weight is 1-T. 
Tissue NCRP No. 132 BEIR VII NASA 2010 
Lung 0.5 0.3 0.5 
Breast 0.5 0* 0 
Thyroid 0.5 1.0* 1.0 
Digestive system 
(stomach, colon, kidney, 
esophagus) 
0.5 0.7 0.7 
Leukemia 0.0 0.7 0.5 
All Others 0.5 0.7 0.5 
*Based on meta-analysis results described in BEIR VII.16 
 
 
There are several considerations with regard to which transfer model is appropriate, least 
considered of which is the possibility of radiation quality dependence of the transfer model. 
Additive risk transfer models suggest that radiation acts independently of promotional effects 
in the population under study. Multiplicative risk transfer models suggest that radiation acts 
independently of other cancer initiators in the population under study.16 Mouse tumor induction 
studies with -rays suggest the multiplicative transfer model is correct for solid cancers and addi-
tive transfer for leukemia.121 The transfer model should depend on tissue type if distinct mecha-
nisms leading to cancer act in different tissues. There could also be transfer model dependences 
on age at exposure since older persons compared to younger ones are presumed to have more 
initiated cells, altered DNA repair capacity, a higher fraction of senescent cells, etc. The transfer 
model may also depend on radiation quality if HZE nuclei and neutrons produce tumors through 
different mechanisms than -rays, or on dose if distinct mechanisms of carcinogenesis occur at 
high vs. low doses. 
 
Lung cancer makes up the highest proportion of the overall cancer risks. BEIR VII assumed 
a higher weight for additive risk transfer for lung cancer based on the observation of additive 
interactions between smoking and radiation. BEIR VI,110 in assessing the interaction between 
smoking and workers exposed to high-LET -particles from radon, found a more than additive 
interaction. Because space radiation is comprised both of low- and high-LET particles, it is not 
clear which if any of these transfer weights is appropriate. The results of Tables 3.4 and 3.5 
imply that gaining the knowledge to decide which lung risk transfer model is correct po-
tentially impacts to space radiation protection more highly than many other considera-
tions, including improved forecasting of SPEs or adding large amounts of radiation 
shielding to spacecraft. In our revised model, we assume equal weights for lung cancer 
transfer to the U.S. population as recommended in NCRP Report No. 132.6 For cancers 
of the digestive system, a strong interaction with dietary factors is expected and BEIR VII 
assumes a higher fraction for the multiplicative transfer model with weight T=0.7. 
 
 
4.6 Baseline Cancer Rates and Life-table Data 
 
Astronauts are surely classified as “healthy workers”; however, in the past, average U.S. 
population data have been used to estimate cancer risks.6,98 Several types of uncertainties 
arise by assuming the average U.S. population to form the risk projection for astronauts. One 
uncertainty is the use of current calendar year data to project risks in the future. The Social 
Security Administration (SSA)122 has assessed changes in median life-span. Recent data show 
a general trend for increase in life span and reduction in cancer mortality, while overall cancer 
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incidence remains roughly constant.100 Errors due to future population evolution are not included 
in our uncertainty assessments, and are assumed as a model assumption. A second type of error 
is due to statistical limitations in population data at older ages, as reported by the NCI surveil-
lance, epidemiology, and end results (SEER) program. Cancer incidence rates above age 85 y 
may have non-negligible SDs, and some reports suggest a downward curvature in these data that 
is perhaps caused by cell senescence. A sensitivity analysis was made by comparing radiation 
risks for the varying assumptions of monotonically increasing, downward curvature and constant 
rates above age 85 y. Because the fraction of a population alive above age 85 y is small, we 
found differences for overall cancer risks to be small (<5%) after comparing different models 
for extrapolation beyond age 85 y. 
 
A third type of uncertainty is due to the choice of reference population, which is always assumed 
to be the average U.S. population. Alternative approaches would include the use of a military 
aviation population as the reference population for astronauts. However, incidence or mortality 
rates for pilots have large statistical errors and there are limitations in data collection.123 To es-
timate the potential size of errors due to the choice of baseline rates, we collected life-table and 
age-specific all-cancers data from each of the 50 states and the District of Columbia in the U.S., 
all of which have a large range in life-span and age-adjusted cancer rates (Appendix B). We 
also compared, in Appendix B, these data to predictions by level of urbanization. From these 
comparisons SDs for REID estimates for the average U.S. population relative to the individual 
states or Washington DC were less than 5%, albeit there is substantial variation in median life 
span or background cancer rates over the range of values for each state. We therefore ignored 
assignment of any error related to the definition of a reference population. As noted above, the 
influence of smoking on background cancer rates and radiation risks in A-bomb survivor data is 
much larger. Statistical errors in population data for never-smokers are generally higher than 
those for the average U.S. population data from SEER,99 and we introduced a normal distribu-
tion for these rates with M=1 and SD=0.15. However, when equal transfer weights are assigned 
for additive and multiplicative transfer models, the additive transfer model term dominates for 
never-smokers, thus reducing the importance of statistical errors in never-smoker cancer rates. 
 
 
4.7 Summary of Past Uncertainty Analysis for Low-linear Energy Transfer 
Radiation 
 
In Table 4.4 we compare the NCRP Report No. 126 CIs to the more recent reports from BEIR 
VII and UNSCEAR. The results are for an average adult population. Although several differences 
in the assumptions of the different models occur, the comparison indicates about a 2-fold 
uncertainty at the 95% CL for low doses of low-LET radiation in each of the models. 
 
 
Table 4.4. Comparison of model uncertainties from past reports on low-LET radiation cancer risks. 
Analysis %Risk for 0.1 Sv Comment 
NCRP Report No. 126 0.37 [0.115, 0.808] Gender avg. with 90% CI 
BEIR VII Males 0.48 [0.24, 0.98] 95% CI 
BEIR VII Females 0.74 [0.37, 1.5] 95% CI 
UNSCEAR Solid Cancer 0.502 [0.28, 0.735] Gender avg. with 90% CI; 
DDREF uncert. not considered 
UNSCEAR Leukemia 0.061 [0.014, 0.118] Gender avg. with 90% CI 
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5. Cancer Risks and Radiation Quality 
 
NASA currently uses the LET, L-dependent radiation QF function, Q(L) that was recommended 
by the ICRP26 to estimate organ dose equivalents for space missions.6,25,73 Organ doses are eval-
uated by a mass average of fluence spectra weighted by LET and QFs, Q(L) over each tissue 
contributing to solid cancer risks. For estimating leukemia risk, organ dose equivalents averaged 
over bone marrow sites as distributed in adults are used. As described by the NCRP,25 NASA 
does not use the ICRP radiation weighting factors, which are defined for external fields at the 
surface of the human body, because of their imprecision and the complex nature of the radiation 
fields in space. The approach developed at NASA is supported by recommendations by the 
NCRP in its Report Nos. 1326 and142.25 
 
The ICRP26 definition of the LET-dependent quality function is given by: 
 







100/300
100102.232.0
/101
)(
LL
L
mkeVL
LQ

 
 
The ICRP and NCRP have noted that the use of Q(L) or the alternative radiation weighting 
factors are simplifications because of lack of knowledge to assign a more precise relationship. 
 
QFs are based on a subjective assessment of maximum RBE values, RBEmax  for relevant 
endpoints from radiobiology experimentation. RBEmax is defined as the ratio of initial slopes for 
the radiation of interest to a reference radiation assuming that both radiation types have linear 
dose response curves at low dose and dose-rates. It is important to note that it is implicitly as-
sumed that DDREFs are not used for ions because RBEmax values are the basis to assign QFs. 
Reference radiation should be taken as Cs or Co -rays to accurately represent LSS exposures. 
RBEs for ions can be underestimated if x rays with energies below about 300 kVp are used as 
the reference radiation because the RBE for x rays relative to -rays is greater than unity and 
observed to exceed 3 at low dose for some endpoints.31 The ICRP and NCRP have noted lim-
itations in radiobiology data to assess radiation QFs.5,31 Other reports have discussed qual-
itative differences that might preclude the usage of QFs for estimating heavy ion effects.1,5 
 
In this section, we review available radiobiology data for RBEs and discuss biophysical models 
of radiation quality effects. We will discuss a rationale for defining new radiation quality functions 
that will 
1) Introduce distinct QFs for solid cancer and leukemia risk estimates. 
2) Replace the QF LET dependence with a differential dependence on Z*2/2  for light (Z4) 
and heavy (Z>4) charged particles. 
3) Discuss an alternative risk calculation using track-structure-based risk coefficients. 
4) Revise the uncertainty assessment of QFs. 
5) Provide an additional uncertainty assessment that considers a nonlinear dose response 
at low doses as suggested by NTE models of cancer risk. 
 
Uncertainty analysis of radiation quality effects need to address several questions that arise with 
regard to the radiation quality function including: 
 
1) Use of LET as a single parameter to describe the biological effectiveness of all particles 
in space, which includes charge numbers from Z=1 to 28, and energies corresponding to 
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low-energy recoil nuclei and stopping particles (<5 MeV/u) to relativistic ions with energies 
of 10 GeV/u or more. 
2) The maximum value of Q to be used. 
3) The shape of the Q function, including the slope in the rise to the maximum taken as 
linear by the ICRP, and the value of descending slope at high-LET or ionization density, 
which is taken as the power p= -1/2 by the ICRP. 
4) Problems related to deviation from linearity and qualitative differences between HZE 
nuclei and low-LET radiation. 
 
Experimental models of human cancer risks should be used to estimate the most meaningful 
RBE for risk assessment. The relevance of experimental models for human risks should be based 
on a small number of criteria,124,125 including: 
 
1) The model should represent tissues of interest for human risks. 
2) The cell of origin for cancer risks in humans is considered. 
3) Possible mechanisms of cancer risk are addressed. 
4) Host factors that modify the expression of cancer in humans must be addressed. 
 
Unfortunately, very few of the existing data sets on radiation quality fulfill one or more of these 
criteria, and very circumstantial endpoints have been used in the past to estimate RBEs for 
assessing cancer risks. NASA is supporting new studies at the NSRL with new approaches; 
however, few data have been reported at this time. 
 
Because of the large number of radiation types and energies in space, a theoretical approach is 
needed to extrapolate limited data to other doses and particle types. There are also limitations 
as to how many particles can be studied in experiments due to both economical and time con-
straints. LET, which is a measure of energy loss, is known to provide a poor descriptor of track-
structure and energy deposition in biomolecules, cells, or tissues. Biologically based methods 
are needed that are founded on fluence and track-structure rather than dose and LET, and that 
consider differences in biophysical events between HZE nuclei and -rays. Accurate QFs are 
not only important for improved risk calculations, but also to guide the design and evaluation of 
mitigation approaches such as radiation shielding and biological countermeasures. Shielding eval-
uations depend critically on the relative contributions of primary and secondary radiation14,69 that 
depend on the definition of QFs. Other questions that have received little attention in the past are 
possible correlations between DDREF and Q-values, variations of RBEs for different types of 
cancer, and approaches to estimate the impact of qualitative differences between heavy ions 
and -rays. The role of differences in the types of initial biological damage, processing of dam-
age, and subsequent signal transduction cascades in relation to aberrant tissue changes 
leading to tumorigenesis are also poorly understood. 
 
 
5.1 Review of Radiobiology Data for Relative Biological Effectivenesses 
 
5.1.1 Relative biological effectivenesses from human epidemiology studies 
Human data for high-LET-induced carcinogenesis are extremely sparse. Limited insights 
are provided from analysis of the neutron contributions to the LSS data from Hiroshima and 
Nagasaki, or from radon daughter exposures to miners and medical patients exposed to α-
emitters. Beyond statistical limitations in such data, there are important difference in the dose 
distribution among tissues and track-structure between the protons, helium and HZE nuclei in 
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space, and low-energy (<10-MeV) neutrons and -particles in terrestrial high-LET exposures. 
The neutron contributions to the A-bomb survivors’ data are usually treated with an RBE of 10; 
however, alternative approaches suggest higher dose-dependent values are plausible.113,115 The 
BEIR VI report110 made a thorough examination of -particle risks of lung cancer. However, the 
local deposition of the dose in the lung from radon is quite different from the low-energy helium 
ions that are produced largely by high-energy GCR protons in all tissues, thus making any infer-
ences from these data for space radiation risks quite difficult. ICRP Publication 9231 noted that 
studies with -emitters have estimated a low RBE compared to human studies for leukemia with 
-rays and x rays. Boice126 estimates, from a study of 1003 patients exposed to thorostrast re-
sulting in -particle exposure to the bone marrow, an effectiveness of -particles 1.33 times 
greater than that of -rays in the LSS of A-bomb survivors. In contrast, analysis of studies of liver 
cancer in thorostrast patients suggests RBEs of about 20 relative to the LSS results .127 These 
estimates carry large uncertainties. For space radiation, the only epidemiology study reported 
was the increased risk of cataracts found at low doses (<100 mSv),7,8 which suggests a large 
RBE (>10) for this endpoint. 
 
 
5.1.2 Animal carcinogenesis studies with heavy ions 
Animal studies generally demonstrate that HZE nuclei have higher carcinogenic effectiveness 
than low-LET radiation. However, the number of studies of animal carcinogenesis made with 
HZE nuclei is extremely limited, as summarized in Table 5.1. Dose response studies comparing 
tumor induction by -rays or electrons to HZE ions were measured for rat skin,128,129 mouse 
Harderian gland,130-132 rat mammary gland,133 and mouse leukemia and liver.134 These studies 
used one or only a few ion types, providing little information on the possible radiation quality 
dependence on RBE. The exception is the Harderian gland experiments, which consisted of 
seven ions of differing LET studied and exposures in a spread-out Bragg peak.130 Figure 5.1 
shows that a similar dose response for solid tumor induction is observed for high-energy Fe 
nuclei in different murine models at low doses with an excess risk of approximately 25% at 0.2 
Gy. Differences in cell sterilization effects or competing risks in the different models lead to 
different responses at higher doses. No data have been reported for murine models of lung, 
colon, and several other tumor types important for human radiation risk assessments. 
 
 
Table 5.1. Tumor induction studies with HZE nuclei. 
Tumor Model Tumor type HZE type Reference 
Mice (B6CF1) Life-shortening C, Ar, Fe Ainsworth et al135 
Mice (B6CF1) Harderian Gland He, C, Ar, Fe Fry et al130 
Mice (B6CF1)  Harderian Gland p, He, Ne, Fe, Nb, 
La 
Alpen et al132,133 
Rat (Sprague-Dawley) Skin tumors Ne, Ar, Fe Burns et al136.137 
Rat (Sprague-Dawley) Mammary tumors Fe Dicello et al133 
Mice (CBA) Leukemia, Liver  Fe Weil et al134 
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Figure 5.1. Excess tumors following iron irradiation for rat mammary133 at 1.0 GeV/u, mouse 
HHarderian gland131 at 0.6 GeV/u, and mouse liver at 1.0 GeV/u (LET=150 keV/m).134 
 
 
RBEs for Harderian gland tumors were estimated in the range from 20 to 40 for heavy ions at 
low doses.130,131 An experiment was also performed to compare 6 weekly fractions of 0.07 Gy of 
Fe nuclei to an acute dose of 0.4 Gy; this experiment showed the fractionated exposure leads to 
about a 50% increase in tumor prevalence compared to acute exposure.132 This suggests that 
even higher RBE values than estimated from acute dose response data are possible. RBEs for 
rat skin and mammary tumor induction by Fe nuclei are difficult to estimate because the low-LET 
radiation employed in these studies has zero initial slope. On one hand, an infinite RBE is esti-
mated if the low-LET initial slope is taken as zero. On the other hand, a modest RBE value of 
about 10 is found if the higher dose points for the low-LET radiation are forced to intersect the 
zero dose point using a linear fit. 
 
Weil et al134 reported the RBE for Fe nuclei at 1 GeV/u for hepatocellular carcinoma (liver 
tumors) was 50.9 ± 9.9 in CBA [carcinoma-bearing animal] mice. In contrast, the RBE for AML 
for Fe nuclei was 0.48 ± 0.007. The small RBE found for Fe-induced leukemia is similar to the 
values for -particles suggested by the thorostrast patient data and with neutron RBE studies of 
AML in mice that showed maximum RBEs of about 3.138,139 In considering leukemia risks, the con-
gruence of modest RBEs from human data, heavy ion, and neutron leukemogenesis studies 
along with studies of cell killing for progenitor cells for leukemias140 or loss of deletions with time 
after exposure141 lends support to a much lower QF assignment for leukemia compared to solid 
cancers. 
 
RBE estimates for heavy-ion- and neutron-induced tumors are confounded by the bending 
of the response curves at modest doses. Alpen et al131 arbitrarily ignored the higher-dose data 
to estimate an RBE using a non-weighted regression model. Edwards142 used a weighted re-
gression model to fit the same data sets while also ignoring the higher dose points in an attempt 
to avoid contributions from the downward curvature as the higher doses in the dose response. 
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Edwards142 notes the problems with this approach in determining the initial slope for -rays as 
well as the heavy ions. Both Edwards142 and Alpen et al131 considered each ion individually in 
their fits to these data. Cucinotta and Chappell24 applied functional forms motivated by TE or 
NTE models, which included a cell sterilization term, and made a global fit to all available data. 
In the NTE model, RBE estimates depend on dose below about 0.2 Gy. These RBE estimates 
are shown in Figure 5.2. Estimates for 600 MeV/u Fe nuclei range from about 25 in the TE model 
to as high as 80 in the NTE model at 0.05 Gy. The decline in RBE at high LET suggests a more 
negative power than p<-1/2, as embodied in the ICRP QF definition. Peak effectiveness was 
also near 200 keV/m instead of 100 keV/m as in the ICRP model. LETs in the range from 
between 30 and 180 keV/m were not measured. The lack of data at these LET values likely 
influences estimates of which LET value would lead to the largest RBE. It is not known whether 
the 600 MeV/u Fe is the most effective GCR ion, but its carcinogenic power is similar to fission 
neutrons for this system. The La and Nb ions studied are high LET, but dissimilar Z from the 
GCR of interest. For other endpoints, fission neutrons are likely to have a higher effectiveness 
than neutrons of different HZE nuclei studied in the past. However for the Harderian gland 
study, tumor response for fission neutrons were dependent on pituitary implants in a manner 
similar to -rays,143 while Fe nuclei showed a largely independent response to the pituitary 
implants.131 A peak in the QF of 30 or higher for HZE nuclei is supported by the Harderian gland 
experiment, and an even higher value in the recent report on Fe-nuclei-induced liver tumors.134 
However, more information is needed, especially in the LET range from 50 to 250 keV/m and 
at low doses, to prove or refute that a nonlinear dose response occurs. 
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Figure 5.2. Calculations of  RBEmax vs. LET in TE model, and the NTE model of RBE for doses 
of 0.05 or 0.2 Gy. 
 
 
5.1.3 Cellular studies on chromosomal aberrations and mutation 
For a large majority of biological endpoints, RBE peaks around 100 to 200 keV/m, and then 
decreases at higher LET values. HZE nuclei are very effective at producing chromosomal ex-
changes with RBE values exceeding 30 in interphase (as visualized using premature chromo-
some condensation)144 and 10 at the first post-irradiation mitosis for HZE nuclei.145 Table 5.2 
shows RBEmax for chromosomal aberrations (CA) human lymphocytes estimates for several 
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energies of Si, Ti, and Fe nuclei. Figure 5.3 compares Si and Fe data to data for neoplastic 
transformation of mouse C3H10T1/2 cells.146 A sharp peak in the RBE curve appears at specific 
LET values similar to those of the ICRP model. However, through use of more energies in the 
CA study, the LET value in which the peak occurs is shown to increase with Z. Individual curves 
for each Z are not observed if LET is varied with limited E resolution. A lower RBE is found for 
the transformation experiments because the RBEs are based on 225-kVp x rays, not -rays, 
and are the RBEs at 50% cell survival levels, which are smaller than RBEmax. 
 
 
Table 5.2. RBEs for chromosomal aberrations in human lymphocytes exposed to HZE nuclei at NSRL 
(George and Cucinotta, unpublished).144 
Ion Type (E (MeV/u)) LET (keV/m) Z*2/2 RBEmax for Total 
exchanges 
Si (93) 158 1133 22.1±1.8 
Si  (170) 99 689 31.6 ±3.8 
Si  (250) 77 519 30.1± 2.4 
Si  (490) 55 344 18.5±1.6 
Si (600) 48 311 11.8±1 .0 
Ti (240) 195 1318 21.4±1.7 
Ti (376) 152 984 23.0±1.8 
Ti (988) 107 633 28.2±2.4 
Fe  (150) 440 2700 4.4±0.4 
Fe (380) 220 1368 11.8±1.1 
Fe (450) 197 1242 27.6±2.2 
Fe (600) 178 1074 31.5±2.6 
Fe (750) 170 976 29.9±2.4 
Fe (1000) 151 881 28.0±2.1 
Fe (5000) 145 693 23.3±1.9 
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Figure 5.3. LET dependence of RBE. Left panel is RBEmax for chromosomal aberrations (total 
exchanges) in human lymphocyte cells for Si, Ti, and Fe nuclei relative to low-dose and dose-rate 
-rays.144 Right panel is RBE at 50% survival relative to 225 kVp x rays for neoplastic 
transformation of C3H10T1/2 mouse fibroblast cells.146 Solid circles are for delayed plating 
conditions, and open squares are for immediate plating. 
 
 
The RBE vs. LET relationship found for total exchanges is similar to earlier studies of gene 
mutation.147,148 For  HPRT mutations, Kiefer found maximum RBEs of about 20 to 25 for He and 
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O nuclei compared to 300 MVp x rays where the lowest x-ray dose tested was 1 Gy.148 Therefore, 
after considering possible differences in biological effectiveness between x rays and -rays for 
lower doses and dose-rates than those tested, RBEmax for HPRT mutations would likely exceed 
values of 30 for nuclei of the most effective Z and E. The CA and gene mutation data, as well as 
other data for cell inactivation, imply a higher-magnitude RBE peak at lower Z for fixed values of 
LET, which is consistent with the predictions of track-structure models. These data also suggest 
the slope, p, of the falloff with LET on the low-energy side of the RBE peak is more negative 
than in the ICRP Q. On the high-energy side of the peak, the RBE appears to decline in a 
manner underrepresented by LET. Here the LET is nearly constant at these energies as nuclei 
approach or exceed minimum ionization (~2 GeV/u). A single experimental campaign was made 
at the Brookhaven National Laboratory (BNL) alternating gradient synchtron (AGS) using ions of 
5 GeV/u allowing for a comparison to results for Fe from NSRL or other facilities. George and 
Cucinotta144 compared CAs for Fe at 0.6, 1, and 5 GeV/u with LE’s of 178, 150, and 145 
keV/m. Results suggest the decline in RBE with increasing E was greater than a LET 
dependence would predict. In fact, the ICRP Q(LET) model estimates an increased 
effectiveness for Fe nuclei as the energy is increased above 600 MeV/u. Track structure models 
that take into account the broadening of a track as velocity is increased predict RBE declines as 
energy is increased above 600 MeV/u.149 
 
The quality of chromosome damage or the mutation spectra has been noted to be different 
when heavy ions are compared to sparsely ionizing radiation.147 Novel multicolor fluorescence 
painting techniques of human chromosomes have clearly demonstrated that -particles and iron 
ions induce many more complex-type chromosomal exchanges in human cells than low-LET radi-
ation.150,151 Most of these complex chromosomal rearrangements will ultimately lead to cell death. 
In fact, only a small fraction of the initial damage is transmitted in mice 2 to 4 months after expo-
sure to energetic Fe ions. A low RBE for induction of late chromosomal damage was observed 
in the progeny of human lymphocytes exposed in vitro to energetic Fe ions, with the interesting 
exception of terminal deletions; this occurred with much higher frequency with heavy ions 
compared to -rays, leading to a very large RBE value.152 
 
 
5.1.4 Delayed effects from in-vivo and in-vitro studies 
Genomic instability in the form of delayed chromosomal aberrations or micronuclei has been 
measured in mice or rats by several groups,153-156 two-dimensional cell culture models,157 and 
more recently three-dimensional cell culture models have also been studied for genomic insta-
bility.158 These studies are typically undertaken to understand mechanisms and verify effects, 
and are often limited by the number of radiation qualities and doses studied. The relationship 
between delayed micronuclei appearance or chromosomal aberrations and cancer risk is also 
poorly understood. In general, high-LET radiation is more effective in producing chromosomal 
instability and delayed micronuclei than low-LET radiation, and in some cases no effect is ob-
served for low-LET radiation. However, RBE or dose-response curves have not been studied 
in any detail for these endpoints. 
 
 
5.1.5 Dose-rate and protraction effects for high-energy and charge nuclei 
 
For proton and HZE nuclei exposures at a low dose-rate of more than a few months, new 
biological factors may influence risk assessments, including redistribution in the cell cycle, 
repopulation, or promotional effects, especially when particle fluences are large enough to lead 
to multiple hits of target cells or surrounding cells and tissue. Very few experimental data are at 
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low dose-rates for HZE nuclei. Burns et al136 found split doses of Ar ions separated by from a few 
hours up to 1 day increased the risk of skin cancer in rats. Alpen et al132 found using seven 2-
week fractions of 0.07 Gy of iron increased risk to 50% compared to a single acute dose of 
0.4 Gy for harderian gland tumors in mice. The Skyhook study of Ainsworth135 considered life 
shortening in mice, comparing single acute with weekly fractions of several ions; however, the 
results were unclear with regard to any increase or decrease in risk as dose-rate is decreased. 
For -rays and neutrons, a number of studies for cancer induction or life shortening in mice were 
made, showing that the sparring effects for -rays and neutron effects may be increased due to 
protraction under certain conditions in some tissues.159,160 Important questions related to the dif-
ferences in life span, cell turnover rates, the role of cell killing, and mechanisms of initiation or 
promotion in humans and mice make difficult the estimates of the effects of protraction on risk. 
Elucidating possible differences in inflammation and immune responses at high vs. low or chronic 
doses is also needed to improve risk estimates. If protraction effects do increase the risk from 
high-LET radiation, such effects would be more important for a Mars mission than for the shorter 
lunar missions. 
 
An additional radiation quality uncertainty is caused by the scaling assumption used when 
applying ERR and EAR functions from low-LET studies. Here time-dependent factors such as 
time to tumor appearance are assumed to be independent of radiation quality. Data on tumors or 
genomic instability in mice with neutrons155,159,160 and the studies of rat or mammary carcinogen-
esis with HZE nuclei133,136 suggest that the latency time is reduced for high-LET radiation com-
pared to low-LET radiation. Few data are available to estimate the impact of these differences 
on risk estimates; however, those that do exist suggest RBEs are likely to depend on time after 
exposure. The so-called initiation-promotion models of cancer risk suggest that ERRs will decline 
with time after exposure16 and RBEs that depend on time after exposure are predicted from 
these models.161 
 
 
5.2 Biophysical Considerations 
 
The term “track-structure” refers to the description of the position of excitations and ionization of 
target molecules from the passage of ions through DNA, cells, or tissues. It is these initial insults 
from particles interacting with biomolecules that lead to all biological damage from radiation. Two 
types of initial damage are considered: (1) DNA damage through direct ionization or oxidative rad-
icals, and (2) oxidative damage to non-DNA structures (water molecules, proteins, etc.) leading 
to changes in signaling or tissue status and function. Track structure descriptions are used in 
theoretical models of biological responses to understand and extrapolate limited radiobiology 
data to other radiation qualities and doses.162 Monte-Carlo track-structure simulation codes 
have been used to study the distribution and types of initial DNA damage, including models of 
single-strand breaks (SSBs) and DSBs, base damage and clusters of different types of DNA 
damage163 and in the description of the oxidative damage.164 
 
Ionization and excitation processes caused by the track of the ion and the electrons liberated 
by an ion lead to a stochastic cascade of biological events. Originating from the primary track 
are the energetic secondary electrons, denoted as -rays, which can traverse many cell layers 
from the track. Figure 5.4 illustrates the stochastic nature of the energy deposition, showing a 
Monte-Carlo simulation of the radioloytic species produced by ions with an identical LET of 150 
keV/m but a differing charge number.164 The ICRP and NCRP approach to describe radiation 
quality assumes that the ions shown in Figure 5.4 produce the same cancer risk, although the 
initial physical-chemical stages are quite distinct. 
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Figure 5.4. Projections over the XY plane of simulated tracks segments (calculated at ~10-12 s) 
for the following impact ions: 4He (0.45 MeV/u), 12C (10 MeV/u), 28Si (90 MeV/u), and 56Fe (1 
GeV/u). Ions are generated at the origin along the Y axis in liquid water at 25C under identical 
LET conditions (~150 keV m-1). Each dot represents a radioloytic species.164 
 
 
Because of the complexity of particle tracks and biological systems and their response to 
radiation, a simplification scheme is always used to describe biological effects of radiation. The 
most commonly used approach is to introduce the concept of energy deposition as an empirical 
description of atomic collisions and ionization and excitation reactions by a given number of radi-
ation tracks (or fluence). Several biophysical models describe how energy deposition changes 
with particle charge and energy at the molecular and cellular level. However, the simplest ap-
proach is to assume that energy loss by particles (or LET) is approximately the same as the 
empirical quantity, energy deposited in the volume of interest. 
 
Values of LET are normally evaluated using the Bethe-Bloch formula or similar expression.33 
LET can also be calculated in terms of the radial distribution of dose as a function of impact 
parameter; denoted as the radial distance, t, about the track of the ion. The radial dose is the 
energy density distribution in a cylindrical shell of radius, t, about the path of the ion.165 Integra-
tion of the radial dose distribution over all values of t up to the maximum allowable value, tM, is a 
measure of the LET: 
 
   Mt exc tDtDtdtLET
0
)]()([2   (5.1)  
 
In Eq(5.1) contributions to the radial dose from ionization are denoted as D, and excitations 
by Dexc. The value of tM, which defines the track width, is a function of particle velocity that corre-
sponds to the range of electrons with maximum energy ejected by the passing particle. At suffi-
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ciently low energies (<0.1 MeV/u), nuclear stopping also contributes to the LET. At very high 
energy and charge number two-photon emission processes contribute to the LET.166 The track 
width can extend well beyond 100 m as the velocity of the ions approaches the speed of light. 
The primary electron spectrum from ion interactions with target atoms is folded with average 
transmission properties of electrons to obtain the spatial distribution of electron dose as a 
function of radial distance from the path of the ion (Kobetich and Katz, 1968):167 
 
 
  dd dnttEtddttD ii  )],(),([21)(  (5.2) 
 
In Eq(5.2)  is the initial electron energy, E is the residual energy of an electron with energy  
after traveling distance t, and (t,) is the transmission probability that an electron with starting 
energy,  penetrates a depth, t.  Equation (5.2) includes an angular distribution for the number 
of primary electrons produced from target atom i, ni, with energy, , and solid angle, . The cross 
sections for electron production from protons are typically scaled to heavy ions using the effective 
charge number, Z*, which includes a velocity-dependent screening correction at low energies. 
The accuracy of the angular distribution is found to substantially modify the radial distribution 
both at large and small radial distances, and to play only a minor role at intermediate values 
where a 1/t2 behavior holds. 
 
An ansatz168 can be used for the radial dependence of the excitation term, Dexc(t), which is 
important at small values of t (<10 nm), 
 
 2
)2/exp(),,()(
t
dtZACtD excexc    (5.3)  
 
where d=/2 hc/(2r), c is the speed of light,  is the ion velocity scaled by c, h is Plank’s 
constant, r = 13 eV for water, and Cexc, is a normalization parameter. In Eq(5.3), the radial 
extension of excitations is confined to very small distances (<10 nm) as characterized by the 
parameter d.168 Characteristics of the two components of the radial dose are illustrated in Figure 
5.5 for nuclei of LET close to 30 keV/m (1 MeV protons and 300 MeV/u Ne).169 The radial dose 
for Ne extends for many microns, while low-energy protons deposit all of their energy within 0.1 
micron of the track. The model of Chatterjee et al170 incorrectly assumes that energy deposition 
in so-called track core and penumbra make equal contributions (50% each), while in truth less 
than 20% of energy deposition is in the so-called “core” (see reviews by Kraft et al;171 Cucinotta 
et al169). 
 
The frequency distribution of energy imparted to a volume of biomolecular dimensions163 is 
more closely related to stochastic aspects of radiation tracks described by Monte-Carlo methods 
than it is to the radial dose. For high-energy ions, frequency distribution can be described using 
the impact parameter of the ion and distinguishing events in which the ion passes through a vol-
ume (primary-ion or -ray events) and outside a volume (-ray events).172 The two components 
can be weighted by considering the number of events as a function of impact parameter. The 
frequency distributions demonstrate energy deposition events in biomolecular targets that occur 
for high-LET radiation that are not possible with low-LET radiation, even at high doses (up to 
100 Gy of low-LET radiation).163 These higher-energy deposition events are usually confined to 
close to the track of the ion, often called the “track core,” and events similar to low-LET radiation 
at larger distances, often called the “track penumbra.” The distinction is somewhat arbitrary 
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because deposition will vary with dimension considered, and because -rays dominate energy 
deposition in both regions. 
 
 
Figure 5.5. Calculations of radial dose distributions to experiments for 1H at 1 MeV (LET=27 
keV/m) (left panel) and 20Ne at 377 MeV/u (LET= 31 keV/m) (right panel).169 
 
 
Goodhead et al173 reviewed energy deposition models and noted that using the probability of 
producing >9 ionizations in small volumes (<5 nm diameter), corresponding to a short segment 
of DNA, provided in the experiments of that time the best description of increased biological ef-
fectiveness at high LET. This number of ionizations is related to energy deposition >300 eV in 
this volume. Microdosimetry approaches, which use micron-size volumes, were shown to be 
inadequate for describing heavy ion effects or the effects of ultra-soft x rays. Ultra-soft x rays 
produce only low-energy electrons with short ranges (typically <20 nm), and are a useful probe 
of mechanisms or radiation action. Ultra-soft x rays were used in several defining experiments 
to demonstrate failed arguments in microdosimetry-based models. These arguments extend to 
the use of microdosimetry models of radiation quality, which are often motivated by detector con-
siderations rather than radiobiology and are often difficult to interpret due to artifacts such as 
wall composition, anode wires, and electronic noise inherent in the measurement. 
 
The spatial distribution of -rays plays an important role in describing RBE. Observations by 
Goodhead et al173 and earlier arguments from Katz174, predict that biological effects would be 
highly influenced by -ray effects rather than by LET alone. Figure 5.6 shows such a description 
comparing the frequency of energy deposition above 300 eV in a volume the size of the nucleo-
some. The comparisons illustrate that the parameter Z*2/ provides an improved descriptor of 
energy deposition in small volumes compared to LET. Deviations from a unique Z*2/ depen-
dence occur at low energy where the curves branch for distinct charge numbers. For identical 
LET values, the ion with the lowest charge is predicted to be more effective at energies above 
a few MeV/u. 
 
Research at the NSRL is making new estimates of radiation quality effects for a variety of 
endpoints with the focus on approaches to mechanistic understanding of biological effectiveness. 
However, very few comprehensive studies have been completed at this time. Here we note that 
in the past very detailed studies of radiation quality were made for DNA breaks, as well as for cell 
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inactivation and mutation for a large number of ion types. Such extensive studies would be dif-
ficult to repeat today because of the higher costs of many current  experimental approaches,  
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Figure 5.6.  Number of nucleosomes per cell receiving 300 eV or more as a function of LET (left 
panel) or Z*2/2 (right panel). Calculations are shown for H, He, Si, and Fe nuclei using methods 
of Cucinotta et al.172 
 
 
and certainly would take many years to complete. These older studies are useful to consider in 
terms of track-structure models. Figure 5.7, from Thacker et al,175 illustrates such track-structure 
effects for cell inactivation with several ions at a variety of LET values. The upper panel shows 
the RBE diverging for ions with similar LET values but differing charge numbers, while the lower 
panel shows much improved convergence when radiation quality is described by the parameter 
Z*2/. Similar observations by Belli et al176,177 suggested that protons were significantly more 
damaging than helium at the same LET for V79 cell inactivation and HPRT mutation. More ex-
pansive studies of diverging biological effectiveness for particles of identical LET, but differential 
Z and E, were made with heavy ions with energies from about 1 to 20 MeV/u. Figure 5.8 shows 
results expressed as an action cross section for inactivation of E. coli Bs-1,178 Bacillus subtilus 
(rec),179 and V79 mammalian cells.148,175,180 These experiments were compared to the Katz track-
structure model by Cucinotta et al,149,181 which is also shown in Figure 5.8. Good agreement is 
found in comparing the model to experiments. LET is a poor predictor of biological effectiveness 
in these comparisons, which was established by the use of many ion types and energies. Track 
structure models of DNA damage endpoints show similar deviation of LET response for nuclei 
with different Z. Figure 5.9 shows predictions from Holley and Chatterjee182 for the production of 
small DNA fragments (0.02 to 20 kbp [kilobase pairs]) by several HZE nuclei. The model shows 
that for two nuclei with the same LET, the one with the lower Z has a larger biological effective-
ness. It is also known that the production of the initial oxidative species varies by Z and E, and 
not by LET alone as shown in Figure 5.9 (right panel). 
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Figure 5.7. Reproduced from Thacker et al,175 the relationship between RBE and ionization 
density for V79 hamster cells (closed symbols) and T1 human cells (open symbols). Panel A: RBE 
vs. LET. Panel B: RBE vs. Z*2/2. 
 
 
 
 
Figure 5.8. Cross sections for inactivation of E. coli (panel A), Bacterial spores (panel B), and V79 mammalian 
cells (panel C) showing charge number branching in the LET dependence of biological responses (see Cucinotta et 
al181 for details). 
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Figure 5.9. Panel A shows calculations of total yields of fragments of double-stranded DNA with sizes from 0.02 to 
20 kbp for He, N, and Fe nuclei (for details see Holley and Chatterjee182) showing that lower Z nuclei have greater 
biological effectiveness at identical LET values than higher Z nuclei. Panel B shows results for Laverne183 of ferric 
ion yields in the Fricke dosimetry illustrating charge branching with LET for oxidative damage effects. 
 
 
The existing evidence therefore suggests that the radiation quality dependence of both the initial 
DNA damage and the non-DNA damage, such as the production of various oxidative species, is 
dependent on Z and LET or alternatively Z and E, and is not well described by LET alone. 
 
Although commonly used endpoints (eg, DNA breaks, cell death, mutation, and chromosomal 
aberrations used to investigate track-structure effects) are limited as surrogate markers to 
cancer risks, they are used under the assumption that cancer risks would follow similar relative 
changes as a function of radiation quality. HPRT mutations are clearly related to the deletion of 
segments of DNA in surviving cells; but the role of mutations and genomic instability that might 
evolve from deletions in cancer risk is still debated. While chromosomal aberrations are found in 
almost all human tumors, they can be both an initiating event or the result of genomic instability 
from an independent event. The NRC1 recommends that endpoints, such as chromosomal 
aberrations or cell inactivation, could be studied to evaluate track-structure and shielding 
effectiveness. However, it would be more useful for track-structure studies to be made with 
endpoints clearly related to cancer risk. 
 
 
5.3 Biophysical Models of Relative Biological Effectiveness 
 
Heavy ion and neutron dose response curves for tumor induction often appear to increase 
linearly at low doses and then bend over at moderate doses of 0.5 Gy or lower due to cell steri-
lization effects or competing risks.160 This bending in the dose response makes determination of 
RBEmax values difficult unless large sample sizes for multiple low doses are used. For describing 
tumor dose-response data in which cell killing or competing risks modifies the dose response at 
higher doses, a commonly used functional form, which we denote as the TE model, is given by: 
 
 2 ( )0 [ ( ) ( ) ]
L D
TEP P L D L D e
      (5.4) 
 
where the dose is denoted, D, and P0 is the background tumor probability. The   and 
coefficients are parameters that will depend on radiation quality. The dose-squared term (with 
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coefficient ) in Eq(5.4) is normally only considered for -rays or other forms of low-LET radiation 
such as high-energy protons or helium ions. Equation (5.4) can be thought of as a Taylor series 
expansion with higher-order terms typically ignored. 
 
It is a common assumption to represent radiation quality dependence in terms of  LET with the 
or linear induction term  rising with increasing LET to a peak and then decreasing at higher LET: 
 
 0 1 2( ) exp( )L L L       (5.5) 
 
And, similarly for the cell sterilization factor: 
 
 0 1 2( ) exp( )L L L       (5.6) 
 
The Do value for cell killing, which varies by LET, is given by 1/(L). 
 
In the TE model, the RBE becomes independent of dose at a sufficiently low dose in which the 
cell sterilization term and the -term can be ignored. RBEmax is defined as a low dose-limit given 
by the ratio of linear-induction coefficients for -rays and ions: 
 
 LTERBE


  (5.7) 
 
At low fluence, where less than one particle intersects the biological target under study, the 
biological action cross section, which is defined as the probability per unit fluence for the end-
point considered (eg, cell inactivation, mutation, or tumor induction), is a very useful quantity for 
discussing particle effects. This concept holds rigorously when exponential or linear dose 
response curves occur such that the simple relationship applies: 
 
 D F   (5.8) 
 
Using a conversion factor to have units of m2 for , keV/m for LET, and Gy for dose leads to: 
 
 / 6.24L   (5.9) 
 
The RBE is expressed in terms of the linear slope for -rays and the action cross section as: 
 
 
6.24RBE
L

  (5.10) 
 
A complication occurs if the dose response curve for particles contains nonlinear terms. The 
initial slope in a dose response curve will then be distinct from the final slope or a slope estimated 
at higher doses. In this case, models of nonlinear terms must be constructed to infer the action 
cross section from dose response data.162 The use of fluence is problematic for -rays, because 
of the complication of the distribution of electrons of varying LET that mediate -ray effects, and 
because a “low electron fluence” regime is difficult to observe experimentally for biological 
endpoints of interest (eg, doses of ~0.01 Gy or less). 
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Because of the large number of particle types and energies in space,  parametric repre-
sentations will be quite limited if no underlying biophysical model is used to describe track-
structure and dose response curves. Instead, a parametric approach built on an underlying track-
structure model would be very useful for extrapolation of experimental data. Biophysical models 
can describe how RBEs vary with radiation quality, and can be compared to the assumption of 
the QF function dependence on LET alone. One consideration is the assumed decline in effec-
tiveness at high LET by the power, p=-1/2, in the ICRP definition of Q(L). Katz and Cucinotta184 
studied the case in which a multi-target model represents the -ray biological response data. In 
the Katz model,162 the action cross section is calculated in terms of the radial dose distribution 
averaged over the target volume )(tD , and -ray dose response function, P(D), integrating over 
all distances from the ions track to the target as: 
 
 2 ( ( ))tdtP D t    (5.11a) 
 
For ions above about 5 MeV/u with Z<30, the cross section model of Katz et al162 is accurately 
described by the function: 
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where m can be interpreted to represent a target number or hit number, 0 is the saturation area 
of the sensitive part of biological system under consideration, and  is a measure of the value of 
Z*2/2 where  approaches 0. These constants are fitted to radiobiological data sets. Equation 
(5.11) predicts the action cross section above energies of about 5 MeV/u for Z<30, which then 
increases with Z*2/2 until reaching a maximum dependent on the value of . If an ion has a charge 
and speed such that Z*2/2 > , saturation occurs. Values of  ranging from 500 to 2000 were 
found in fits to a large number of radiobiology experiments with heavy ions.185 The action cross 
section deviates from this form at lower E where thin-down occurs (narrowing of the track relative 
to the biological target size) or for very high Z where >0. At low fluence, the RBE is found to 
follow the following relationship (Katz and Cucinotta, 1991):184 
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where D0 is a radiosensitivity parameter for the -ray data being considered. Equation (5.12) 
predicts that the RBE declines once the cross section saturates to its asymptotic value, 0, as 
higher LET values are reached with a power, p=-1. Katz has also described a “final slope” cross 
section for high doses that shows a distinct dependence on Z*2/2 and LET rather than Eq(5.12). 
At high dose, LET is shown to be a reasonable predictor of radiation quality effects, as should 
be expected because here -rays from many overlapping particle tracks occur. 
 
Of the biophysical models developed to describe heavy ion effects, the Katz model provides the 
most robust description of heavy ion dose responses and radiation quality. Mechanistically, the 
model contains several deficiencies,169,186 including neglect of stochastic aspects of radiation 
tracks and ignoring differences in biological effectiveness of electrons of different energies. In 
many applications, the multi-target model is also used, which ignores a linear response term for 
-rays and a time-dependent description of damage repair. The idea of an effective target size 
continues to be debated in radiobiology.187 There appear to be several important dimensions. 
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These are target sizes on the order of: (1) small segments of DNA (<10 nm) leading to DNA 
breaks including complex DSB, gene mutation, and also leading to chromosomal aberrations 
through a one-hit mechanism involving DNA mis-repair; (2) a micron related to the interaction 
between DSBs as a second mechanism for chromosomal aberrations; and (3) one to a few cells 
related to distributed oxidative damage leading to signal transduction processes and perhaps to 
NTE. The Katz model, which did not assume any specific ideas on target size, allowed fits to 
radiobiology data to determine characteristic size – perhaps one of the reasons for its 
parametric efficiency. 
 
A linear kinetics repair/mis-repair model188,189 that uses the Katz model track-structure model, 
but allows for a linear term in the -ray dose response that leads to an RBE model at low fluence 
given by: 
 
 0max 0(1 / ) mis
D
RBE k
L
     (5.13) 
 
where kmis is a constant representing the fraction of initial damage that is mis-repaired. The 
inclusion of the linear term for -rays does not reduce the accuracy of fits of the cross section as 
long as a multi-hit or multi-targeted term is dominant. This result predicts the same characteristic 
of declining RBE at high LET or Z*2/2 as Eq(5.12), which is due to saturation; however, it differs 
by reaching a maximum RBE at sufficiently low fluence, which is not true for Eq(5.12) when m>1. 
The RBE is predicted to decline like p=-1 at high ionization density. We note biophysical models 
and radiobiology experiments suggest that for identical LET values, the ion with the lowest charge 
will have the highest RBE as predicted by Eq(5.12) or Eq(5.13), at least for velocities above where 
the track is wider than the characteristic size of the biological target. Whether stochastic track-
structure models would alter these observations has not been studied in sufficient detail. In 
contrast, the ICRP model assumes p=-1/2, and the ICRP report states that ions with larger Z 
would have the higher RBE for a fixed value of LET.31 
 
 
5.3.1 Relative biological effectiveness in the non-targeted effects model 
We next consider an alternative to the linear dose response assumed by the TE model. A 
model that  considers deviations from linearity at low doses is motivated by studies of NTE. 
Non-targeted effects, including bystander effects and genomic instability in the progeny of ir-
radiated cells, have been shown to lead to nonlinear dose responses at a low dose (<0.1 Gy). 
Evidence for NTE effects are more extensive for high-LET than for low-LET radiation; however, 
this has largely been observed in cell culture models. More recently, the harderian gland tumor 
study with heavy ions was found to be better described by an NTE model as compared to a TE 
model.24 The BEIR VII16 and UNSCEAR17 reports reviewed recent scientific literature on NTE for 
low-LET radiation. Other research suggests that for high-LET radiation at low doses, NTE are 
clearly important and lead to nonlinear responses. Figure 5.10 illustrates2 the potential impor-
tance of NTE to NASA. NTEs would lead to different expectations for mission length, radiation 
shielding, and mechanisms of risk compared to TEs; therefore, understanding their role in risk 
assessment is of major importance to NASA. 
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Figure 5.10. Schematic of importance of uncovering basic mechanisms of cancer induction by 
space radiation.2 Determining the role of DNA damage vs. non-targeted effects has large implica-
tions for radiation shielding and mission duration, and in approaches to the design of biological 
countermeasures. In a DNA model, a linear response is expected with research focus on slope of 
response as function of radiation quality and radiation sensitivity. In the non-targeted model, 
shielding is ineffective and distinct targets for biological countermeasures are pursued. 
 
 
Many bystander experiments have focused on establishing effects and possible mecha-
nisms using cell culture models such as medium transfer from irradiated cells to un-irradiated 
cells.190,191 A second approach is the use of low-energy H and He microbeams of relatively high 
LET that target a fixed number of cell traversals of hit cells with concurrent identification of non-
hit cells that receive bystander signals.192 These experiments are not able to provide data on the 
shape of the dose response curve at low doses. Other experiments have used low doses of -
particles of high LET (90 to 120 keV/m) in which the average fraction of cell hits can be estimated 
based on the cell area. Data for sister chromatid exchanges,193,194 chromosomal aberrations,195 
and neoplastic transformation196,197 suggest that dose responses for high-LET radiation deviate 
from linearity at low doses, which is defined as less than one track per cell nuclei in which a flat 
or shallow dose response is observed. These experiments, under broad-beam irradiation condi-
tions, mimic conditions for exposures of interest for radiation protection on Earth or in space 
travel. 
 
The functional form of an NTE model includes a constant (dose-independent) term above a 
certain dose threshold. It can be assumed that the NTE term saturates as LET is increased for 
the radiation quality dependence of the NTE term. The NTE dose response model is written: 
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In the model, NTE are reduced as the dose is increased and all cells are hit. Because high-
energy ions deposit energy through -rays in many cells adjacent to cells directly traversed by 
a particle, Cucinotta and Chappell24 reasoned that it was more useful to reduce the NTE term by 
the cell survival probability as dose is increased rather than by the probability of cell traversal by 
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ions. The different choices should have only a minor effect since the TE term in Eq(5.14) is 
expected to dominate at higher doses. 
 
The dependence of NTE on LET can be described by a term that increases linearly with LET 
with an exponentially decreasing modifying factor at high LET as given by: 
 
 1 2( ) exp( )L L L     (5.15) 
 
where the parameter  represents the strength of the non-targeted effect,  is a saturation of 
NTE at high LET, and the step function  represents a likely threshold dose for the NTE, which 
is ignored in the data analysis and arbitrarily set at 0.01 Gy as it is assumed to occur at a dose 
lower than the experiments considered. The addition of the nonlinear induction term motivated 
by the NTE model was found by Cucinotta and Chappell24 to provide an improved fit compared 
to the TE model to the Harderian gland tumor data of Alpen et al.131 These results are modified 
here to consider the  additional data for lanthanum nuclei  from Alpen et al.132 Results in Table 
5.3 include statistical tests of quality of fit with the NTE fits providing an improved fit compare to 
the TE model for each test considered. 
 
 
Table 5.3. Parameters that result from global fits to all ions for Harderian gland tumor dose-
response data in the TE and NTE models as described. Also shown are test statistics for the good-
ness of fits of the models, including the Bayesian information criteria (BIC), Akaiki information 
criteria (AIC), and adjusted R2 test. Each test resulted in the NTE model providing an improved fit 
compared to the TE model. 
Parameter TE Model NTE 
Model  
P0   2.93±0.47 2.54±0.4 
, Gy-1 7.53±3.96 10.02±2.07 
Gy-1 (keV/m)-1 1.261±0.213 0.679±0.187 
 Gy-1 (keV/m)-1 0.0037±0.00058 0.0033±.0006 
 Gy-2 6.3±3.41 5.08±3.0 
Gy-1 0.25±0.065 0.231±0.016 
 Gy-1 (keV/m)-1 0.0051±0.0029 0.0033±0.0042 
 Gy-1 (keV/m)-1 0.0034±0.0027 0.005±0.0064 
 (keV/m)-1 - 0.12±0.06 
(keV/m)-1 - 0.0053±0.002 
Adjusted R2 0.933 0.954 
AIC 208.52 193.6 
BIC 222.42 209.24 
 
 
The diameter of the epithelial cell nucleus transformed in mouse Harderian gland tumors is 
about 5.5 m with a cell nucleus area, A, of about 24 m2. Using the relationship between dose, 
D (in units of Gy), and fluence, F (in units of m2), as D = F x L / 6.24, the number of ion hits per 
Gy per cell nucleus, H, is given by: 
 
 
6.24DAH
L
  (5.16) 
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Figure 5.11 shows the model fit to the Harderian gland experiment. The comparison shows 
that less than 1 Fe ion per 100 cells, which is more than double the tumor prevalence. The 
response curves for the heavy ions display a characteristic change in slope from a low-fluence 
region, in which NTE effects dominate, to intermediate regions, in which TE dominate and then 
bend and decrease as cell sterilization contributes at even higher fluence. 
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Figure 5.11. Comparison of NTE2 model24 to experiments131  for prevalence of  harderian gland 
tumors vs. the number of radiation tracks per cell nuclei (diameter of 5.5 m). Error bars represent 
standard errors. A mean LET of 0.23 keV/m is used to convert dose to number of radiation tracks 
for -rays. 
 
 
The RBE can be estimated near the crossover dose in which the linear induction term is equal 
to the nontarget term. The crossover dose can be found, for example, from Eq(5.14) as: 
 
 
( )
( )cr
LD
L

  (5.17) 
 
A dose-dependent RBE in then found for the NTE model given for ions of LET, L, at dose, DL by: 
 
 
( ) ( ) (1 )crNTE TE
L L
DL LRBE RBE
D D 
 
     , (5.18) 
 
which is assumed to hold down to a possible threshold dose for the non-targeted effect. The 
RBE is thus seen to be dose dependent even at doses below where cell sterilization and the -
term no longer contribute. For chronic irradiation at low fluence as occurs in space, the lower 
limit or a threshold dose for NTEs becomes an important consideration, and little is known in 
this regard. Many other considerations need to be addressed including the role of protective 
NTEs such as the induction of apoptosis, the tissue specificity of NTEs, and temporal aspects. 
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5.3.2 Saturation mechanisms in biological responses 
The declining biological effectiveness at the high ionization density observed in radiobiology 
experiments can be due to several mechanisms, as described in Table 5.4. The first mechanism 
is what is termed “overkill effects,” which occur due to energy deposition exceeding a value that 
is needed to cause an effect. In terms of an action cross section, saturation occurs when the 
cross section reaches a nearly constant value for increasing ionization densities. A second 
mechanism is denoted as “thindown,” which results when the spatial distribution of the -ray 
brush from an ion becomes limited by kinematics to a size smaller than the biological target 
size, although the ionization density is still large, often occurring at a velocity at which the Bragg 
ionization peak occurs. Since thindown depends only on the velocity of the ion and not on Z, it is 
determined by kinematics. A third mechanism may occur for endpoints such as mutation, neoplas-
tic transformation, or perhaps cancer induction when a significant cell killing probability reduces 
the viability of mutant or carcinogenic cells. Each of these mechanisms needs to be considered 
when describing the dependence of RBE or QFs with energy and charge as well as dose. A 
further consideration for cancer data is the role of competing risks from other causes of death, 
which also may vary with dose and radiation quality. 
 
 
Table 5.4. Summary of mechanisms for decline in biological effectiveness at high-energy densities. 
Mechanism Impact on RBE Impact on Cross Section,  
Overkill RBE declines like 1/LET  constant 
Thindown RBE declines >1/LET  decreases rapidly 
Competing risks from cell 
death or other tumors 
Dose dependent decrease at 
higher doses 
 does not apply at H>1 
 
H = number of cell hits per particle. 
 
 
5.4 Risk Cross Sections and Coefficients 
 
Descriptions of radiobiology data in terms of action cross sections lead naturally to the idea of 
a risk cross section, which originates in the ideas of Katz162,165,198 and is considered by Hoffman 
et al.199 and Curtis et al.200 Such an approach was  also discussed in NCRP Report No. 137.201 
In this approach, the form for a risk calculation as R = R0  D  Q/DDREF is replaced by R = R0 
   F were  denotes a risk cross section. Parametric forms for , as dependent on LET or 
Z*2/2 fit to available experimental data or to the ICRP quality function, were considered in NCRP 
Report No. 137.201 At first glance, it appears that the risk cross section is merely an alternative 
algebraic representation of the existing calculation replacing dose and Q by fluence and 
respectively. What was lacking in NCRP Report No. 137201 was a description of particle 
track-structure and biophysical considerations on the extrapolation to low dose. We hypothesize 
that risk cross sections would be useful to NASA if placed in the context of using track-structure 
and biophysical models to extrapolate experimental observations to other particle types and 
from acute responses at relatively high doses or fluences to chronic exposures of interest. 
 
Another approach was developed by which to consider the neutron components of the Atomic-
bomb exposures in Japan. Here, Kellerer and Walsh114 made a direct estimate of a neutron risk 
coefficient for a typical fission neutron spectrum. Using LSS data to estimate the neutron risk 
directly avoids the need for the use of the DDREF and its associated uncertainties. The method 
would not be applicable to space radiation or even other neutron energies, however, because no 
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human data fit a risk coefficient for these radiation types. One idea is that a neutron risk 
coefficient would represent the maximum value to be expected for any cosmic ray. However, the 
uncertainties associated with the neutron risk coefficient – especially with its smaller contribution 
in the dose estimates from DS02 compared to the earlier DS86 estimates as well as the 
complex mixture of particles in space – make knowledge of such a maximum estimate of limited 
value. Furthermore, the space radiation environment is variable, including solar cycle modulation 
of the GCR energies, random SPE occurrences with variable energies and total fluence, and 
shielding modifications to the proportion of secondary radiation. Therefore, as in the NCRP 
Report No. 137 description of a risk cross section, the lack of an underlying track-structure 
description and dose response model of proton and heavy ion radiobiology limits the 
applicability of such an approach for describing space radiation risks. 
 
The ideas discussed above on track-structure models can be used to allow a risk cross section 
to be written as188,189: 
 
 )),(1(
24.6
),(),( 0 EZP
LET
EZPEZ    (5.19) 
 
with 
 
 mZEZP ))/exp(1(),( 22*   (5.20) 
 
where the parameters, 0, m, and  should be based on subjective estimates from radiobiology 
experiments, and the low-LET slope, ,  estimated from human epidemiology data for -rays. 
Using Eqs(5.19) and (5.10), a QF function is then written: 
 
 ),(
)/(24.6
)),(1( 0 EZP
LET
EZPQNASA
  (5.21) 
 
The interpretation of the parameters is quite general, and is not tied to a particular track-
structure models per se, but rather is an efficient parameterization of radiobiology data for 
particles. The parameters can be described as follows: 0  is the maximum value of the cross 
section, which is  related to RBEmax for the most biologically effective particle types. m is the 
slope of the cross section for increasing ionization density, with values m>1 necessary to have 
RBE>1.  determines the saturation value of the cross section, where the RBE begins to decline. 
To estimate these parameters, high-energy protons of about 150 MeV have an LET similar to 
-rays as well as a kinetic energy below where nuclear reactions become important and many 
experiments have shown a biological effectiveness very similar to -rays. For this energy proton, 
we have P(Z,E)<<1, and Q ~1. For solid cancer risks, radiobiology data are sparse. However, 
the largest RBE for HZE nuclei is in the range from 20 to 50 for solid tumors in rodents, and for 
chromosomal aberrations and mutations in human cells (see Figure 5.12). A lower value is found 
for leukemia. This assumes a linear dose response at low particle dose, ignoring NTEs or other 
possible mechanisms, leading to deviation from linearity. Thus, for example, if a peak RBE value 
of approximately 40 is assumed for Si at 100 keV/m where P(Z,E)~1, 0 / can be estimated 
as 40100/6.24, with the inclusion of the DDREF discussed below. Only the ratio, 0 /  is 
considered here to simplify parameter estimates. Alternative choices for the monoenergetic 
particle in which the peak occurs would not change numerical estimates appreciably, and  
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Figure 5.12. Action cross sections vs. Z*2/2 for several biological endpoints in mammalian cells. 
Experimental data for total exchanges (George and Cucinotta, unpublished),144 dicentrics,202,203 
HPRT mutations in human fibroblasts,204,205 human lymphoid cells,206 HPRT mutations in V79 
Chinese hamster cells,148,175,177 and C3H10T1/2 neoplastic transformation.146,196,207,208 
 
 
calculations should include uncertainty analysis through the use of PDFs to represent subjective 
assessments of ranges for each parameter. A similar estimate of 0 could be made from the 
Kellerer and Walsh114 estimate of the neutron risk coefficient if one chooses the particle with the 
maximum effectiveness.  
 
Defining uncertainty ranges for the three parameters of Eq(5.21) can be made in the following 
manner: Based on studies of past radiobiology experiments, values of m are narrowly defined 
over the interval from >1 to 4 with m=2 and 3 occurring most frequently,161,185,209 including fits 
to Harderian gland tumor data, and neoplastic transformation as well as gene mutation or chrom-
osomal aberrations in mammalian cells with heavy ion beams. The uncertainty range of 0 cor-
responds to the range for the maximum Q value for the most effective particle. Lastly, the value 
of  requires studies of ions with different energy and Z to identify the most effective energy or 
value for Z*2/2. Values can be estimated from past radiobiology experiments. Table 5.5 illus-
trates how E changes for different Z for fixed values of Z*2/2; eg, the maximum effectiveness for 
protons and He is expected near 0.5 MeV and 1 MeV/u, respectively. Experiments with Fe nuclei 
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suggest the peak effectiveness is approximately 600 MeV/u, with experiments performed at 
lower or higher E showing a lower effectiveness (Figures 5.3 and 5.12). A reasonable range for 
the RBE peak for Fe is energies of 500 to 1000 MeV/u, which correspond to Z*2/2 between 900 
and 1300 (Table 5.5). (Note: The value of  corresponds to roughly one half the value of Z*2/2 
in which the peak for the RBE occurs.) Less is known for other Z values. Basing QFs or risk 
cross sections related to an underlying track-structure model provides improved confidence in 
these descriptions, including that the energy at which the Q is maximum, would be similar to the 
value of Z*2/2 for the maximum found for Fe nuclei. PDFs describing possible ranges of values 
are described below. 
 
 
Table 5.5. Kinetic energy values for different charge number, Z, corresponding to fixed Z*2/2. Calculations use the 
Barkas model210 of the effective charge number. 
  Kinetic Energy (MeV/u) for Charge Number (Z) at fixed Z*2/2 
Z*2/2  1  2  6  10  14  20  26 
100  4.7  19.3  234  >10 000  NA  NA  NA 
250  1.85  7.5  75.5  272  1070  NA  NA 
500  0.93  3.75  35.5  110  264  1155  NA 
750  0.61  2.5  23.3  69.4  153  424  2042 
1000  0.45  1.85  17.2  50.5  108  272  707 
1250  0.35  1.46  13.7  39.8  83.2  199  445 
1500  0.28  1.2  11.3  31.6  65.4  157  326 
1750  0.24  1.01  9.7  27.8  57.1  130  258 
2000  0.2  0.88  8.4  24.2  49.4  110  214 
 
 
Describing radiation quality effects in terms of Z*2/2 is consistent with radial dose models 
of track-structure, and describes some aspects of stochastic track-structure models. Both LET 
and the ionization cross section for -ray production are proportional to Z*2/2; however, LET has 
other important Z- and dependent terms at low energy due to atomic shell structure and nuclear 
stopping corrections, and at high energies due to the Fermi density effect. The use of Z*2/2 does 
not take into account differences in track-width between two particles with identical Z*2/2. This 
effect will be most important at low energy (<10 MeV/u). Only light ions make important contribu-
tions at these energies for GCR because of their longer ranges and the large nuclear production 
cross sections for hydrogen and helium in tissue. Possible deficiencies of radial dose in describ-
ing track-structure would include the absence of a description of differences in biological effec-
tiveness of different -rays energies, especially for energies below 10 keV. Tracks of low-energy 
hydrogen and helium nuclei will contain a higher fraction of -rays of these energies, thus possibly 
increasing their biological effectiveness compared to higher Z nuclei of the same Z*2/2. Stochastic 
track-structure models have not been applied to any great extent in describing heavy ion effects, 
except for modeling DNA damage. It will be important to extend these models to endpoints that 
are more closely related to cancer risk in future to understand any shortcomings in using Z*2/2 
in the description of risk cross sections. 
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6. Revised NASA Model for Cancer Risks and Uncertainties 
 
In this section, we integrate the new findings and observations described in this report to in-
troduce a revised NASA assessment model of space radiation cancer risk. Figure 6.1 shows 
a flow chart of the major components of the calculation. In using the BEIR VII approach, we 
recommend a departure from NCRP Report No. 1326 whereby we transfer incidence rates from 
exposed cohorts to the U.S. rather than use mortality rate transport. The ratio of U.S. background 
rates for mortality to incidence are then used to convert REIC to REID estimates. Arithmetic weight-
ing of multiplicative and additive risk transfer models are used to transfer to the U.S. population 
in the same manner as NCRP Report No. 132.6 The preferred multiplicative transfer weights, T, 
are listed in the last column of Table 4.3. An alternative calculation for lifetime never-smokers 
(NS) is also described by the revised NASA model using the adjusted rates for never-smokers 
for lung, stomach, bladder, oral cavity, and esophagus cancers described in Section 3 of this 
report. For the ERR and EAR functions, we prefer the UNSCEAR model fitted to the LSS data. 
The BEIR VII report assumes no age at exposure dependence of cancer rates above age 30 y, 
and uses LAR instead of REID in fitting the LSS data. Furthermore, Appendix D of the UNSCEAR 
report17 showed an improved fit to the LSS data for Eq(3.11) used by UNSCEAR as compared 
to Eq(3.9) with c=0 used by BEIR VII. Therefore, the UNSCEAR17 models are recommended for 
most tissue sites. For several tissues that UNSCEAR did not consider, we use the results from 
Preston et al,92 however, and the remainder term adjusted accordingly. For breast and thyroid 
cancers, we follow the BEIR VII recommended models based on meta-analysis of several ex-
posed cohorts. Table 6.1 summarizes the sources of ERR and EAR functions used in the rec-
ommended NASA model. We assume an average DDREF value of 1.75 for solid cancer risks 
similar to the value by the NIH,93 which is the GM value of the PDF for the DDREF used in our  
 
 
Figure 6.1. Flow chart for REID and REIC calculations. 
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uncertainty analysis. In calculating leukemia risk, no DDREF value is used. The quadratic dose 
response term in fits to the LSS data are to be ignored; however, they should be considered as 
SPEs with dose-rates >0.1 Gy/hr. 
 
The tissue-specific cancer incidence rate for an organ dose equivalent, HT, is written: 
 
 0( , , ) [ ( , ) ( ) (1 ) ( , )] TI T E T E I T E
HH a a v ERR a a a v EAR a a
DDREF
     (6.1) 
 
where ERR and EAR are the excess relative risk and excess additive risk per Sievert, 
respectively. The tissue-specific cancer mortality rate for each tissue site is written: 
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The rates for each tissue using Eq(6.2) are summed to estimate the REID using Eq(3.4). A 
comparison of Effective doses that lead to REID=3%, under the assumption of equal organ 
dose equivalents for each tissue, can be made to the current dose limits at NASA. These com-
parisons are shown in Table 6.2 where we also show a similar calculation using the BEIR VII 
model. All calculations used recent cancer incidence and life-table data for the U.S. population, 
which is for 2005 (SEER, 2008).211 In the recommended NASA model, dose limits are slightly 
less restrictive at younger crew ages (<40 y), but become more restrictive above age 40 y and 
older. We also show in Table 6.2a and 6.2b the dose limits that are recommended for lifetime 
never-smokers based on the analysis described in Section 3. The recommended never-smoker 
limits are more than 20%, or 30% less restrictive for males and females at age 30 y, respectively, 
than the model based on the average U.S. population with larger differences at older ages of 
exposure. However, estimates for never-smokers are more restrictive than those for the NCRP 
model; ie, above about age 50 y. 
 
 
Table 6.1. Tissue-specific cancer risks considered in recent studies that are used in the NASA revised model. 
Tissue BEIR VII UNSCEAR Preston et al NASA 2010 
Stomach X X X UNSCEAR 
Colon X X X UNSCEAR 
Liver X X X UNSCEAR 
Lung X X X UNSCEAR 
Breast X X X BEIR VII 
Prostate - - X Preston et al 
Uterus X - X Preston et al 
Ovary X - X Preston et al 
Bladder X X X UNSCEAR 
Esophagus - X X UNSCEAR 
Brain-CNS - X X UNSCEAR 
Thyroid X X X BEIR VII 
Oral Cavity - - X Preston et al 
Remainder X X X Preston et al 
Leukemia X X - UNSCEAR (Little 
et al10) 
Nonmelanoma 
Skin 
X X X Future work 
Bone Cancer - X X Future work 
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Table 6.2a. Effective dose limits for females on 1-y missions for a 3%REID assuming equivalent organ dose 
equivalents. 
Age, y NASA 2005 BEIR VII NASA 2010 
Avg. U.S. 
NASA 2010  
Never-smokers 
30 0.5 Sv 0.55 Sv          0.49 Sv 0.68 Sv 
40 0.6 0.59 0.52 0.76 
50 0.9 0.64 0.57 0.84 
60 1.6 0.73 0.66 0.97 
 
 
Table 6.2b. Same at Table 6.2.b but for males. 
Age, y NASA 2005 BEIR VII NASA 2010 
Avg. U.S. 
NASA 2010  
Never-smokers 
30    0.6 Sv     0.79 Sv    0.73 Sv 0.93 
40 0.8 0.80 0.79 1.04 
50 1.15 0.83 0.87 1.17 
60 2.0 0.94 1.0 1.38 
 
 
6.1 Track-structure-based Risk Model 
 
As shown by Eq(5.19), calculations with radiation QFs and a risk cross section are related 
to each other through a simple algebraic formula. However, the approach of Eq(5.19) more 
naturally aligns with track-structure descriptions of radiation quality, including models for the 
extrapolation of experimental data from acute to low dose and dose-rates and other radiation 
qualities. In the track-structure-based model, Eq(6.1), or similarly Eq(6.2), is replaced by: 
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where I is the inner-bracketed term in Eq(6.1) that contains the ERR and EAR functions. 
 
Recommended parameters for the risk cross section are shown in Table 6.3. The model 
contains the three parameters (m, , and 0) that describe variations with particle type as well 
as the -ray slope (). However, we also assume a description of “thindown” at low energies. 
Here Eq(5.19) accounts for the saturation, but not for the thindown, mechanism where the track 
width becomes smaller than the biological target. For low energies, we modify the cross section 
by the factor PE=1-exp(-E/ETD) to account for thindown. The value of ETD=0.2 is based on exper-
imental data for H and He. This factor has a very small impact for heavy ions since at low E they 
make a very small contribution for GCR or SPEs. The values for 0/ correspond to maximum Q 
values of 40 and 10 for solid cancer and leukemia, respectively. We assume the parameter  has 
distinct values for light and heavy ions (Table 6.3). Equation (5.19) was suggested by radial 
dose models of track structure. Radial dose models do not account for some aspects of track  
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Table 6.3. Cancer risk cross section or QF parameters for solid cancer and leukemia risks.*. 
Parameter Solid Cancer Leukemia 
m 3 3 
 550 (1000) 550 (1000) 
0/ m2 Gy 7000/(6.24) 1750/6.24 
ETD 0.2 MeV/u 0.2 MeV/u 
*Values in parenthesis for when distinct values for light ions (Z  4) are to be used. 
 
 
structure, as discussed in Section 5, which suggests that the models do not allow us to describe 
light and heavy particles  with a single parameter set. 
 
Radiobiological experiments have shown the peak effectiveness at about 600 MeV/u for Fe, 
0.5 MeV for protons, and 1 MeV/u for helium, which led to our distinct choices for heavy and 
light nuclei. As another example, several studies show the peak for Si to be in the range of 90 to 
300 MeV/u for CA (George and Cucinotta, unpublished),144 gene mutation,206 and neoplastic 
transformation.146,212 However, more detailed studies are needed to improve estimates. The 
absence of animal tumor data for Si an important issue. The PDF describing  discussed below 
covers the range of existing data. Although there is likely some further dependence of on Z, 
there is little information to make more informed choices. This approach simplifies the calcula-
tion of uncertainties to two distributions of particles at each tissue site – FLI for Z<5, and FHI for 
Z≥5 – and provides flexibility in uncertainty analysis. Future studies can aim to improve these 
descriptions of particle track structure. An alternative approach would assume Q(L) is similar to 
the form used by the ICRP, but with the peak value (currently 100 keV/m) shifting with Z to 
higher values. Such an approach would require LET spectra for each Z to be determined, while 
the approach used here allows a simplification into just two spectra for light and heavy particles, 
and includes considerations of the uncertainty in the rising and falling slope of Q with changing 
ionization density. 
 
The use of a DDREF in Eq(6.3) needs to be addressed. Since we are assuming a model extrap-
olation from high to low dose, the DDREF is included in the scaling approach. The alternative 
would be to ignore the DDREF; however, the possibility of dose and dose-rate dependencies for 
low and medium ionizing particles would need to be considered in more detail than is allowed by 
the current approach. 
 
The model represents several changes from the ICRP QF: First, we assume a smaller max-
imum Q for leukemia than for solid cancer based on existing animal and human data. The RBE 
value for leukemia for fission neutrons is reported in the range of 3 to 5 for AML.138,160 However, 
there is little data for other types of leukemia. Data for heavy ions are sparse but also suggest a 
value below 10 and perhaps as low as 1. We assume the maximum Q is 10 for low-energy pro-
tons (~0.5 MeV). For projecting solid cancer risk, a maximum Q value of 40 is used. This value 
is about the average of the different values of RBEmax for the most effective particle found in 
animal tumor induction studies or cellular endpoints, such as chromosomal aberrations or gene 
mutation, and is consistent with values for neutrons for similar endpoints. Second, the NASA QF 
accounts for experimental and theoretical observations that radiation quality is a function of Z 
and E. The cancer risk cross section or related QF is expressed in terms of the track structure 
parameter, Xtr= Z*2/2, and we assume the Barkas form for the effective charge function210. The 
QF has an additional dependence on LET in the denominator of Eq(5.21), which relates the 
particle track structure to the absorbed dose. Figure 6.2 compares the NASA QF to the ICRP 
model used at NASA in the past for p, C, Si, and Fe nuclei vs. LET, thus illustrating the differ-
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ences as described. The preferred slope on the rising side with increasing ionization density of 
m=3 is different than the ICRP Q(LET), which rises approximately as m=2.  Our expectation is  
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Figure 6.2. Comparison of LET dependence for H, C, Si, and Fe nuclei in the proposed NASA 
QFs for solid cancer and leukemia risk estimation to QFs from ICRP.26 
 
that the proposed NASA QFs will not modify point estimates of risk substantially, except for 
smaller GCR-induced leukemia estimates. This will lead to different assessments of radiation 
shielding effectiveness, and an improved model of the uncertainty distribution because of the 
better representation of existing radiobiology knowledge than is provided by LET-dependent 
QFs. 
 
 
6.2 Updates to Radiation Transport Codes 
 
Using the HZETRN code or similar radiation transport codes, the fluence spectra, F(Xtr), can be 
found by transforming the energy spectra, j(E), for each particle, j of mass number, and charge 
number Aj and Zj, respectively, as: 
 
 
1
( ) ( )trtr j
j
XF X E
E

      (6.4) 
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where we evaluate the Jacobian in Eq(6.4) using the Barkas210 form for the effective charge 
number given by 
 
 
2 / 3* 125 /(1 )ZZ Z e    (6.5) 
 
The tissue-specific cancer incidence rate for GCR or SPEs can be written as: 
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The first term on the right side of Eq(6.6) can be well approximated by the tissue-averaged 
absorbed dose times the low-LET risk coefficient. This approximation can be shown to lead 
to <10% overestimation of its true value. However, in the REID calculation, the error is even 
smaller because the second term of the right side of Eq(6.6) is dominant. We modified the 
HZETRN and BRYNTRN codes to perform the exact calculation; but for the Monte-Carlo un-
certainty analysis we can use the following form for the radiation cancer rate for the mixed 
particle and energy fields in space: 
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where we separate out spectra for light ions with Z≤4, FLI from heavy ions, and FHI with higher 
charges as described above. A summation of all cancer types is made for the radiation contri-
bution to the survivor function that enters into the REID or REIC formula in evaluating specific 
tissue risks, and to evaluate the overall cancer risk. Fluence spectra are averaged over each 
tissue using body-shielding models. Previous versions of HZETRN and BRYNTRN had included 
Z=1 and Z=2 target fragments as part of the transported particle energy spectra. However, the 
Z=3 to Z=8 target fragments in tissues that are of low energy (<10 MeV/u) and have very small 
ranges were modeled using parametric dose functions. To more readily include their contribu-
tions to the revised risk model and associated error analysis, we modified these codes by adding 
the target fragment spectra into the Z=3 to Z=8 energy spectra for primaries and projectile frag-
ments on entry to the existing DMETRIC and the new cancer risk cross-section subroutines in 
these codes. 
 
We show the resulting differential REID spectra vs. Xtr at solar minimum behind increasing 
amounts of aluminum shielding in Figure 6.3. Calculations are made with the HZETRN code 
using the Badhwar and O’Neill GCR model51 and QMSFRG nuclear cross-section database.39,72 
Results are shown on a linear-log plot such that the area under the curve for each decade of Xtr 
is equally weighted. Leukemia risk shows a reduced maximum Q-value compared to solid cancer 
risks, resulting in particles at lower values of Xtr that make larger contributions compared to solid 
cancer risks. Figure 6.3 shows sharp spikes at the integer value of Z2 corresponding to different 
GCR charge groups. For example, at small values of Xtr we see peaks at 1 and 4 corresponding 
to protons and He nuclei. At large values of Xtr we observe a prominent peak near 626, which 
corresponds to Fe nuclei. These sharp peaks correspond to the contributions from relativistic 
particles. 
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Figure 6.3. Leukemia and solid cancer risk distribution vs. Z*2/2 for increasing amounts of 
aluminum shielding for 1 y in deep space at solar maximum with the August 1972 SPE. 
 
 
6.3 Effective Dose and Tissue Weights 
 
In the approach described above, tissue weights, wT, do not appear in the calculation of REID or 
REIC; however because Effective dose is still a useful summary variable for mission operations, 
we estimated gender-specific wT values (Table 6.4) averaged over typical astronaut ages (30 to 
60 y). The use of the terminology, “Effective dose” of course refers specifically to the ICRP 
definition. However NASA continues to make adjustments to methods from the ICRP and NCRP 
based on the unique circumstances of space radiation protection. The use of this terminology 
with modified values is intended strictly for internal NASA usage. Several differences in values 
for the tissue weights estimated here compared to the ICRP values. First, the ICRP includes 
hereditary risk and nonlethal cancer in its considerations of radiation detriment in recommending 
wT values. In comparison, NASA uses cancer-mortality-based risk limits (REID) based on NCRP 
recommendations6. The ICRP averages tissue weights over age and gender, including values 
for preadults because its simplified methods are intended for use in both occupational and 
public exposures. Comparison of the ICRP values to gender-specific estimates in the NASA 
model for adults (30 to 60 y) are shown in Table 6.4. Distinct values would occur for different 
radiation fields because of the different QF used for the leukemia risk estimate. Never-smokers 
also have different tissue weights than the average U.S. population due to lower contributions 
from smoking-attributable cancers. The ICRP wT values for skin, gonad, and thyroid, which make 
negligible contributions to the REID, can lead to very high estimates of Effective doses for SPEs in 
which steep dose gradients occur, especially for extravehicular activity risk assessments. The 
values in Table 6.4 are good approximations for SPEs or trapped protons; however, for GCR, 
the leukemia weights are reduced and solid cancer weights are increased as indicated by 
values in parentheses. 
 
We compare calculations of annual Effective dose in the ICRP model to the NASA-recommended 
model for ISS missions at solar minimum and maximum in Figure 6.4. Comparisons for aluminum 
and polyethylene shielding are shown. The AP8 model of trapped protons is used, as is the 
Badhwar and O’Neill model of the GCR environment with quiet-time geomagnetic cutoffs. The 
CAM [computerized anatomical man] and CAF [computerized anatomical female] models of 
tissue self-shielding213 are used to evaluate of organ dose equivalents. Figure 6.5 shows similar 
comparisons for 1 y in deep space. The ICRP model, due largely to its higher estimation of con-
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tributions for relativistic particles than described here, provides higher estimates at shallow 
shielding depth. At deep shielding depths, the NASA model is larger due to its assignment of 
higher biological effectiveness to low-energy proton and helium nuclei produced by neutrons and 
other particles and from atomic slowing down of primaries. For the various mission scenarios, 
differences in Effective doses are on the order of 10% to 30%; but the NASA model allows for a 
more precise uncertainty assessment to be made than the ICRP Q function, whose parameters 
are difficult to relate to biophysical interpretation. Figure 6.6 shows predictions of the Effective 
dose map on the surface of Mars using the MOLA [Mars orbiter laser altimeter] data to determine 
the vertical height of the carbon dioxide atmosphere and assuming a 10 g/cm2 aluminum habitat. 
Shown are results for the 1972 SPE using the King spectra (and the annual GCR at solar min-
imum. GCR Effective doses will be much larger than SPEs on the martian surface due to the 
attenuation of the SPEs by the martian atmosphere. Comparisons of Figure 6.6 will be useful 
for the selection of future crew landing sites on the Mars surface to minimize crew risks. 
 
 
Table 6.4. Tissue weights from past ICRP reports, which are gender-average and gender-specific values estimated 
from the NASA 2010 model for the average U.S. population and a population of never-smokers. 
Tissue ICRP 
1991 
ICRP 
2007 
NASA  
Avg. U.S.  
Males 
NASA 
Avg. U.S. 
Females 
NASA NS 
Males 
NASA NS 
Females 
Colon 0.12 0.12 0.098 0.057 0.107 0.093 
Stomach 0.12 0.12 0.085 0.061 0.125 0.086 
Liver 0.05 0.04 0.067 0.047 0.076 0.053 
Lung 0.12 0.12 0.289 0.495 0.192 0.322 
Bladder 0.05 0.04 0.075 0.033 0.062 0.045 
Breast or 
Prostate 
0.05 0.12 0.021 0.053 0.035 0.083 
Ovary/Uterus or 
Testis 
0.2 0.08 0 0.044 0 0.067 
Brain - 0.01 0.016 0.01 0.022 0.016 
Esophagus 0.05 0.04 0.048 0.01 0.019 0.007 
Salivary Gland 
or Oral Cavity 
- 0.01 0.015 0.006 0.003 0.003 
Skin 0.01 0.01 0 0 0 0 
Thyroid 0.05 0.04 0.002 0.003 0.002 0.004 
Bone Marrow 0.12  0.12 0.194(0.15)# 0.10 (0.07)# 0.284 (0.21) 0.138(0.1) 
Bone Surface 0.01 0.01 0 0 0 0 
Remainder 0.05** 0.12** 0.089 0.079 0.073 0.083 
Total Solid 
cancers 
0.88 0.88 0.806 
(0.85)# 
0.90 (0.93)# 0.716(0.79) 0.862(0.9) 
*Remainder organ/tissue defined in ICRP 60: adrenals, brain, trachea, small intestine, kidneys, muscle, pancreas, 
spleen, thymus, and uterus. 
**Remainder organ/tissue defined in ICRP 103: adrenals, extra-thoracic (ET) region, gallbladder, heart, kidneys, 
lymphatic nodes, muscle, oral mucosa, pancreas, prostate, small intestine, spleen, thymus, and uterus/cervix. 
# Bone marrow weights in parenthesis are appropriate for GCR where impact of lower Q for leukemia becomes 
important. The resulting adjustment for over solid cancer weight is shown, and individual tissue weights should then 
be adjusted accordingly. 
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Figure 6.4. Comparison of annual Effective dose for males in ISS orbit (51.6 deg  400 km) vs. 
depth of shielding. Values for solar minimum and maximum are shown, comparing ICRP model 
to recommended NASA model. 
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Figure 6.5. Annual GCR Effective doses in deep space vs. depth of shielding for males. Values for 
solar minimum and maximum are shown, comparing ICRP model to recommended NASA model. 
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meters
 
 
 
Figure 6.6. (Upper panel) MOLA topography data from the Mars Global Surveyor (http://tharsis.gsfc.nasa.gov) for 
atmospheric density on Mars surface vs. longitude and latitude. (Lower panel) Effective doses (mSv) from August 
1972 SPE (left panel) and annual GCR (right panel) at solar minimum on surface of Mars behind 10 g/cm2 Al shield. 
 
 
6.4 Revised Uncertainty Assessment 
 
PDFs describing the uncertainties to the quantiles, x, for the various parameters in the model 
are described in Table 6.5. Space physics uncertainties were described in Section 2, low-LET 
uncertainties were described in Section 4, and radiation quality uncertainties were described in 
Section 5. The subjective PDFs are then employed in Monte-Carlo calculations to describe a 
given space radiation scenario, as described previously.12.14,15,20 Figure 6.7 illustrates the uncer-
tainties in the Q value for solid cancer for monoenergetic particles (Si and Fe) vs. kinetic energy. 
The median values and 95% CIs are shown. The largest contributor to the Q-uncertainty is the 
maximum value, Qmax, or the value of 0. Our point estimates for Qmax of 40 or 10 for solid 
cancers or leukemia, respectively occur for the most effective proton energy (~0.5 MeV). Values 
assigned give more weight to the animal model solid tumor data and are influenced by 
fractionation studies that suggest that higher RBEs are possible. These values are also 
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consistent with RBEs for gene mutation and chromosomal aberrations in human cells. The 
resulting PDF has a 95% CI for the maximum value of Qmax for solid cancer as [14, 70], which 
covers most of the range of values from Fe nuclei tumor induction and earlier neutron studies 
reflective of low-energy protons. The possibility of NTEs suggests that higher values are 
possible. NTE contributions to uncertainties estimates are discussed below. we use in Table 6.5 
a GM=0.9 for the PDF associated with 0 with the expectation that some tissues would have 
lower values as found for leukemia; however, there is a lack of information to make a more 
informed choice. We did not consider uncertainty quantiles for the characteristic energy for 
thindown, Eth, and the m parameter in Eq(5.19). Estimates of values for these parameters are 
likely correlated with the values of m, ,and 0, and the addition of quantiles with small 
influence would not add to the analysis.214 The addition of a quantile for Eth would also create the 
complication of performing uncertainty analysis for each charge group, rather than the light and 
heavy charge groups considered here. The possible correlations between DDREF and Qmax (or 
0/) are difficult to estimate with existing data, however should be considered in future work. 
 
Table 6.5. Summary of PDF for uncertainty components in NASA model. 
Uncertainty Contribution PDF form for Quantile, xj Comment 
Low-LET Model: 
Statistical Errors Normal (M=1.0; SD=0.15) Revised since NCRP Report No. 
126 
Bias in Incidence Data Normal (M=1.0; SD=0.05) Based on NCRP Report No. 126 
Dosimetry Errors Log-normal (GM=0.9, 
GSD=1.3) 
Based on Preston et al;92 
UNSCEAR27 
Transfer Model Weights Uniform distribution about 
preferred weight 
Ignored for breast and thyroid 
cancers 
DDREF Log-normal (GM=1.0; 
GSD=1.4) 
DDREF=1.75; truncated at 0.75 
for inverse dose-rate probability 
<0.05 
Risk Cross Section or Q: 
0/ Log-normal(GM=0.9; GSD=1.4) GM<1 assumes existing data 
are biased to higher values 
 Normal (M=1, SD=0.2) Position of peak estimates 
suggests variation on sensitivity, 
target size/distributed targets 
m Discrete M=[1.5,2,2.5,3,3.5,4] 
with weights [0.05,0.1,0.2, 
0.4,0.2.,0.05] 
Values restricted over (1.5,4) 
Physics Uncertainties: 
F(Z*2/2) for Z<5 Normal (M=1.05; SD=1/3) HZETRN does not account for 
mesons, e-rays, and -rays that 
are low charge and high velocity; 
may underestimate neutron 
recoils of low charge 
F(Z*2/2) for Z5 Normal (M=1.0; SD=1/4) HZETRN accurate at high Z 
   
   
Non-targeted Effects:   
xNTE Uniform over [0,0.5] Maximum probability of 
occurrence of 0.5 
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Figure 6.7. Most likely QF values for solid cancer and 95% CIs vs. kinetic energy that results from Monte-Carlo 
evaluation using 20 000 trials. 
 
 
In an alternative model of the radiation quality uncertainties, we assume that the slope, m, is 
correlated with the position of the maximum value of Q as determined by the value of . After 
studying the functional dependence of the parameters of Eq(5.21), we find that the position of 
the maximum Q is held fixed for different values of m if we use the constraint: 
 
 0
4( )
( 1)
m
m
    (6.7) 
 
where 0 is the estimated value from Table 6.3, the results of which are shown in Figure 6.8. 
This alternative uncertainty assessment assumes that risk cross section for cancer induction in 
humans is fairly well described by the existing data, as reviewed in Section 5. In contrast, ignor-
ing the condition of Eq(6.7) places more emphasis on the lack of data for specific models of human 
cancer such as lung, colon, stomach, etc., such that a wider range of parameter variation is esti-
mated. Equation (6.7) allows uncertainties in the maximum Q value, slope of Q with changing 
Xtr, and kinetic energy at the Q maximum to occur; however values are more constrained com-
pared to the uncertainty analysis described above. A large part of the uncertainty is for particles 
with small to intermediate Z values, especially at high energy as illustrated by the differences 
between m=2 and m=3 shown in Figure 6.8. The alternative uncertainty model was applied 
using conditional Monte-Carlo sampling, where a random value of m is selected from its PDF 
prior to sampling for the  value with central estimate defined by Eq(6.7). 
 
The cancer risk projection for space missions is found by folding predictions of the tissue-
weighted Xtr spectra behind spacecraft shielding, F(Xtr), with the radiation cancer rate to form a  
rate for a Monte-Carlo trial . Results from each trial are binned to form an overall PDF function 
after a sufficient number of trials (on the order of 50 000) are made. Table 6.6a breaks down the 
contributors to the uncertainty at solar minimum. Table 6.6b shows comparisons near solar max-
imum, assuming the 1972 SPE occurred during a 1-y deep-space mission. The low-LET uncer-
tainties lead to an upper 95% CI approaching 2 times the point estimate, and can be compared 
to the estimates made in the past listed in Table 4.4. The Q uncertainties make up the largest 
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fraction of the uncertainty. The overall uncertainty is about 3.6, and this factor will increase mod-
estly as mission length is shortened because competition with other risks is smaller at lower risk 
levels. Table 6.7 shows a similar calculation using the alternative Q uncertainty model that in-
cludes the constraint of Eq(6.7). Uncertainties are significantly reduced in this model with a 
2.8-fold overall uncertainty. 
 
 
Table. 6.6a. Contributions of various uncertainties for 40-y females on a 1-y mission at solar minimum in deep 
space with a 20-g/cm2 aluminum shield. 
Uncertainties 
considered 
Expected Mean Median STD Lower 
95% 
Upper 
95% 
Fold 
Uncert. 
Epidemiology 3.23 2.95 2.84 0.78 1.61 4.64 1.44 
DDREF 3.23 3.40 3.23 1.02 1.78 5.78 1.79 
Epidemiology 
DDREF, 
Transfer 
3.23 3.10 2.79 1.36 1.17 6.44 1.99 
Q 3.23 3.92 3.19 2.30 1.87 10.8 3.34 
Q and Physics 3.23 3.99 3.28 2.35 1.91 11.1 3.44 
All uncertainties 3.23 3.78 2.97 2.70 1.03 11.5 3.56 
 
 
Table. 6.6b. Contributions of various  uncertainties for 40-y females on a 1-y mission at solar maximum with 
August 1972 SPE in deep space with a 20-g/cm2 aluminum shield. 
Uncertainties 
considered 
Expected Mean Median STD Lower 
95% 
Upper 
95% 
Fold 
Uncert. 
Epidemiology 1.89 1.73 1.63 0.54 0.87 2.94 1.56 
DDREF 1.89 2.00 1.89 0.59 1.04 3.38 1.79 
Epidemiology 
DDREF, Transfer 
1.89 1.82 1.63 0.81 0.68 3.79 2.01 
Q 1.89 2.16 1.71 1.52 0.60 6.49 3.43 
Q and Physics 1.89 2.42 1.99 1.53 0.86 6.87 3.63 
All uncertainties 1.89 2.24 1.75 1.66 0.60 6.91 3.66 
 
 
Table. 6.7a. Alternative estimate of radiation quality uncertainties using constraint of Eq(6.7) for 40-y females on a 
1-y mission at solar minimum in deep space for a 20-g/cm2 aluminum shield. 
Uncertainties 
considered 
Expected Mean Median STD Lower 
95% 
Upper 
95% 
Fold 
Uncert. 
Q 3.23 3.58 3.15 1.48 1.94 7.44 2.05 
Q and Physics 3.23 3.64 3.20 1.53 1.99 7.59 2.35 
All uncertainties 3.23 3.47 2.90 2.09 1.03 8.9 2.77 
 
 
Table. 6.7b. Alternative estimate of radiation quality uncertainties using constraint of Eq(6.7) for 40-y females on a 
1-y mission at solar maximum with August 1972 SPE in deep space for a 20-g/cm2 aluminum shield. 
Uncertainties 
considered 
Expected Mean Median STD Lower 
95% 
Upper 
95% 
Fold 
Uncert. 
Q 1.89 2.10 1.84 0.89 1.16 4.41 2.33 
Q and Physics 1.89 2.15 1.87 0.92 1.46 4.52 2.39 
All uncertainties 1.89 2.04 1.72 1.25 0.60 5.29 2.80 
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Figure 6.8. Most likely solid cancer QF vs. kinetic energy for C, Si, and Fe nuclei comparing m=2 
and m=3 with  constrained by Eq(6.7). 
 
 
6.4.1 Uncertainties for never-smoker risk estimates 
The uncertainty assessment for never-smokers considers larger errors in background cancer 
rates for never-smokers compared to average U.S. rates. A distinct transfer weight uncertainty 
also occurs because of the larger difference between predictions of the additive and multiplica-
tive transfer models. We introduced a normally distributed quantile with M=1 and SD=0.15 to 
represent statistical errors in background cancer rates for never-smokers. Transfer model uncer-
tainties were treated in the same manner as the average U.S. population with a uniform distribu-
tion about the most likely transfer weight value, T. Table 6.8 shows the results for males and 
females on 1-y deep-space missions at solar minimum. Decreases for never-smokers compared 
to the average U.S. population are more than 20% and 30% for males and females, 
respectively, with larger decreases at older ages of exposure. Several implications are apparent 
from this comparison. First, risks for astronauts may be significantly overestimated when based 
on the average U.S. population due to smoking effects inherent in epidemiology data. Second, 
estimates made here for a mixture model would be reduced even further if a higher 
multiplicative transfer weight were used. Third, the value of crew selection is substantial when 
compared to the costs for extra radiation shielding or constraints to launch windows or mission 
timelines that would lead to a similar risk reduction as this comparison has shown. This is 
 
 
Table 6.8. %REID predictions and 95% CI for never-smokers and average U.S. population for 1 y in deep space at 
solar minimum with 20 g/cm2 aluminum shielding. 
 %REID for Males and 95% CI %REID for Females and 95% CI 
aE, y Avg. U.S. Never-smokers Decrease
(%) 
Avg. U.S. Never-smokers Decrease
(%) 
30 2.26 [0.76, 8.11] 1.79 [0.60, 6.42] 21 3.58 [1.15, 12.9] 2.52 [0.81, 9.06] 30 
40 2.10 [0.71, 7.33] 1.63 [0.55, 5.69] 22 3.23 [1.03, 11.5] 2.18 [0.70, 7.66] 33 
50 1.93 [0.65, 6.75] 1.46 [0.49, 5.11] 24 2.89 [0.88, 10.2] 1.89 [0.60, 6.70] 34 
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Table 6.9.  Estimates of safe days in deep space defined as maximum number of days with 
95% CL to be below 3%REID limit. Calculations are for solar minimum with 20-g/cm2 aluminum 
shielding. Values in parenthesis are for the alternative assessment that assumes extra constraint on 
QF uncertainties as given by Eq(6.7). 
aE, y NASA 2005 NASA 2010 
Avg. U.S. 
NASA 2010 
Never-Smokers 
  Males 
35 158 140 (186) 180 (239) 
45 207 150 (200) 198 (263) 
55 302 169 (218) 229 (297) 
  Females 
35 129 88 (120) 130 (172) 
45 173 97 (129) 150 (196) 
55 259 113 (149) 177 (231) 
 
 
further illustrated in Table 6.9, in which we report calculations for the number of safe days in 
space at solar minimum for 20 g/cm2 of aluminum shielding. The gain in the number of safe 
days for never-smokers compared to the average U.S. population can be contrasted with the 
results of Figure 6.5 for large amounts of aluminum or polyethylene shielding. Clearly, gaining 
knowledge to improve risk assessments has the potential to lead to more substantial reductions 
in risk projections than the addition of costly radiation shielding or the use of alternative radiation 
shielding materials. In addition, there are other radiogenic cancers that are also increased by 
tobacco use that should be considered in future analysis, including colon cancer and leukemia.  
 
 
6.4.2 Uncertainties Due to Non-targeted Effects 
To estimate the uncertainty contribution from NTEs, we introduced a dose-dependent QF trial 
function and an additional quantile representing the probability that NTEs contribute to cancer 
risks. Using the harderian gland data as a basis for parameters for the uncertainty assessment, 
we assume, for a Monte-Carlo trial, the modified QF function: 
 
 (1 )NTE TE crossS S NTE
T
DQ Q x
D
   (6.8) 
 
where the quantile, xNTE  represents the uncertain contribution of NTEs to space radiation 
cancer risk. We assumed a uniform PDF for this quantile, but with a limited maximum probability 
of 0.5. We chose not to vary the parametric dependence of Dcross and used the harderian gland 
estimates with no modifications. Figure 6.9 shows results for risks and uncertainties for absorbed 
doses of 0.01 and 0.1 Gy  of 600 MeV/u Fe. Further comparisons are shw in Table 6.10. These 
results show that about a 2-fold increase in uncertainties compared to TEs alone occurs at low 
dose (<0.1 Gy) representative of GCR exposures. Extension of the calculations for mixed-
particle space environment will depend not only on the NTE probability, but also on information 
on temporal aspects and likely lower dose or fluence (threshold) for NTE occurrence. Results 
could be higher or lower depending on these assumptions. The current recommendation is that 
research using chronic exposures to simulate GCR studying cancer-related processes should 
be prioritized because of the large impact of the results for NASA. Efforts to validate or refute 
the importance of NTEs should consider in-vivo experiments with representative tissues of 
human cancer risks, as well as differences between chronic and acute irradiation for small total 
absorbed doses (<0.3 Gy). 
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Figure 6.9. Uncertainty assessment for REID distribution for 600 MeV/u Fe nuclei at 0.01 or 0.1 Gy for 40-y males 
with a limit of 0.5 for maximum probability that NTE occur and average probability of 0.25. 
 
 
Table 6.10. Influence of NTE on average and upper 95% CL REID for 40-y males exposed to 0.01 Gy (1 rad) of 
HZE nuclei for different average probability of NTE occurrence, PNTE. 
PNTE %REID for 0.01 Gy of Fe (600 MeV/u) %REID for 0.01 Gy of Si (1000 MeV/u) 
 Avg.  Upper 95% CL  Avg.  Upper 95% CL 
0 1.02  4.41  0.50  2.29 
0.1 1.19  5.39  0.56  2.48 
0.2 1.58  7.27  0.67  2.74 
0.25 1.81  7.84  0.73  2.86 
0.35 2.34  8.44  0.89  3.02 
0.5 3.31  8.83  1.19  3.18 
 
 
6.5 Considerations for Implementation of New Methods 
 
Implementation of the recommendations made in this report should consider several areas, 
including dosimetry requirements, application for the ISS Program, historical records or future 
epidemiology studies, and new or ongoing NASA trade studies for exploration mission planning. 
The NCRP recommends updating radiation worker records when revised assessments exceed 
potential changes of more than 30%.25 Our recommendations for Effective doses and REID pro-
jections would include instances in which assessments would be above or below a 30% differ-
ence. Exposure records at NASA include mission dosimetry values, Effective dose and organ 
dose equivalents using the HZETRN/QMSFRG and CAM/CAF models,73 and projections of 
REID and REIC. It will be a small undertaking to reassess past ISS exposures and risk levels 
using the revised approach, but a much larger effort for past shuttle missions. Effective doses 
on shuttle missions were small; typically below 10 mSv. We recommend that exposures for the 
past and future ISS missions be updated using the new methods. For space shuttle and other 
past missions, there is no strong rationale to update organ dose equivalent records; however, 
REID and REID values could easily be updated using existing databases. For NASA trade 
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studies, the approaches here are recommended for future mission analysis. Models of radiation 
risks and uncertainty analysis are subjective when applied to human risk estimates from space 
radiation. Nevertheless, it continues to be a reasonable approach to carry acceptable levels of 
risk as specific REID values, and to make uncertainty assessments of the upper 95% CL as an 
additional safety consideration. Trade studies can explore the value of potential mitigation mea-
sures to reduce uncertainty factors and REID projections, but radiobiological research remains 
the primary method to reduce uncertainties for all space missions. 
 
Dosimetry in space flight is complex because of the many types of particles and energies 
comprising space radiation. Mission dosimetry includes area and crew personnel dosimetry. 
Area dosimetry used in the past includes TEPCs, charged-particle hodoscopes to measure Z 
and E spectra over a limited range, and passive dosimeters made up of TLDs and CR-39 nuclear 
track detectors. Typically, passive dosimeters used as area detectors are also carried by crew 
members as their dosimeter of record. Each of these dosimeters can measure various aspects 
of the radiation environment in space, but none can measure all radiation components. Further-
more, cancer risks are evaluated at sensitive tissue sites, which, of course, are not directly mea-
sured and must be estimated with computer models. NASA thus uses area and crew dosimetry 
in conjunction with the HZETRN/QMSFRG code to make estimates of organ dose equivalents in 
which mission-specific predictions are normalized to the dosimetry of record.25 The recommen-
dations of this report would not change this approach; however the new NASA QFs and REID/ 
REIC calculations would be employed. Biodosimetry results from the ISS crew would be un-
changed, and these results already include track structure effects described in this report. 
 
Implementation of the recommendation made in this report to estimate cancer risks and 
Effective dose limits for never-smokers should consider several factors. Ensuring continued 
never-smoker status for the  remainder of a lifetime should be a minor concern because most 
individuals make a decision on tobacco usage at a young age. The influence of secondhand 
smoke and risks for former smokers also needs to be considered. The CDC has estimated the 
number of secondhand smoke-attributable cancers,101 which indicates that the number is a much 
smaller fraction of cancer risks than the corrections considered in this report. The potential impact 
of secondhand smoke should be emphasized in occupational health programs at NASA, however. 
The genetic basis for individual radiation sensitivity is an active research area, although there is 
no consensus on whether or how to use such information at this time. Other nongenetic factors 
besides tobacco usage that could modify cancer risks from space radiation are: the age of first 
pregnancy for breast cancer risks, and skin pigment and history of ultraviolet exposures for skin 
cancer risks. Possible interactions between these factors and space radiation exposures should 
be considered in future research.
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7. Conclusions 
 
Important changes to the calculation of cancer risks from space radiation were proposed in this 
report. Several of these changes are based on recent reports from international committees on 
low-LET radiation effects, or reanalysis of older heavy ion data sets with the notable exception 
of new data on leukemia and liver tumors induced by Fe nuclei.134 Several reviews2,3,5 summarize 
more recent radiobiology findings on the qualitative and quantitative differences between space 
radiation and terrestrial low-LET radiation. However, very few comprehensive data sets related 
to radiation quality or dose-rate modifiers from space radiation have been reported in recent 
years, although many new studies are in progress. Uncertainties, described as the ratio of the 
upper 95% CL to the point projection, were slightly improved from our earlier estimates, with im-
provements partially negated by higher assessments of LSS dosimetry errors in recent reports 
compared to the earlier NCRP assessment.15 GCR uncertainties estimates at solar minimum 
were about 3.6 fold in our revised assessment. In an alternative model that relies on more strin-
gent track structure constraints on QFs, uncertainties are estimated as 2.8 fold. The goal of the 
NASA Space Radiation Program (SRP) is to achieve less than a 50% error for risk projections for 
a Mars mission, which is estimated to be the necessary tolerance level because of the higher radi-
ation risks associated with Mars exploration. The underlying scaling approach to the LSS and 
other human radio-epidemiology data used to estimate space radiation risks has an inherent 
uncertainty of about 2-fold, which is a severe limitation to the current approach to space radi-
ation risk estimates. Thus, the current approach will need to be replaced in future to achieve 
the SRP goal for a Mars mission. 
 
Changes recommended, based on the available new information, include: 
 
 Revisions to low-LET risk coefficients to scale space radiation cancer risks, based 
largely on the UNSCEAR17 fits to the most recent LSS incidence data. 
 Use of incidence-based risk transfer from the LSS to an average U.S. population as 
recommended by the BEIR VII report. 
 Development of an alternative risk calculation for never-smokers that reduces radiation 
risks for lung, esophagus, stomach, oral cavity, and bladder cancers compared to calcu-
lations for the average U.S. population. 
 Revisions to PDFs for uncertainties from low-LET radiation, including a revised PDF 
for the solid-cancer-risk DDREF with a point estimate of DDREF=1.75 compared to the 
NCRP value of 2 and BEIR VII recommendation of 1.5. 
 Development of a track-structure-based model of radiation QFs and an alternative risk 
cross-section approach, which rely on both E and Z and not LET alone. 
 Recommendation of a lower QF for leukemia risk compared to solid cancer risks. 
 Revisions to uncertainty assessment for space physics and radiation QFs. 
 Use of probabilistic models of SPE size, frequency, and spectral parameters for mission 
design for a given set of mission parameters (solar cycle, mission length, and shielding). 
 
The RERF in Hiroshima, Japan has made important updates to the LSS data within the last 
decade, including longer follow-up time and implementation of the DS02 dosimetry system.96 
The BEIR VII, UNSCEAR, and RERF92 reported on models of incidence or mortality rates for 
these data sets. The BEIR VII report16 ignored the age at exposure dependence in EAR and 
ERR functions above age 30 y, while arguing that the effects were small or the data lacked 
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significant power to detect this effect. The UNSCEAR report27 used more general functions of 
age as well as age at exposure dependences of ERR and EAR functions to describe temporal 
effects, and also used a Bayesian model of dosimetry errors. UNSCEAR showed that its approach 
provided improved fits to the LSS incidence data in comparison to the mathematical functions 
used in the BEIR VII report. Because the UNSCEAR report did not consider several tissues with 
smaller rates that may be of interest for future attributable risk calculations for ISS crew and ex-
ploration planning, we used the RERF model92 for these tissues (esophagus, oral cavity, ovary, 
and uterus) and adjusted the remainder calculation accordingly. we used the BEIR VII recom-
mended rates from meta-analysis of several populations, including the LSS data, for radiation 
risks of breast and thyroid cancer. 
 
The most significant change compared to the NCRP model6 that was recommended in this 
report is the use of incidence rates from the LSS to project mortality risks for astronauts. When 
using incidence-based transfer, cancer rates from the LSS are transferred to the current U.S. 
population and then converted to mortality risks using ratios of mortality-to-incidence in the U.S. 
for each tissue site. Mortality-based risk transfer was shown to lead to a much larger decrease 
in risk with increasing age at exposure compared to incidence-based risk transfer, while yielding 
similar results around ages 40 to 45 y. We prefer incidence-based risk transfer because these 
rates are more stable with time compared to mortality rates. Mortality rates have changed appre-
ciably over time since 1945, and are likely to continue to change in future. We recommend that 
Bayesian or other uncertainty analysis methods be used to fit the LSS incidence and mortality 
data simultaneously to improve the ERR and EAR functions used in assessments. Tissue-
specific estimates also are needed for attributable risk calculations, which will be described 
in a future report. 
 
Tissue-specific incidence calculations offer improved representation of cancer risks from SPE 
exposures. In the past, Effective dose calculations were made by averaging organ dose equiva-
lents using tissue weights, wT,  recommended by the ICRP that are age and gender averaged. 
In the recommended approach, Effective doses do not enter into risk calculations and instead 
tissue-specific organ dose equivalents are used. For operational radiation protection purposes, 
Effective doses are useful summary variables, and we recommended the use of gender-specific 
tissue weights for an average population of ages 30 to 60 y representative of NASA crew ages, 
and alternative weights for never-smokers. The recommended wT values are important for SPE 
risk estimates, in which large dose gradients occur, often leading to high skin, thyroid, an gonad 
dose equivalents. Therefore, an overestimate of SPE fatal cancer risks occurs when calculated 
using the ICRP-defined Effective dose. In the recommended wT values, skin dose equivalent is 
absent and the values for the thyroid and gonad are reduced. 
 
Because astronauts and many other individuals should be considered as healthy workers, 
including never-smokers (lifetime use of tobacco below 100 cigarettes), we considered a pos-
sible variation in risks and dose limits that would occur due to the reference population used for 
estimates. After adjusting U.S. average cancer rates to remove smoking effects, radiation risks 
for lung, and other smoking-attributable cancers including esophagus, oral cavity, stomach, and 
bladder cancer, estimates were made using a mixture model. Overall cancer risks were found to 
be more than 20% and 30% lower for males and females, respectively, for never-smokers com-
pared to the average U.S. population. We recommended age- and gender-specific dose limits, 
based on incidence-based risk transfer for never-smokers, that could be used by NASA. This 
analysis illustrates that gaining knowledge to improve risk transfer models, which entails knowl-
edge of cancer initiation and promotion effects, could significantly reduce uncertainties in risk 
projections. Larger reductions than were estimated in this report could occur if higher weight is 
given to multiplicative risk transfer compared to the transfer weights used herein. The effects 
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of secondhand smoke and post-mission use of tobacco need to be taken into account when 
considering distinct radiation limits based on never-smoker risk estimates. 
 
A large number of radiobiology experiments show that biological effects depend on both particle 
charge number and velocity (or kinetic energy) and not on LET alone. Theoretically based track 
structure models have for many years predicted this effect. In this report, we developed a simple 
approach to take into account track structure effects using the improved physical descriptor of 
Z*2/2 and breaking risk calculations into distinct response models for light (Z )4 and heavy 
(Z>4) charged nuclei. Finer groupings into individual charge spectra can be made in future as 
more data become available. The revised approach to QFs described here corrects an important 
shortcoming in the ICRP definition of QF. Deficiencies in the ICRP model included that: the LET 
value of the maximum Q was independent of Z, and the slope of the Q function with varying E is 
incorrect both on the ascending and the descending side of a peak value. The resulting NASA 
model evaluates risks using particle spectra dependent on Z*2/2  for light and heavy nuclei groups, 
and the total absorbed dose at sensitive tissue sites. We recommended QFs for leukemia risks 
with much smaller values than for solid cancer risks, based on limited but important data from 
human, animal, and cellular studies. Although the revised calculations of Effective doses differ 
by about 10% to 30% from the ICRP-recommended QFs for varying shielding thicknesses, these 
calculations lead to distinct conclusions on the effectiveness of radiation shielding and improved 
method to assess uncertainties and target critical experiments to further reduced uncertainties. 
 
The ICRP QF is not informed by existing radiobiology data for HZE nuclei. Uncertainty analysis 
is improved in the revised approach as the underlying QF parameters are more readily related to 
results from radiobiology experiments than to an LET-based approach such as the ICRP model. 
An alternative uncertainty assessment was described that assumes that the energy where the 
maximum QF occurs for each Z is highly constrained. Existing experimental data for Fe nuclei 
were used to estimate the most likely value and its standard deviation, while the underlying track 
structure model was used to predict the position for other nuclei with lower Z. The alternative un-
certainty assessment led to a 2.8-fold uncertainty for GCR behind 20-g/cm2 aluminum shielding 
compared to a 3.6-fold uncertainty for the analysis without this constraint. These results suggest 
research strategies to improve parameter uncertainties with well-defined particle choices can be 
made. Tissue-specific estimates of the parameters 0 and  using validated experimental models 
such as transgenic tumor models of human cancers, and a human cell culture model of cancer 
processes would be optimal in estimating these parameters. Such data would narrow uncertainty 
factors substantially from current estimates. Alternative uncertainty assessment approaches 
such as Bayesian methods should be used in the design and analysis of such experiments. 
 
Our revised approach allows for REIC and REID estimates in terms of track-structure-
dependent risk cross sections. Risk cross sections, which have been suggested by several 
biophysical models of heavy ion effects, are useful for considering the extrapolation of radio-
biology data to low doses. The changes recommended replace LET with Z*2/2 for different charge 
groups, but do not lead to any inconsistencies with current space dosimetry approaches, which 
scale transport code prediction or organ exposure to crew dosimeters and area monitors. How-
ever, the recommended approach places more emphasis on measurements of Z and E spectra, 
which can be estimated using CR-39 plastic track detectors worn by crew, and area detectors 
such as particle hodoscopes that resolve charge and energy. These methods can also be used 
to validate the accuracy of radiation transport code predictions as has been described in the 
past.73 
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The uncertainties to cancer risk projections can be broken down into the low-LET risk coef-
ficients, space physics, and radiation QF uncertainties. This breakdown assumes that other 
uncertainties are smaller and thus ignored. There was an increased estimate of the LSS 
dosimetry errors in recent reports compared to the NCRP description in 1997.15 Space physics 
uncertainties continue to be a minor component of the overall uncertainty. For very thick 
shielding there is a need for continued analysis of particle production processes that produce 
largely low-LET radiation (eg, mesons, electrons, and photons) that are less well studied by 
space transport codes than are protons, neutrons, and heavy nuclei. QFs with values below 
unity may be appropriate at sufficiently high energy for electrons and photons, and should be 
considered in uncertainty assessments. There are uncertainties related to estimating the 
fraction of the U.S. population that are current or former smokers, and the types of cancers 
attributable to tobacco usage and related relative risk factors. Models of these uncertainties 
should be the focus of future work.  
 
DDREF values are based on subjective assessment of dose and dose-rate responses across 
available data sets (human epidemiology, animal studies, and cell culture studies). The ICRP117 
and NCRP6 recommend DDREF values of 2. However, the recent BEIR VII report recommended 
a DDREF of 1.5. The impact of a wide range of DDREF values can be evaluated through error 
assessment methods for uncertainty assessments. We used a PDF for the DDREF that was 
similar to the NIH Working Group analysis93 with a median value of DDREF=1.75. This DDREF 
is at the high end of estimates based on human data for solid cancer risks, and near the lower 
values found for mouse tumor induction studies for solid cancers. 
 
Uncertainties not addressed are the “unknown” uncertainties discussed by the NCRP, and 
uncertainty factors related to the distinct time after exposure dependence of cancer risks with 
radiation quality. There is very little information available to understand how an earlier time of 
appearance of tumors would impact risk assessments. Uncertainties due to deviation from lin-
earity at low doses of heavy ions were explored with calculations motivated by nontargeted 
effects.NTEs could increase uncertainties by more than 2-fold for HZE nuclei, and may also 
depend on mission length. NTEs are a potential “game-changer” for NASA because they may 
impact radiation protection paradigms with regard to mission length and shielding. Research 
with chronic exposures at low doses in appropriate models is needed to better understand the 
importance of NTE in cancer risks. No recommendation to use NTEs for mission requirements 
is made at this time; however, NTEs should be considered when deciding on research 
emphasis. 
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Appendix A 
 
The following tables list REIC and REID values for 1-y missions in deep space at solar minimum 
for 20 g/cm2 of aluminum shielding. Calculations for the average U.S. and never-smoker 
populations are listed. 
 
Table A1. %REIC for average U.S. males vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.357  0.344  0.327  0.306  0.281  0.252  0.218 
Colon  0.616  0.564  0.515  0.464  0.41  0.351  0.285 
Liver  0.153  0.15  0.146  0.14  0.131  0.121  0.108 
Lung  0.783  0.782  0.775  0.761  0.735  0.693  0.63 
Prostate  0.312  0.309  0.302  0.29  0.272  0.246  0.211 
Bladder  0.682  0.687  0.69  0.692  0.687  0.671  0.631 
Esophagus  0.114  0.114  0.113  0.111  0.106  0.099  0.088 
Brain‐CNS  0.064  0.056  0.048  0.041  0.035  0.029  0.023 
Thyroid  0.07  0.044  0.027  0.016  0.009  0.005  0.003 
Oral Cavity  0.026  0.023  0.02  0.018  0.015  0.013  0.01 
Remainder  0.659  0.544  0.445  0.36  0.286  0.222  0.166 
Leukemia  0.71  0.682  0.652  0.617  0.576  0.528  0.471 
Total Solid  3.836  3.616  3.408  3.198  2.968  2.7  2.373 
Total  4.547  4.298  4.06  3.816  3.544  3.228  2.844 
 
 
 
Table A2. %REIC for never-smoker males vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.339  0.327  0.31  0.29  0.266  0.239  0.207 
Colon  0.617  0.566  0.516  0.465  0.411  0.352  0.285 
Liver  0.153  0.151  0.146  0.14  0.132  0.121  0.108 
Lung  0.349  0.348  0.345  0.339  0.331  0.319  0.3 
Prostate  0.313  0.309  0.303  0.291  0.273  0.246  0.212 
Bladder  0.406  0.408  0.41  0.411  0.408  0.399  0.377 
Esophagus  0.035  0.035  0.034  0.033  0.031  0.029  0.026 
Brain‐CNS  0.064  0.056  0.048  0.041  0.035  0.029  0.023 
Thyroid  0.071  0.044  0.027  0.016  0.009  0.005  0.003 
Oral Cavity  0.025  0.022  0.02  0.017  0.015  0.012  0.01 
Remainder  0.661  0.545  0.446  0.361  0.287  0.222  0.166 
Leukemia  0.711  0.683  0.654  0.619  0.577  0.529  0.472 
Total Solid  3.033  2.811  2.605  2.405  2.197  1.973  1.717 
Total Cancer  3.745  3.494  3.259  3.023  2.775  2.502  2.189 
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Table A3. %REIC for average U.S. females vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.381  0.367  0.349  0.328  0.303  0.274  0.242 
Colon  0.623  0.555  0.495  0.439  0.385  0.331  0.274 
Liver  0.125  0.124  0.122  0.119  0.115  0.109  0.1 
Lung  2.217  2.207  2.182  2.133  2.049  1.914  1.724 
Breast  1.405  1.075  0.813  0.605  0.425  0.292  0.195 
Uterus  0.158  0.151  0.141  0.13  0.117  0.102  0.086 
Ovary  0.179  0.173  0.164  0.154  0.142  0.128  0.112 
Bladder  0.343  0.344  0.344  0.343  0.338  0.329  0.312 
Esophagus  0.037  0.037  0.036  0.035  0.034  0.032  0.029 
Brain‐CNS  0.063  0.055  0.048  0.042  0.036  0.03  0.024 
Thyroid  0.409  0.244  0.142  0.08  0.044  0.023  0.012 
Oral Cavity  0.03  0.027  0.024  0.021  0.018  0.015  0.013 
Remainder  0.814  0.656  0.522  0.41  0.317  0.239  0.175 
Leukemia  0.459  0.441  0.424  0.405  0.38  0.349  0.312 
Total Solid  6.785  6.014  5.382  4.839  4.322  3.82  3.299 
Total     7.244  6.455  5.806  5.244  4.702  4.168  3.611 
 
 
 
Table A4. %REIC for never-smoker females vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.378  0.364  0.346  0.325  0.301  0.272  0.24 
Colon  0.627  0.559  0.498  0.442  0.388  0.333  0.276 
Liver  0.126  0.125  0.123  0.12  0.116  0.11  0.101 
Lung  0.808  0.805  0.797  0.784  0.763  0.731  0.686 
Breast  1.413  1.081  0.817  0.608  0.427  0.294  0.196 
Uterus  0.159  0.151  0.142  0.131  0.117  0.102  0.087 
Ovary  0.18  0.174  0.165  0.155  0.143  0.129  0.113 
Bladder  0.284  0.285  0.285  0.284  0.281  0.274  0.261 
Esophagus  0.018  0.017  0.016  0.016  0.015  0.013  0.012 
Brain‐CNS  0.063  0.055  0.048  0.042  0.036  0.03  0.024 
Thyroid  0.41  0.245  0.142  0.08  0.044  0.023  0.012 
Oral Cavity  0.03  0.027  0.024  0.021  0.018  0.015  0.013 
Remainder  0.818  0.659  0.525  0.412  0.319  0.241  0.176 
Leukemia  0.461  0.443  0.426  0.406  0.381  0.35  0.313 
Total Solid  5.314  4.547  3.93  3.42  2.967  2.568  2.196 
Total  5.774  4.99  4.356  3.827  3.348  2.918  2.51 
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Table A5. %REID for average U.S. males vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.21  0.201  0.19  0.178  0.165  0.152  0.137 
Colon  0.259  0.236  0.215  0.196  0.177  0.156  0.134 
Liver  0.125  0.125  0.124  0.121  0.116  0.109  0.1 
Lung  0.635  0.638  0.638  0.636  0.628  0.608  0.571 
Prostate  0.052  0.052  0.053  0.054  0.055  0.056  0.056 
Bladder  0.156  0.157  0.158  0.159  0.16  0.161  0.16 
Esophagus  0.107  0.107  0.106  0.104  0.1  0.094  0.085 
Brain‐CNS  0.05  0.044  0.039  0.034  0.03  0.025  0.02 
Thyroid  0.009  0.006  0.004  0.003  0.002  0.001  0.001 
Oral Cavity  0.006  0.006  0.005  0.005  0.004  0.004  0.003 
Remainder  0.19  0.161  0.135  0.112  0.092  0.074  0.058 
Leukemia  0.477  0.469  0.458  0.447  0.432  0.413  0.387 
Total Solid  1.799  1.733  1.668  1.602  1.528  1.44  1.325 
Total  2.276  2.201  2.127  2.049  1.96  1.854  1.713 
 
 
 
Table A6. %REID for never-smoker males vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.2  0.191  0.181  0.169  0.157  0.144  0.13 
Colon  0.26  0.237  0.216  0.197  0.177  0.157  0.135 
Liver  0.125  0.125  0.124  0.121  0.116  0.11  0.101 
Lung  0.317  0.315  0.312  0.306  0.296  0.283  0.264 
Prostate  0.052  0.053  0.053  0.054  0.055  0.056  0.057 
Bladder  0.094  0.095  0.095  0.096  0.096  0.097  0.097 
Esophagus  0.033  0.033  0.032  0.031  0.03  0.028  0.025 
Brain‐CNS  0.05  0.044  0.039  0.034  0.03  0.025  0.02 
Thyroid  0.009  0.006  0.004  0.003  0.002  0.001  0.001 
Oral Cavity  0.006  0.005  0.005  0.005  0.004  0.004  0.003 
Remainder  0.19  0.161  0.135  0.113  0.093  0.075  0.059 
Leukemia  0.478  0.47  0.459  0.448  0.433  0.414  0.388 
Total Solid  1.336  1.265  1.197  1.128  1.056  0.978  0.89 
Total  1.814  1.735  1.656  1.576  1.489  1.393  1.278 
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Table A7. %REID for average U.S. females vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.219  0.213  0.206  0.197  0.187  0.175  0.16 
Colon  0.241  0.216  0.194  0.174  0.157  0.14  0.123 
Liver  0.113  0.112  0.111  0.109  0.105  0.101  0.094 
Lung  1.71  1.709  1.701  1.682  1.641  1.566  1.446 
Breast  0.354  0.274  0.21  0.16  0.117  0.085  0.06 
Uterus  0.017  0.017  0.016  0.016  0.015  0.014  0.012 
Ovary  0.136  0.135  0.133  0.129  0.124  0.115  0.104 
Bladder  0.108  0.108  0.108  0.108  0.108  0.108  0.106 
Esophagus  0.033  0.032  0.032  0.031  0.03  0.029  0.027 
Brain‐CNS  0.047  0.043  0.039  0.034  0.03  0.026  0.022 
Thyroid  0.023  0.015  0.01  0.007  0.004  0.003  0.002 
Oral Cavity  0.007  0.007  0.006  0.006  0.005  0.005  0.004 
Remainder  0.293  0.246  0.205  0.169  0.137  0.109  0.084 
Leukemia  0.306  0.3  0.293  0.284  0.274  0.261  0.244 
Total Solid  3.302  3.127  2.971  2.822  2.661  2.475  2.246 
Total  3.608  3.428  3.264  3.106  2.935  2.736  2.49 
 
 
 
Table A8. %REID for never-smoker females vs. age at exposure (y). 
Tissue  30  35  40  45  50  55  60 
Stomach  0.217  0.211  0.204  0.195  0.185  0.173  0.159 
Colon  0.243  0.218  0.195  0.175  0.158  0.141  0.124 
Liver  0.114  0.113  0.112  0.11  0.106  0.102  0.095 
Lung  0.676  0.675  0.672  0.665  0.654  0.636  0.606 
Breast  0.357  0.276  0.212  0.161  0.118  0.086  0.061 
Uterus  0.017  0.017  0.016  0.016  0.015  0.014  0.012 
Ovary  0.137  0.136  0.134  0.13  0.125  0.116  0.105 
Bladder  0.09  0.091  0.091  0.091  0.091  0.091  0.09 
Esophagus  0.015  0.015  0.014  0.014  0.013  0.012  0.011 
Brain‐CNS  0.047  0.043  0.039  0.035  0.03  0.026  0.022 
Thyroid  0.023  0.016  0.01  0.007  0.004  0.003  0.002 
Oral Cavity  0.007  0.007  0.006  0.006  0.005  0.005  0.004 
Remainder  0.295  0.248  0.206  0.17  0.138  0.11  0.085 
Leukemia  0.308  0.302  0.294  0.286  0.275  0.262  0.245 
Total Solid  2.24  2.065  1.911  1.774  1.643  1.513  1.375 
Total  2.548  2.366  2.206  2.06  1.918  1.776  1.621 
118 
 
Appendix B 
 
Using the methods described in the text, risk calculations were made for each U.S. state and 
the District of Columbia using the NCRP No. 132 Model (as described in the text) and the BEIR 
VII model. The following tables show REID results for females and males at ages of exposure of 
35, 45, and 55 y. The median life span and age-adjusted cancer mortality rate are also shown. 
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Table B1. REID per Sv for males at different ages at exposure in NCRP and BEIR VII models. 
State Median lifespan Cancer rate 35 45 55 35 45 55
Utah 80.2 96.0 3.78 3.69 3.46 3.69 2.85 1.95
North Dakota 79.2 103.8 3.98 3.86 3.64 3.96 3.03 2.05
Colorado 79.7 107.4 3.90 3.80 3.57 3.86 2.97 2.02
Wyoming 78.3 108.2 3.84 3.76 3.54 3.78 2.91 1.96
Alaska 78.4 112.8 4.03 3.93 3.69 4.08 3.13 2.14
Montana 78.5 113.5 3.92 3.85 3.66 3.88 2.97 2.02
Minnesota 80.1 115.0 4.18 4.06 3.84 4.09 3.12 2.11
Idaho 79.2 118.1 4.01 3.90 3.74 3.89 2.98 2.03
Connecticut 79.4 120.8 4.09 3.99 3.75 4.07 3.10 2.10
California 79.4 123.0 3.92 3.81 3.57 3.91 3.00 2.05
Vermont 79.6 123.9 4.08 3.94 3.73 4.02 3.06 2.06
Nebraska 79.0 125.8 3.96 3.85 3.59 3.90 2.96 1.99
New Mexico 78.1 126.0 3.76 3.69 3.48 3.76 2.91 2.01
Washington 79.3 126.5 4.06 3.95 3.73 3.99 3.04 2.07
New Hampshire 79.4 129.1 4.14 4.01 3.76 4.11 3.12 2.10
Wisconsin 78.9 130.6 4.10 3.99 3.76 3.99 3.03 2.04
New Jersey 78.7 132.7 3.99 3.88 3.65 3.97 3.02 2.04
Arizona 78.7 134.2 3.85 3.76 3.55 3.89 2.99 2.06
South Dakota 78.6 135.0 4.03 3.93 3.70 3.96 3.02 2.04
Oregon 78.8 135.9 3.98 3.87 3.63 3.95 3.01 2.04
Iowa 78.9 140.4 4.12 4.01 3.78 3.99 3.02 2.04
Nevada 76.5 140.4 3.70 3.61 3.40 3.68 2.80 1.91
Massachusetts 79.0 141.0 4.06 3.94 3.70 4.06 3.08 2.09
New York 79.1 141.5 3.96 3.84 3.60 3.92 2.99 2.03
Hawaii 80.3 144.5 3.91 3.76 3.53 3.99 3.07 2.11
Kansas 78.2 144.9 3.95 3.84 3.61 3.86 2.93 1.98
Texas 77.4 149.1 3.84 3.73 3.50 3.80 2.89 1.95
Maryland 77.7 150.2 3.89 3.78 3.55 3.90 2.97 2.02
Virginia 77.9 150.6 3.94 3.81 3.55 3.93 2.97 2.00
Illinois 77.8 151.2 3.99 3.88 3.65 3.92 2.97 2.00
Rhode Island 78.5 152.7 4.00 3.86 3.57 4.04 3.06 2.07
Michigan 77.7 157.0 3.90 3.79 3.56 3.84 2.91 1.97
Pennsylvania 77.3 158.8 3.91 3.80 3.56 3.86 2.92 1.96
Indiana 76.8 158.9 3.89 3.79 3.55 3.83 2.89 1.94
Maine 78.3 165.3 4.11 3.98 3.72 4.03 3.04 2.04
Ohio 76.9 168.3 3.87 3.76 3.52 3.83 2.88 1.94
Georgia 76.1 169.1 3.70 3.58 3.34 3.70 2.79 1.88
Delaware 77.4 170.9 3.97 3.88 3.63 3.96 3.00 2.03
Missouri 76.7 171.5 3.88 3.78 3.54 3.81 2.88 1.94
Florida 78.4 174.1 3.99 3.88 3.67 3.95 3.02 2.08
North Carolina 76.5 175.1 3.80 3.68 3.44 3.78 2.85 1.92
Kentucky 75.2 185.1 3.80 3.69 3.45 3.79 2.86 1.91
West Virginia 75.3 185.2 3.69 3.59 3.32 3.66 2.77 1.85
Oklahoma 75.4 187.5 3.66 3.56 3.34 3.60 2.72 1.82
South Carolina 75.5 196.2 3.77 3.66 3.45 3.74 2.82 1.91
Alabama 74.6 196.2 3.64 3.53 3.30 3.63 2.73 1.84
Tennessee 75.2 196.7 3.74 3.64 3.43 3.70 2.79 1.88
Arkansas 75.4 202.0 3.82 3.71 3.49 3.75 2.83 1.91
District of Columbia 73.2 205.0 3.48 3.41 3.29 3.56 2.72 1.90
Louisiana 74.2 212.3 3.67 3.57 3.34 3.68 2.77 1.87
Mississippi 73.7 219.0 3.59 3.49 3.27 3.59 2.70 1.81
BEIR VII NCRP 132
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Table B2. REID per Sv for females at different ages at exposure in NCRP and BEIR VII models. 
State Median lifespan Cancer rate 35 45 55 35 45 55
Alaska 82.6 89.6 5.43 5.26 4.85 4.82 3.62 2.42
Utah 83.1 99.4 4.84 4.64 4.21 4.27 3.22 2.13
Colorado 83.1 108.6 5.34 5.14 4.72 4.72 3.52 2.34
North Dakota 84.0 109.6 5.60 5.40 4.92 4.98 3.72 2.46
Idaho 83.0 111.5 5.45 5.25 4.86 4.71 3.52 2.33
Nebraska 83.2 114.3 5.47 5.27 4.84 4.80 3.58 2.37
Hawaii 85.6 114.4 5.46 5.22 4.76 4.93 3.73 2.50
Minnesota 84.0 117.1 5.74 5.54 5.09 5.04 3.76 2.49
Montana 82.8 117.5 5.50 5.32 4.91 4.85 3.62 2.40
Oregon 82.5 119.7 5.52 5.32 4.87 4.89 3.63 2.40
Connecticut 83.6 120.6 5.69 5.48 5.03 5.05 3.76 2.49
Washington 82.9 120.8 5.58 5.38 4.94 4.94 3.67 2.44
Wyoming 82.2 121.1 5.33 5.16 4.73 4.68 3.50 2.32
California 83.4 123.8 5.46 5.25 4.80 4.84 3.61 2.40
Maine 82.3 123.9 5.65 5.44 4.97 4.97 3.68 2.41
Wisconsin 83.3 126.0 5.61 5.40 4.95 4.91 3.65 2.41
Arizona 83.4 126.3 5.33 5.13 4.70 4.72 3.54 2.36
Vermont 83.3 127.4 5.53 5.31 4.83 4.89 3.63 2.39
New Mexico 83.1 127.5 5.25 5.05 4.62 4.67 3.50 2.33
Texas 82.2 128.8 5.18 4.96 4.52 4.56 3.39 2.24
Massachusetts 83.2 129.0 5.66 5.44 4.98 5.01 3.72 2.45
New Hampshire 83.1 129.2 5.64 5.39 4.92 5.01 3.71 2.45
Nevada 81.5 129.8 5.32 5.13 4.69 4.73 3.51 2.32
South Dakota 83.6 130.2 5.59 5.39 4.92 4.91 3.67 2.43
Rhode Island 83.0 130.7 5.64 5.44 5.00 4.92 3.65 2.41
Iowa 83.4 131.7 5.62 5.41 4.94 4.90 3.65 2.41
Virginia 82.2 135.2 5.37 5.14 4.67 4.74 3.51 2.31
New York 83.3 135.6 5.51 5.29 4.82 4.88 3.63 2.40
New Jersey 82.8 135.6 5.64 5.43 4.96 4.98 3.70 2.44
Kansas 82.4 135.9 5.36 5.15 4.71 4.68 3.48 2.30
Michigan 82.0 138.6 5.37 5.16 4.72 4.70 3.48 2.30
Illinois 82.4 139.5 5.50 5.28 4.82 4.84 3.58 2.36
Maryland 82.2 140.6 5.42 5.20 4.75 4.80 3.56 2.35
Pennsylvania 82.2 140.6 5.46 5.25 4.77 4.81 3.56 2.35
Georgia 81.2 142.7 5.07 4.85 4.41 4.43 3.28 2.16
North Carolina 81.7 143.6 5.18 4.96 4.51 4.56 3.39 2.23
Indiana 81.6 143.7 5.38 5.15 4.68 4.72 3.49 2.29
Missouri 81.7 145.3 5.34 5.12 4.65 4.69 3.47 2.28
Oklahoma 80.7 146.4 5.02 4.81 4.36 4.39 3.25 2.14
Florida 83.7 146.4 5.50 5.29 4.85 4.86 3.64 2.43
Ohio 81.5 147.2 5.36 5.14 4.67 4.70 3.47 2.28
Delaware 82.2 150.0 5.54 5.33 4.85 4.84 3.59 2.37
Alabama 80.5 152.2 4.97 4.77 4.33 4.33 3.21 2.11
West Virginia 80.4 153.1 5.21 5.01 4.54 4.56 3.36 2.19
South Carolina 81.3 154.0 5.11 4.88 4.44 4.50 3.34 2.21
Kentucky 80.8 156.9 5.34 5.13 4.62 4.66 3.43 2.24
Tennessee 80.8 158.6 5.15 4.93 4.48 4.52 3.34 2.20
Louisiana 80.1 161.7 5.10 4.87 4.42 4.48 3.31 2.17
Arkansas 81.3 163.5 5.24 5.02 4.56 4.58 3.39 2.23
Mississippi 80.4 165.1 5.04 4.82 4.38 4.36 3.23 2.13
District of Columbia 81.6 165.6 5.22 5.05 4.72 4.58 3.44 2.33
BEIR VII NCRP 132
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The CDC101 has published life-table and cancer mortality rates for different levels of 
urbanization. We applied these rates using the NCRP No. 132 model with the LSS report solid 
cancer (DDREF=2) and the BEIR VII model (DDREF=1.5) to study age and gender dependence 
of REID values (Figures B1 and B2) for different locality as described by the CDC. 
 
 
 
Figure B1. %REID per Sv for males and females in BEIR VII model with vT=0.5. 
 
 
 
 
Figure B2. %REID per Sv for males and females in NCRP6 model with vT=0.5. 
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